Page last updated: 2024-12-05

ropinirole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ropinirole is a non-ergot dopamine agonist used to treat Parkinson's disease and restless legs syndrome. It works by stimulating dopamine receptors in the brain, mimicking the effects of dopamine, a neurotransmitter that is deficient in people with Parkinson's disease. Ropinirole is synthesized through a multi-step process involving a series of chemical reactions. It is typically administered orally and is available in immediate-release and extended-release formulations. Ropinirole is an important treatment for Parkinson's disease, offering symptom relief, including tremor, rigidity, bradykinesia, and postural instability. It can also improve motor function, reduce the severity of restless legs syndrome, and enhance quality of life. Research on ropinirole focuses on understanding its mechanisms of action, optimizing treatment regimens, investigating potential adverse effects, and exploring its use in other neurological disorders.'

Cross-References

ID SourceID
PubMed CID5095
CHEMBL ID589
CHEBI ID8888
SCHEMBL ID35212
MeSH IDM0135070

Synonyms (84)

Synonym
4-(2-(di-n-propylamino)ethyl)-2(3h)-indolone
BIDD:GT0826
BRD-K15933101-003-01-2
AKOS015843123
2h-indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-
skf 101468
sk&f 101468
ropinirol
ropinirolum [inn-latin]
ropinirol [inn-spanish]
lopac-r-4152
NCGC00015893-01
LOPAC0_001101
ropinirolum
CHEBI:8888 ,
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2h-indol-2-one
ropinirole
91374-21-9
C07564
DB00268
NCGC00096064-01
SPECTRUM1505178
NCGC00096064-02
HMS2093K04
NCGC00015893-04
4-(2-(dipropylamino)ethyl)indolin-2-one
L000520
CHEMBL589 ,
nsc-758917
ropitor (tn)
ropinirole (usan/inn)
D08489
FT-0652500
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
bdbm50020680
NCGC00015893-02
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one
narapin
nsc758917
pharmakon1600-01505178
cas-91374-21-9
tox21_110256
dtxcid6025195
dtxsid8045195 ,
CCG-205177
ropinirole [usan:inn:ban]
nsc 758917
hsdb 8252
unii-030pyr8953
4-(2-(dipropylamino)ethyl)-1,3-dihydro-2h-indol-2-one
030pyr8953 ,
NCGC00015893-03
ropinirole [mi]
ropinirole [who-dd]
ropinirole [inn]
ropinirole [vandf]
ropinirole [usan]
ropitor
sk&f-101468
4-[2-(dipropylamino)ethyl]-3h-indol-2-ol
gtpl7295
SCHEMBL35212
tox21_110256_1
NCGC00015893-06
4-[2-(dipropylamino)ethyl]-1.3-dihydro-2h-indol-2-one
skf-101468
4-[2-(dipropylamino)ethyl]2-indolinone
AB01563044_02
AB01563044_01
STL454344
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1h-indol-2-one
SR-01000076215-3
Q420590
BCP09383
SDCCGSBI-0051070.P002
NCGC00094373-12
SB65618
HY-B0623
CS-0009561
EN300-708794
ropinirolum (inn-latin)
ropinirol (inn-spanish)
n04bc04
ropinirolum (latin)

Research Excerpts

Overview

Ropinirole (ROP) is a dopamine agonist that has been used as therapy for Parkinson's disease. It has been licensed for the therapy of idiopathic Parkinson syndrome in mono- and add-on therapy for more than 10 years.

ExcerptReferenceRelevance
"Ropinirole is a very important treatment option for Parkinson's disease (PD), a major threat to the aging population. "( Orally-dissolving film for sublingual and buccal delivery of ropinirole.
Chow, SF; Fang, Y; Han, H; Lai, KL; Lam, TN; Lee, WYT; Li, HY; Li, Q; Zhang, S, 2018
)
2.16
"Ropinirole (ROP) is a dopamine agonist that has been used as therapy for Parkinson's disease. "( Ropinirole alters gene expression profiles in SH-SY5Y cells: a whole genome microarray study.
Jin, G; Le, WD; Zhu, MZ, 2016
)
3.32
"Ropinirole is a non-ergolinic dopamine agonist, which has been used for over 10 years for the treatment of Parkinson's disease. "( Initial experience with ropinirole PR (prolonged release).
Buhmann, C; Fuchs, G; Greulich, W; Hummel, S; Jost, WH; Korchounov, A; Müngersdorf, M; Schwarz, M; Spiegel-Meixensberger, M, 2008
)
2.1
"Ropinirole is a non-ergoline dopamine agonist with medium elimination half time, which has been licensed for the therapy of idiopathic Parkinson syndrome in mono- and add-on therapy for more than 10 years. "( [Clinical data of the prolonged-release formulation of ropinirole].
Bergmann, L; Jost, WH, 2010
)
2.05
"Ropinirole is a pharmacologically active agent used in the treatment of Parkinson's disease (PD) that directly acts on dopamine receptors. "( Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism.
Oh, MS; Park, G; Park, YJ; Yang, HO, 2013
)
3.28
"Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors. "( Ropinirole: for the treatment of restless legs syndrome.
Bang, LM; Cheer, SM; Keating, GM, 2004
)
3.21
"Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination therapy against idiopathic Parkinson's disease. "( Ropinirole: current status of the studies.
Jost, WH, 2004
)
3.21
"Ropinirole is an original nonergoline dopamine agonist indicated for the treatment of Parkinson's disease. "( Ropinirole in the treatment of restless legs syndrome.
Kakar, RS; Kushida, CA, 2005
)
3.21
"Ropinirole is a non-ergot-selective D2 dopamine agonist. "( [Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study].
Angersbach, D; Buchwald, B; Reichmann, H, 2005
)
1.98
"Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease."( Ropinirole, a non-ergoline dopamine agonist.
Angersbach, D; Jost, WH, 2005
)
2.49
"Ropinirole is a non-ergot dopaminergic agonist with a high affinity for D2 dopaminergic receptors which improves the symptoms of Parkinson's disease (PD) and delays the appearance of motor complications. "( [Ropinirole in the treatment of Parkinson's disease: an update].
Vivancos-Matellano, F,
)
2.48
"Ropinirole is a modern dopamine agonist with a half-life of medium extent that is highly selective for D(2)-receptors. "( Clinical studies with ropinirole in Parkinson's disease and RLS.
Angersbach, D; Jost, WH; Rascol, O, 2006
)
2.09
"Ropinirole is a nonergoline dopamine D(2)-receptor agonist and has been proven to be effective in both monotherapy and combination therapy for idiopathic Parkinson's disease. "( The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.
Bi, LL; Chen, XY; Jia, YY; Luo, XX; Wen, AD; Zhong, DF, 2007
)
2.04
"Ropinirole is a non-ergoline selective D2 dopamine agonist. "( [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Angersbach, D; Buchwald, B; Jost, WH, 2007
)
2.01
"Ropinirole, which is a non-ergot dopamine agonist derivative, exerts therapeutic benefits in Parkinson's disease (PD). "( Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Borlongan, CV; Hara, K; Kim, KM; Maki, M; Matsukawa, N; Morgan, JC; Sethi, KD; Xu, L; Yasuhara, T; Yu, G, 2007
)
2.03
"Ropinirole is a non-ergoline dopamine agonist, highly selective for the D2 receptor subtype D3. "( [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease].
Chacon, J, 2007
)
1.78
"Ropinirole is a novel, non-ergoline dopamine agonist chemical name with a very high specificity for dopamine D2-like receptors, currently being investigated for the symptomatic treatment of Parkinson's disease. "( Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks, DJ; Burn, DJ; Torjanski, N, 1995
)
3.18
"Ropinirole is a new nonergoline dopamine agonist that binds specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4)."( Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
Tulloch, IF, 1997
)
1.32
"Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease."( Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.
Adler, CH; Bertoni, J; Davis, TL; Hammerstad, JP; Hauser, RA; O'Brien, CF; Sanchez-Ramos, J; Sethi, KD; Taylor, RL, 1997
)
2.46
"Ropinirole is a specific non-ergoline dopamine D2-receptor agonist with antiparkinsonian properties. "( Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
Brefel, C; Bullman, S; Citerone, DR; Fitzpatrick, K; Lopez-Gil, A; Montastruc, JL; Rascol, O; Rayet, S; Taylor, AC; Thalamas, C, 1998
)
2.01
"Ropinirole is a novel, nonergoline, selective D2-type dopamine agonist developed to treat Parkinson's disease. "( The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Brooks, DJ; Brunt, E; Fuell, D; Korczyn, A; Poewe, W; Quinn, NP; Rascol, O; Schrag, AE; Stocchi, F,
)
1.93
"Ropinirole is a nonergoline dopamine agonist that binds to dopamine D2-receptors; the drug is indicated for use in the symptomatic treatment of early and late Parkinson's disease (PD)."( Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel, MD, 1999
)
2.47
"Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. "( Clinical pharmacokinetics of ropinirole.
Kaye, CM; Nicholls, B, 2000
)
2.04

Effects

Ropinirole has a low rate of manic switching and significantly reduces bipolar depression severity. Ropini Role has alow potential to interact with other drugs.

Ropinirole PR has shown good efficacy and tolerability in controlled trials in monotherapy in early patients as well as in add-on studies in advanced patients. The drug has no serious or common side effects that would limit its use significantly.

ExcerptReferenceRelevance
"Ropinirole has a low rate of manic switching and significantly reduces bipolar depression severity."( Ropinirole in Bipolar Disorder: Rate of Manic Switching and Change in Disease Severity.
Beecher, J; Capote, HA; Gengo, FM; Rainka, M; Westphal, ES, 2018
)
3.37
"Ropinirole has a low potential to interact with other drugs likely to be administered to PD patients."( Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel, MD, 1999
)
2.47
"Ropinirole has been shown to provoke vomiting in dogs by activating the dopamine D2-like receptors in the chemoreceptor trigger zone. "( Metabolism of ropinirole is mediated by several canine CYP enzymes.
Koskinen, M; Tervahauta, T; Uutela, P, 2023
)
2.71
"Ropinirole has a low rate of manic switching and significantly reduces bipolar depression severity."( Ropinirole in Bipolar Disorder: Rate of Manic Switching and Change in Disease Severity.
Beecher, J; Capote, HA; Gengo, FM; Rainka, M; Westphal, ES, 2018
)
3.37
"Ropinirole PR has shown good efficacy and tolerability in controlled trials in monotherapy in early patients as well as in add-on studies in advanced patients."( [Clinical data of the prolonged-release formulation of ropinirole].
Bergmann, L; Jost, WH, 2010
)
1.33
"Ropinirole has been evaluated in different studies both in monotherapy and as adjunctive therapy with levodopa."( [Ropinirole in the treatment of Parkinson's disease: an update].
Vivancos-Matellano, F,
)
1.76
"Ropinirole has no serious or common side effects that would limit its use significantly."( Ropinirole treatment for restless legs syndrome.
Fornadi, K; Molnar, MZ; Shapiro, CM, 2006
)
2.5
"Ropinirole has been studied for treatment of moderate to severe primary RLS in a comprehensive clinical development program. "( Ropinirole treatment for restless legs syndrome.
Bogan, RK, 2008
)
3.23
"Ropinirole has beneficial adjuvant effects in parkinsonian patients with moderate motor disability and motor fluctuations."( Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
Fuell, D; Lees, AJ; Montastruc, JL; Pirtosek, Z; Rascol, O; Senard, JM, 1996
)
2.46
"Ropinirole has demonstrated efficacy in two standard preclinical models of PD and has shown a very low propensity to induce dyskinesia in these studies."( Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
Tulloch, IF, 1997
)
1.32
"Ropinirole has a low potential to interact with other drugs likely to be administered to PD patients."( Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel, MD, 1999
)
2.47
"1. Ropinirole, SK&F 101468 has been characterized preclinically as a specific dopamine D2-receptor agonist. "( Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.
de Mey, C; Enterling, D; Meineke, I; Yeulet, S, 1991
)
1.18

Actions

ExcerptReferenceRelevance
"Ropinirole did not cause marked stereotypies."( Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
Costall, B; Domeney, AM; Eden, RJ; Gerrard, PA; Harvey, CA; Kelly, ME; Naylor, RJ; Owen, DA; Wright, A, 1991
)
1.3

Treatment

Ropinirole-SR adjunctive treatment showed a tendency towards more improvement in UPDRS-ADL score. Patients also had 14% less sleep disturbance and 8% less daytime somnolence than patients receiving placebo.

ExcerptReferenceRelevance
"Ropinirole treatment was also able to attenuate mitochondrial reactive oxygen species (ROS) production, as well as block the mitochondrial permeability transition pore (mPTP), in the tMCAO injury model."( Ropinirole induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in Wistar rats.
Andrabi, SS; Parveen, S; Parvez, S; Tabassum, H, 2020
)
2.72
"Ropinirole-SR adjunctive treatment showed a tendency towards more improvement in UPDRS-ADL score (MD 1.24; 95% CI 0.23, 2.24) than adjunctive treatment of pramipexole-ER."( Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Cooper, J; Ni, X; Ning, Y; Parks, D; Refoios Camejo, R; Yi, B; Zhao, H, 2019
)
1.55
"Ropinirole (1.5mg/kg) pretreatment with sub-effective dose of a Ceftriaxone (100mg/kg) had significantly enhanced the protective effect of Ceftriaxone as compare to its effect with per se group."( Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
Bisht, R; Gupta, H; Kaur, B; Prakash, A, 2014
)
1.12
"Ropinirole-treated patients also had 14% less sleep disturbance and 8% less daytime somnolence than patients receiving placebo."( Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials.
Calloway, MO; Gilsenan, AW; Hansen, RA; Kim, MM; Moore, CG; Murray, MD; Song, L, 2009
)
1.48
"Ropinirole treatment yielded a significant clinical improvement (mean UPDRS score subitem III 13.4 at baseline, 9.4 at follow-up; p < 0.001 at a paired t-test) which was combined with lower activation in the left parietal superior and inferior gyri and in right parietal and occipital superior gyri with respect to their baseline fMRI examination."( fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease.
Baldacci, F; Bonuccelli, U; Cecchi, P; Diciotti, S; Giannelli, M; Lucetti, C; Mascalchi, M; Tessa, C, 2013
)
1.32
"Ropinirole treatment significantly improved patients' ability to initiate sleep (P < .05) and the amount of Stage 2 sleep compared with placebo (P < .001)."( Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome.
Allen, R; Becker, PM; Bogan, R; Fry, JM; Kushida, CA; Poceta, JS; Schmidt, M; Winslow, D, 2004
)
2.49
"Ropinirole successfully treated long-standing RLS and can be considered a viable short-term treatment for this condition."( Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise, DL; Chakravorty, S; Freeman, A; Ingram, CD; Rye, DB; Watts, RL, 2005
)
2.01
"Ropinirole treatment was also associated with improvements in measures of sleep and quality of life."( A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.
Dom, R; Dreykluft, T; Garcia-Borreguero, D; Grunstein, R; Lainey, E; Montagna, P; Moorat, A; Roberts, J; Sridhar, G, 2007
)
1.31
"Ropinirole treatment was continued but some animals also received l-dopa BID or four times daily (QID) with and without entacapone or vehicle for a further 16 days."( The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M, 2007
)
1.06
"Ropinirole treatment was associated with rapid translocation and phosphorylation of the PI-3K substrate Akt and phosphorylation of Akt substrates."( Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses.
Nair, VD; Olanow, CW, 2008
)
1.07
"Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001)."( Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group.
Adler, CH; Bertoni, J; Davis, TL; Hammerstad, JP; Hauser, RA; O'Brien, CF; Sanchez-Ramos, J; Sethi, KD; Taylor, RL, 1997
)
2.46
"Ropinirole and levodopa treatments were similar in efficacy as measured by UPDRS ADL scores, although ropinirole recipients showed significantly less improvement on UPDRS motor scores at the 5-year study end-point in a multicentre, randomised double-blind trial."( Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson, AJ; Spencer, CM, 2000
)
2.47

Toxicity

In all the included studies, dopamine agonists, including ropinirole, exhibited a higher incidence of adverse events than placebo. In the group of patients with prior dopamine-agonist therapy, more patients reported adverse events in the roPinirole group (90% versus 79%, p < 0.1)

ExcerptReferenceRelevance
" In early therapy, the emergent adverse experiences more common with the ropinirole group compared with placebo were nausea, somnolence, leg edema, abdominal pain, vomiting, dyspepsia, and hallucinations."( The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Brooks, DJ; Brunt, E; Fuell, D; Korczyn, A; Poewe, W; Quinn, NP; Rascol, O; Schrag, AE; Stocchi, F,
)
0.72
" There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug."( Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan, M; Gill, S; Samii, A, 2003
)
0.56
"To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature."( Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan, M; Gill, S; Samii, A, 2003
)
0.81
" In the first analysis, we estimated the pooled relative risk (RR) of adverse events with either pramipexole or ropinirole as compared with levodopa."( Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan, M; Gill, S; Samii, A, 2003
)
0.77
"3%) reported > or = 1 adverse event."( A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.
Dom, R; Dreykluft, T; Garcia-Borreguero, D; Grunstein, R; Lainey, E; Montagna, P; Moorat, A; Roberts, J; Sridhar, G, 2007
)
0.59
" In order to minimize the adverse events of the dopamine agonists, the dose of these drugs should be titrated."( [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease].
Chacon, J, 2007
)
0.34
" Treatments were divided between standard and non-standard schemes and a single branch meta-analysis of the most relevant adverse events was performed."( [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease].
Chacon, J, 2007
)
0.34
"When using the non-standard treatment scheme, the only adverse event whose incidence increases significantly is dizziness."( [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease].
Chacon, J, 2007
)
0.34
"To determine whether adding orally disintegrating selegiline (ODS) while decreasing dopamine agonist (DA) dosages would reduce DA-related adverse effects (AEs) of excessive daytime sleepiness (EDS), pedal edema, hallucinations, and impulse control disorders (ICDs) without compromising efficacy in Parkinson disease (PD) patients."( Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Elmer, LW; Friedman, JH; Hauser, RA; Hermanowicz, N; Hersh, BP; Isaacson, SH; Lew, MF; Lyons, KE; Pahwa, R; Parashos, SA; Silver, DE; Struck, LK; Tetrud, JW,
)
0.13
" The Cochrane Collaboration guidelines were followed and the following data were extracted from each study: identifier (title and bibliographical reference), classification of the quality of the evidence (Jadad criteria), type and design of the study, number of patients, patient demographics (average age, sex), Parkinson's disease stage (Hoehn and Yahr Scale), treatment (monotherapy or adjuvant to levodopa), drugs used (including dosage and duration), study objective (safety or tolerability), method of evaluation of results, randomization and blinding, and description of all the adverse events in all treatment groups."( Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky, J; Pagonabarraga, J, 2010
)
0.66
"In all the included studies, dopamine agonists, including ropinirole, exhibited a higher incidence of adverse events than placebo."( Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky, J; Pagonabarraga, J, 2010
)
0.9
" The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole, ropinirole, and rasagiline."( Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
Tarrants, ML; Zagmutt, FJ, 2012
)
0.79
" The most frequent adverse event experienced in the ropinirole PR group was dyskinesia."( The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
Cai, M; Cao, H; Chen, S; Cheng, Y; Li, J; Liu, C; Qu, Q; Wang, J; Wang, Z; Zhang, B; Zhang, X; Zhang, Z; Zhu, R, 2013
)
0.94
" The adverse events observed were consistent with the established safety profile of ropinirole, with no new safety signal identified."( The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
Cai, M; Cao, H; Chen, S; Cheng, Y; Li, J; Liu, C; Qu, Q; Wang, J; Wang, Z; Zhang, B; Zhang, X; Zhang, Z; Zhu, R, 2013
)
0.91
" The safety was assessed on the basis of adverse events, blood pressure, pulse, laboratory measurement and electrocardiographic recordings."( [Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial].
Chen, HB; Li, SH; Ma, J; Sun, XR; Tang, RH; Wang, ZF; Yang, JS; Zhang, XY; Zhao, WQ, 2013
)
0.7
" The adverse events occurring at a ratio of over 5% caused by ropinirole included orthostatic hypotension, nausea, dizziness, upper abdominal discomfort, insomnia and palpitation."( [Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial].
Chen, HB; Li, SH; Ma, J; Sun, XR; Tang, RH; Wang, ZF; Yang, JS; Zhang, XY; Zhao, WQ, 2013
)
0.94
"Ropinirole is both effective and safe in the treatment of Chinese patients with Parkinson's disease."( [Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial].
Chen, HB; Li, SH; Ma, J; Sun, XR; Tang, RH; Wang, ZF; Yang, JS; Zhang, XY; Zhao, WQ, 2013
)
2.14
" However, long-acting NEDA were also associated with a higher incidence of adverse events, especially in early PD patients, compared with placebo."( Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
Peng, GG; Wang, M; Zhang, JW; Zhou, CQ, 2014
)
0.4
" Safety outcomes that were investigated included frequency of adverse events (AEs)."( Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Asgharian, A; Ellis, J; Jimenez, T; Makumi, CW; Shaikh, S; VanMeter, S, 2016
)
0.69
" Safety assessments included monitoring adverse events (AEs), neurological examination, Gambling Symptom Assessment Scale questionnaire, liver chemistry, and laboratory tests."( An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease.
Cai, M; Chen, S; Cheng, Y; Hu, J; Li, J; Liu, C; Qu, Q; Wang, J; Wang, Z; Zhang, B; Zhang, X; Zhang, Z; Zhu, R, 2015
)
0.66
"It is necessary to conduct a meta-analysis of the clinical randomized controlled trials (RCTs) on ropinirole in the treatment of Parkinson disease (PD), to explore the effects and safety of ropinirole, and to provide a theoretical basis for clinically safe and rational drug use."( The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis.
Chen, M; Zhu, J, 2021
)
1.14
"Ropinirole can help improve the ability of daily living and exercise function of PD patients, but it will increase the incidence of related adverse reactions, which needs to be further confirmed by subsequent large-scale, high-quality RCTs."( The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis.
Chen, M; Zhu, J, 2021
)
2.37

Pharmacokinetics

Study of pharmacokinetic parameters (AUC, C(max), and T(max) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel. Ropinirole shows approximately linear pharmacokinetics when given as single or repeated doses.

ExcerptReferenceRelevance
" The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food."( Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
Brefel, C; Bullman, S; Citerone, DR; Fitzpatrick, K; Lopez-Gil, A; Montastruc, JL; Rascol, O; Rayet, S; Taylor, AC; Thalamas, C, 1998
)
0.84
"This was an open, randomized, two sessions cross over study in 12 patients with Parkinson's disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: 'fasted' and 'fed'."( Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
Brefel, C; Bullman, S; Citerone, DR; Fitzpatrick, K; Lopez-Gil, A; Montastruc, JL; Rascol, O; Rayet, S; Taylor, AC; Thalamas, C, 1998
)
0.76
"The mean Cmax was lower in the 'fed' regimen than in the 'fasted' one (-25%, P=0."( Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
Brefel, C; Bullman, S; Citerone, DR; Fitzpatrick, K; Lopez-Gil, A; Montastruc, JL; Rascol, O; Rayet, S; Taylor, AC; Thalamas, C, 1998
)
0.56
"Thirty patients with Parkinson's disease not previously treated with dopamine agonists, of whom 28 produced evaluable pharmacokinetic data for ropinirole and 23 for L-dopa."( Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Beerahee, A; Burns, E; Citerone, DR; Cyronak, MJ; Fitzpatrick, KL; Leigh, TJ; Lennox, G; Lopez-Gil, A; Taylor, AC; Vakil, SD, 1999
)
0.74
"Primary end points were AUC0-8 and Cmax for ropinirole, and AUC0-8, AUC0-infinity and Cmax for L-dopa."( Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Beerahee, A; Burns, E; Citerone, DR; Cyronak, MJ; Fitzpatrick, KL; Leigh, TJ; Lennox, G; Lopez-Gil, A; Taylor, AC; Vakil, SD, 1999
)
0.81
"There are no pharmacokinetic grounds for adjusting dosages of either ropinirole or L-dopa when given in combination."( Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Beerahee, A; Burns, E; Citerone, DR; Cyronak, MJ; Fitzpatrick, KL; Leigh, TJ; Lennox, G; Lopez-Gil, A; Taylor, AC; Vakil, SD, 1999
)
0.78
" The parameters AUC, Cmax and tmax for ropinirole were compared before, during and after oral theophylline co-treatment."( Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
Brefel-Courbon, C; Eagle, S; Fitzpatrick, K; Rascol, O; Taylor, A; Thalamas, C, 1999
)
0.83
"0 microg x h(-1) x ml(-1), respectively: mean Cmax with and without ropinirole: 11."( Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
Brefel-Courbon, C; Eagle, S; Fitzpatrick, K; Rascol, O; Taylor, A; Thalamas, C, 1999
)
0.8
"These results suggest a lack of significant pharmacokinetic interaction between the two drugs at current therapeutic doses."( Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease.
Brefel-Courbon, C; Eagle, S; Fitzpatrick, K; Rascol, O; Taylor, A; Thalamas, C, 1999
)
0.56
" Ropinirole shows approximately linear pharmacokinetics when given as single or repeated doses, and is eliminated with a half-life of approximately 6 hours."( Clinical pharmacokinetics of ropinirole.
Kaye, CM; Nicholls, B, 2000
)
1.51
"This review describes the pharmacologic and pharmacokinetic properties of selected DAs and relates these characteristics to clinical outcomes, with an emphasis on adverse events."( A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Burger, E; Härtter, S; Kvernmo, T, 2006
)
0.33
" Pharmacokinetic parameters were calculated for both treatments."( The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.
Bi, LL; Chen, XY; Jia, YY; Luo, XX; Wen, AD; Zhong, DF, 2007
)
0.59
" Intensive pharmacokinetic blood sampling was performed over 24 hours."( Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson, DJ; Vearer, D, 2007
)
0.56
" Statistical analysis indicated that the dose strengths were equivalent when a single pharmacokinetic outlier was excluded from the analysis."( Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson, DJ; Vearer, D, 2007
)
0.56
" Sparse blood samples were collected for pharmacokinetic evaluations through population analysis."( Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Oliver-Willwong, R; Tompson, D,
)
0.38
" This novel method has been applied to a pharmacokinetic study of RPR in humans."( Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study.
Bharathi, DV; Hotha, KK; Jagadeesh, B; Kumar, SS; Lakshmi, RN; Mullangi, R; Naidu, A, 2009
)
0.61
" Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor)."( Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012
)
0.84
" In vivo pharmacodynamic studies were executed to compare therapeutic efficacy of prepared nasal PLN formulation against marketed oral formulation of same drug."( Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation.
Belgamwar, VS; Pardeshi, CV; Surana, SJ; Tekade, AR, 2013
)
0.61

Compound-Compound Interactions

ExcerptReferenceRelevance
" This was combined with two different doses of fluoxetine (10 and 20 mg/kg)."( Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats.
Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011
)
0.64
" Therefore, the present study was designed to evaluate the neuroprotective effect of quercetin in combination with piperine against rotenone- and iron supplement-induced model of PD."( Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats.
Raj, K; Sharma, S; Singh, S, 2020
)
0.56

Bioavailability

Ropinirole hydrochloride (RH) is an anti-Parkinson drug with relativity low oral bioavailability owing to its extensive hepatic first pass metabolism. Upon buccal/sublingual administration of the oral films, ropinirole reached the systemic circulation within 15’min.

ExcerptReferenceRelevance
" On the basis of relative cumulative urinary recoveries of radiolabeled drug, all three compounds are well absorbed in rats and dogs."( Pharmacokinetics of dopamine-2 agonists in rats and dogs.
DeMarinis, RM; Mico, BA; Swagzdis, JE; Wittendorf, RW, 1986
)
0.27
"Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption."( Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
Brefel, C; Bullman, S; Citerone, DR; Fitzpatrick, K; Lopez-Gil, A; Montastruc, JL; Rascol, O; Rayet, S; Taylor, AC; Thalamas, C, 1998
)
0.83
" The bioavailability is approximately 50%."( Clinical pharmacokinetics of ropinirole.
Kaye, CM; Nicholls, B, 2000
)
0.6
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" These relative bioavailability data indicated that patients may switch overnight from ropinirole immediate release to ropinirole 24-hour prolonged release while maintaining similar daily exposure."( Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson, DJ; Vearer, D, 2007
)
0.79
" Formulations were tested for gelation time, thermosensitivity, mucoadhesion, in vitro release and permeation, in vitro cytotoxicity, nasal clearance, in vivo bioavailability and brain uptake."( Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats.
Bobade, N; Gaikwad, R; Khan, S; Patil, K; Yeole, P, 2010
)
0.59
"Ropinirole, a recent introduction in the clinical treatment of Parkinson's disease, suffers with the problems of low oral bioavailability and frequent dosing."( Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012
)
2.07
"Ropinirole hydrochloride (RPN), a nonergot dopamine D2-agonist used in the management of Parkinson's disease, has poor oral bioavailability (52%) due to extensive hepatic metabolism."( Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: in-vitro-ex-vivo studies.
Patil, GB; Surana, SJ, 2013
)
2.04
" Intranasal drug administration may be useful for Parkinson's treatment because this route avoids first-pass metabolism and increases bioavailability in the brain."( Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
Chen, JC; Hsieh, YT; Kuo, YH; Lao, CL, 2013
)
0.39
" The absolute bioavailability of both drug loaded anionic and cationic NLCs in situ gels was enhanced compared to that of the intranasal solution (IN) of the drug with values of 44% and 77."( Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
Elshafeey, AH; Gabal, YM; Kamel, AO; Sammour, OA, 2014
)
0.4
" However, orally it undergoes degradation in gastrointestinal tract and extensive first pass metabolism, resulting in its poor and variable bioavailability of the commercially available oral tablets."( Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: ex vivo and in vivo evaluation.
Kalaria, DR; Kalia, YN; More, S; Patel, P; Patravale, VB; Pol, A, 2014
)
0.4
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" Upon buccal/sublingual administration of the oral films, ropinirole reached the systemic circulation within 15 min and bioavailability was significantly improved, which may be attributable to avoidance of first-pass metabolism via absorption through the oral cavity."( Orally-dissolving film for sublingual and buccal delivery of ropinirole.
Chow, SF; Fang, Y; Han, H; Lai, KL; Lam, TN; Lee, WYT; Li, HY; Li, Q; Zhang, S, 2018
)
0.97
"Ropinirole hydrochloride (RH) is an anti-Parkinson drug with relativity low oral bioavailability owing to its extensive hepatic first pass metabolism."( Spray-dried alginate microparticles for potential intranasal delivery of ropinirole hydrochloride: development, characterization and histopathological evaluation.
Ahmed, W; Albed Alhnan, M; Elhissi, A; Hussein, N; Ismael, A; Omer, H, 2020
)
2.23
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The drug's low bioavailability in brain however, limits its therapeutic efficacy."( Crafting ɣ-L-Glutamyl-l-Cysteine layered Human Serum Albumin-nanoconstructs for brain targeted delivery of ropinirole to attenuate cerebral ischemia/reperfusion injury via "3A approach".
Abdin, MZ; Ahmad, FJ; Ali, M; Beg, S; Fatima, S; Mishra, P; Parvez, S; Quadri, SN; Samim, M, 2022
)
0.93

Dosage Studied

There was no significant dose-response relationship between the ropinirole dosage and plasma AVP levels. Data were collected in a retrospective manner from 95 patients who were tracked over the course of their therapy.

ExcerptRelevanceReference
" There were no further relevant clinical events, and the postural responses at 200 and 360 min after dosing remained in general well maintained, with the exception of a slight reduction of standing systolic blood pressure."( Effects of the novel D2-dopaminergic agonist ropinirol on supine resting and stimulated circulatory and neuroendocrine variables in healthy volunteers.
Brendel, E; de Mey, C; Enterling, D; Meineke, I, 1990
)
0.28
" By using LC-MS-MS with the third quadrupole (Q3) set up in multiple ion detection (MID) mode, a number of metabolites were subsequently detected in the human urine and plasma samples despite very low dosing regimes."( Application of thermospray liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry for the identification of cynomolgus monkey and human metabolites of SK & F 101468, a dopamine D2 receptor agonist.
Beattie, IG; Blake, TJ, 1989
)
0.28
" Both drugs are relatively well-tolerated, with the exception of dyskinesias that require reduction of the levodopa dosage and occasional diarrhea."( New pharmacotherapy for Parkinson's disease.
Alldredge, BK; Aminoff, MJ; Bainbridge, JL; Dowling, GA; Gottwald, MD, 1997
)
0.3
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, dosage and administration, and formulary considerations of ropinirole are reviewed."( Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
Kuzel, MD, 1999
)
1.95
" Also, when given as adjunctive therapy with levodopa, they can allow the levodopa maintenance dosage to be reduced without loss of symptom control."( Clinical pharmacology of dopamine agonists.
Lam, YW, 2000
)
0.31
") produced an inverted-U dose-response curve in the percentage time spent in the open arms."( Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.
Costall, B; Domeney, AM; Gerrard, PA; Greener, M; Hagan, JJ; Hunter, AJ; Kelly, ME; Rogers, DC, 2000
)
0.62
"A randomised, double-blind trial in which 555 patients were assigned to three treatment groups according to the level of daily dosage of L-dopa, presence of motor fluctuations, and use of dopamine agonist before study entry."( A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
Brooks, DJ; Brunt, ER; Korczyn, AD; Montastruc, JL; Stocchi, F, 2002
)
0.53
" The main risk factor associated with pathologic daytime sleep latency was high levodopa dosage equivalents (>867."( Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Lang, AE; Razmy, A; Shapiro, CM, 2004
)
0.32
" Physicians concerned with daytime hypersomnolence in PD patients treated with dopamine agonists and receiving high levodopa dosage equivalents should consider polysomnographic monitoring for impaired daytime sleep latency."( Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Lang, AE; Razmy, A; Shapiro, CM, 2004
)
0.32
" The dosage of ropinirole needed to treat the symptoms of restless legs syndrome appears to be much smaller than what is necessary for Parkinson's disease therapy."( Ropinirole in the treatment of restless legs syndrome.
Kakar, RS; Kushida, CA, 2005
)
2.12
" Tolerability was monitored with the Dosage Record Treatment Emergent Symptom Scale."( Ropinirole in treatment-resistant depression: a 16-week pilot study.
Abelli, M; Battistini, G; Cassano, GB; Cassano, P; Fava, M; Lattanzi, L; Navari, S, 2005
)
1.77
" The dosage of L-dopa could be reduced in 31% of the patients."( [Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study].
Angersbach, D; Buchwald, B; Reichmann, H, 2005
)
0.54
" Given the linear dose-response relation it presents, the drug has a wide "therapeutic window" that allows the dosage to be increased as the disease progresses."( [Ropinirole in the treatment of Parkinson's disease: an update].
Vivancos-Matellano, F,
)
1.04
") produced S-shaped dose-response curve in the percentage decrease in immobility period."( Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
Dhir, A; Kulkarni, SK, 2007
)
0.55
" Steady-state C(max), C(min), AUC from time zero to 24 hours after dosing (AUC(0-24)), and T(max) were determined by noncompartmental methods."( Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson, DJ; Vearer, D, 2007
)
0.56
" D(2)-like receptor activation produced an inverted "U"-shaped dose-response curve on plasticity for facilitatory tDCS and PAS and for inhibitory tDCS."( Dose-dependent inverted U-shaped effect of dopamine (D2-like) receptor activation on focal and nonfocal plasticity in humans.
Kuo, MF; Liebetanz, D; Monte-Silva, K; Nitsche, MA; Paulus, W; Thirugnanasambandam, N, 2009
)
0.35
" Several potential advantages of ropinirole prolonged release compared to the immediate release formulation include maintaining more consistent dopaminergic activity with steadier plasma levels, increased tolerability, greater compliance from a simpler once-daily dosing regimen and ease in dose titration."( A review of ropinirole prolonged release in Parkinson's disease.
Lyons, KE; Nashatizadeh, MM; Pahwa, R, 2009
)
1.01
" Data were collected in a retrospective manner from 95 patients who were tracked over the course of their therapy to determine whether psychosis or associated behavioral symptoms developed as a result and whether an intervention was needed to adjust ropinirole dosing or if additional medications had to be added to control features associated with psychosis."( An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Carver, LJ; Dahmen, MM; Lea, JW; Makos, M; Rasu, RS; Stoner, SC, 2009
)
0.8
" The Cochrane Collaboration guidelines were followed and the following data were extracted from each study: identifier (title and bibliographical reference), classification of the quality of the evidence (Jadad criteria), type and design of the study, number of patients, patient demographics (average age, sex), Parkinson's disease stage (Hoehn and Yahr Scale), treatment (monotherapy or adjuvant to levodopa), drugs used (including dosage and duration), study objective (safety or tolerability), method of evaluation of results, randomization and blinding, and description of all the adverse events in all treatment groups."( Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky, J; Pagonabarraga, J, 2010
)
0.66
" Visits were scheduled at screening, baseline, and weeks 1, 4, and 12 with additional telephone contacts for dosing decisions."( Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.
Banik, N; Benes, H; Bergmann, L; Dreykluft, T; Hansen, C; Hornyak, M; Kohnen, R; Mattern, W; Peglau, I; Schoen, SW, 2011
)
1.81
" Despite dosing differences, the PR titration regimen was generally well tolerated, with an AE profile similar to that of IR."( PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.
Giorgi, L; Hunter, B; Schapira, AH; Stocchi, F, 2011
)
0.62
" One patient required a dosage reduction of ropinirole because of sleepiness and one patient assigned to aripiprazole who reported moderate akathysia had the dosage reduced to 5 mg/day."( Aripiprazole and ropinirole treatment for cocaine dependence: evidence from a pilot study.
Ameglio, M; Biasci, L; Cecconi, D; Cellesi, V; Forgione, RN; Meini, M; Moncini, M; Pellegrini, M; Rucci, P; Simoni, G, 2011
)
0.97
" Effects of escalating ropinirole dosage on plasma AVP levels were evaluated using a one-way analysis of variance for repeated measures, an a priori Dunnett multiple comparison test, and a regression analysis."( Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Arai, M, 2012
)
2.13
" There was no statistically significant dose-response relationship between the ropinirole dosage and plasma AVP levels."( Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Arai, M, 2012
)
2.05
"A minimal therapeutic dosage of ropinirole did not affect plasma AVP levels in patients with PD taking levodopa."( Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Arai, M, 2012
)
2.11
" However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals."( Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease.
Jeon, BS; Kim, HJ; Kim, JM; Kim, JS; Kim, YE; Lee, JY; Yun, JY, 2013
)
0.63
" Subjects were consecutively enrolled into either once-daily first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for 8 weeks respectively in a crossover manner without a washout period."( Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease.
Jeon, BS; Kim, HJ; Kim, JM; Kim, JS; Kim, YE; Lee, JY; Yun, JY, 2013
)
0.63
" PGI-improvement on wearing off defined was better in twice-daily dosing regimen."( Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease.
Jeon, BS; Kim, HJ; Kim, JM; Kim, JS; Kim, YE; Lee, JY; Yun, JY, 2013
)
0.63
"RPR is a once-daily formulation, but multiple dosing was preferred in many patients."( Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease.
Jeon, BS; Kim, HJ; Kim, JM; Kim, JS; Kim, YE; Lee, JY; Yun, JY, 2013
)
0.63
" It may be related with using a similar dosage of dopaminergic drugs."( Augmentation in restless legs syndrome patients in Korea.
Cho, YW; Jeon, JY; Lee, HB; Moon, HJ; Song, ML, 2015
)
0.42
" Both patients exhibited the clinical features of serotonin syndrome, coinciding with an increase in dosage of each drug."( Serotonin syndrome in stroke patients.
Chang, MC; Jang, SH; Kwon, YM, 2015
)
0.42
" Long-term treatment with ropinirole XL/PR was not associated with any new or unexpected safety concerns in patients with early and advanced PD, and a majority of subjects preferred the once-daily dosing regimen."( Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Asgharian, A; Ellis, J; Jimenez, T; Makumi, CW; Shaikh, S; VanMeter, S, 2016
)
0.99
" In early PD, this may avoid dose escalation or allow a reduction in dopamine agonist dosage without a loss of efficacy and prevent dopaminergic side-effects from becoming treatment limiting."( The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Okita, E; Soshiroda, K; Uchida, S, 2015
)
0.42
" Dosage of levodopa and oral DA (pramipexole ≤1."( Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Bauer, L; Chung, SJ; Ikeda, J; Jeon, BS; Kim, JM; Kim, JW; Singh, P; Thierfelder, S, 2015
)
0.42
"This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR)."( A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.
Chriscoe, S; Jimenez, T; Upward, J; VanMeter, S; Zesiewicz, TA, 2017
)
0.93
"This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR) in subjects with advanced Parkinson's disease."( A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease.
Chriscoe, S; Davy, M; Jimenez, T; Upward, J; VanMeter, S; Zesiewicz, TA, 2017
)
0.91
" This work hypothesizes that suitable solvent based ink formulations can be developed that allow the production of solid dosage forms that meet the standards required for pharmaceutical tablets, whilst offering a platform for flexible and personalized manufacture."( 3D printing of tablets using inkjet with UV photoinitiation.
Alexander, MR; Clark, EA; Hague, RJM; Irvine, DJ; Roberts, CJ; Sharpe, S; Tuck, CJ; Wallace, MJ; Wildman, RD; Yoo, J, 2017
)
0.46
" Indeed, taking this drug in solid oral dosage forms (e."( Orally-dissolving film for sublingual and buccal delivery of ropinirole.
Chow, SF; Fang, Y; Han, H; Lai, KL; Lam, TN; Lee, WYT; Li, HY; Li, Q; Zhang, S, 2018
)
0.72
" We extracted data including dosing schedule and the proportion of patients reporting nausea and/or vomiting."( Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis.
Bielefeldt, K; Kurin, M; Levinthal, DJ, 2018
)
0.73
"Five female subjects with prolactinomas participated in this dose-response study."( Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas.
Bies, R; Cremers, S; Hu, C; Liu, S; Page-Wilson, G; Peters, J; Tsang, A, 2019
)
0.78
"75]) taking one of three types of non-ergot extended-release DAs (rotigotine 32; pramipexole 44; ropinirole 36) with or without L-dopa (median daily total dosage of antiparkinsonian drugs 525."( Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Ando, H; Doyu, M; Fujikake, A; Fukuoka, T; Hayashi, M; Ito, C; Izumi, M; Kawagashira, Y; Koide, H; Nakashima, K; Niwa, JI; Ogawa, K; Oiwa, H; Okada, Y; Taguchi, S; Tokui, K; Tsunoda, Y; Yasumoto, A; Yuasa, T, 2021
)
0.84
"For the whole PD patient cohort, the PDSS-2 sleep disturbance domain score and the scores for item 1 assessing sleep quality and item 8 assessing nocturia were positively correlated with daily total dosage of antiparkinsonian drugs and dosage of L-dopa, but not with the dosage of DAs."( Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Ando, H; Doyu, M; Fujikake, A; Fukuoka, T; Hayashi, M; Ito, C; Izumi, M; Kawagashira, Y; Koide, H; Nakashima, K; Niwa, JI; Ogawa, K; Oiwa, H; Okada, Y; Taguchi, S; Tokui, K; Tsunoda, Y; Yasumoto, A; Yuasa, T, 2021
)
0.62
" Thus, adjusting both the total dosage of antiparkinsonian drugs and the dose-ratio of L-dopa might be key actions for alleviating poor sleep quality in patients with PD."( Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Ando, H; Doyu, M; Fujikake, A; Fukuoka, T; Hayashi, M; Ito, C; Izumi, M; Kawagashira, Y; Koide, H; Nakashima, K; Niwa, JI; Ogawa, K; Oiwa, H; Okada, Y; Taguchi, S; Tokui, K; Tsunoda, Y; Yasumoto, A; Yuasa, T, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
dopamine agonistA drug that binds to and activates dopamine receptors.
antiparkinson drugA drug used in the treatment of Parkinson's disease.
central nervous system drugA class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system.
antidyskinesia agentAny compound which can be used to treat or alleviate the symptoms of dyskinesia.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
indolones
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.00700.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.48520.000229.305416,493.5996AID743069
cytochrome P450 2D6Homo sapiens (human)Potency2.75400.00108.379861.1304AID1645840
arylsulfatase AHomo sapiens (human)Potency6.74561.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.16230.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency39.81070.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency28.18380.01789.637444.6684AID588834
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency29.93490.133725.412989.1251AID588795
gemininHomo sapiens (human)Potency0.18840.004611.374133.4983AID624296
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.31620.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency15.95410.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.31621.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki1.70600.00010.532610.0000AID4447
D(2) dopamine receptorHomo sapiens (human)Ki0.34950.00000.651810.0000AID353684; AID63977
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.02930.00010.25675.8000AID513739; AID750046
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)6.81000.00100.79948.0000AID62165
D(3) dopamine receptorHomo sapiens (human)Ki0.03880.00000.602010.0000AID353683; AID65774; AID773370
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki2.67400.00000.437510.0000AID513738; AID750047
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)0.19110.00000.18743.9000AID1189844; AID1340444; AID1448003; AID1448005; AID1448008; AID1464184; AID1464186; AID310686; AID446400; AID461562; AID513741; AID62577
D(1A) dopamine receptorHomo sapiens (human)EC50 (µMol)0.10000.00020.47959.5000AID62577
D(4) dopamine receptorHomo sapiens (human)EC50 (µMol)0.10000.00140.08892.2300AID62577
D(1B) dopamine receptorHomo sapiens (human)EC50 (µMol)0.10000.00140.04100.1000AID62577
5-hydroxytryptamine receptor 2AHomo sapiens (human)EC50 (µMol)0.14120.00000.22763.4750AID1340445
D(3) dopamine receptorHomo sapiens (human)EC50 (µMol)0.04060.00010.02470.6690AID310687; AID446402; AID461563; AID513742; AID62577
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (195)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1B) dopamine receptorHomo sapiens (human)
response to amphetamineD(1B) dopamine receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinD(1B) dopamine receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureD(1B) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(1B) dopamine receptorHomo sapiens (human)
associative learningD(1B) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1B) dopamine receptorHomo sapiens (human)
negative regulation of NAD(P)H oxidase activityD(1B) dopamine receptorHomo sapiens (human)
wound healingD(1B) dopamine receptorHomo sapiens (human)
response to cocaineD(1B) dopamine receptorHomo sapiens (human)
positive regulation of adenylate cyclase activityD(1B) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(1B) dopamine receptorHomo sapiens (human)
regulation of female receptivityD(1B) dopamine receptorHomo sapiens (human)
sensitizationD(1B) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1B) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1B) dopamine receptorHomo sapiens (human)
reactive oxygen species metabolic processD(1B) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1B) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1B) dopamine receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1B) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1B) dopamine receptorHomo sapiens (human)
protein bindingD(1B) dopamine receptorHomo sapiens (human)
dopamine bindingD(1B) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1B) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
ciliumD(1B) dopamine receptorHomo sapiens (human)
brush border membraneD(1B) dopamine receptorHomo sapiens (human)
synapseD(1B) dopamine receptorHomo sapiens (human)
ciliary membraneD(1B) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1B) dopamine receptorHomo sapiens (human)
plasma membraneD(1B) dopamine receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (132)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1189844Agonist activity at human dopamine D2L receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID65774Binding affinity towards Dopamine receptor D3 by displacement of [3H](+)-7-OH-DPAT.1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID750046Displacement of [3H]spiperone from rat cloned dopamine D3 receptor expressed in HEK293 cells after 1 hr2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
AID63977Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID461574Effect on behavioral activity in 6-OHDA-induced unilateral lesion Sprague-Dawley rat model assessed as turning behavior at 5 umol/kg, sc measured for 11 hrs2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID446403Agonist activity at human dopamine D3 receptor expressed in mouse AtT-20 cells assessed as stimulation of [35S]GTPgamma binding relative to 100 uM dopamine2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID1189843Inhibition of human adenosine A2A receptor expressed in FlpIn-CHO cells assessed as inhibition of NECA-induced cAMP accumulation incubated for 30 mins by fluorescence assay2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID1630282Reversal of reserpine-induced hypolocomotion in Sprague-Dawley rat assessed as locomotor stimulation at 10 umol/kg, ip administered 18 hrs post reserpine challenge measured over 6 hrs
AID513744Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID446404Selectivity index, ratio of EC50 for human dopamine D2L receptor to EC50 for human dopamine D3 receptor by [35S]GTPgamma binding assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID446583Induction of rotational activity in 6-OHDA induced unilaterally lesioned Sprague-Dawley rat Parkinson's disease model assessed as duration of action at 5 umol/kg, sc2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID461564Agonist activity at human dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to dopamine2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID513739Displacement of [3H]spiperone from rat D3 receptor expressed in HEK293 cells2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID513742Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1075440Antiparkinsonian activity in Sprague-Dawley rat assessed as reversal of reserpine-induced akinesia at 5 umol/kg, sc administered in deionized water measured up to 400 mins2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.
AID353684Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.
AID446402Agonist activity at human dopamine D3 receptor expressed in mouse AtT-20 cells assessed as stimulation of [35S]GTPgamma binding2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID353683Displacement of [3H]spiperone form human cloned dopamine D3 receptor expressed in CHO cells2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.
AID1448004Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay relative to quinpirole2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID446401Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgamma binding relative to 1 mM dopamine2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID446407Induction of rotational activity in 6-OHDA induced unilaterally lesioned Sprague-Dawley rat Parkinson's disease model assessed as duration of action at 10 umol/kg, sc2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID513738Displacement of [3H]spiperone from rat D2 receptor expressed in HEK293 cells2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID461562Agonist activity at human dopamine D2 receptor expressed in CHO cells by [35S]GTPgammaS binding assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID513743Selectivity ratio of EC50 for human dopamine D2 receptor to EC50 for human dopamine D3 receptor2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID1448009Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay relative to quinpirole2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID310688Selectivity for human dopamine D3 receptor over human dopamine D2 receptor2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
AID1448003Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID1464186Agonist activity at human D2SR expressed in HEK293 cell membranes co-expressing PTX insensitive variant of Galphao1 incubated for 30 mins by [35S]GTP-gammaS binding assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID513740Selectivity ratio for Ki for rat D2 receptor to Ki for rat D3 receptor2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID461563Agonist activity at human dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID750039Selectivity ratio for human recombinant dopamine D2 receptor to human recombinant dopamine D3 receptor2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
AID513741Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1075443Antioxidant activity assessed as inhibition of DPPH free radical scavenging activity2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.
AID353685Selectivity ratio of Ki for human dopamine D2 receptor to Ki for human dopamine D3 receptor2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors.
AID4447Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID1576365Solubility of the compound in water2019MedChemComm, Nov-01, Volume: 10, Issue:11
Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1448005Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [35S]GTPgammaS binding 2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID773370Agonist activity at dopamine D3 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and binding affinity of new 1,4-disubstituted triazoles as potential dopamine D(3) receptor ligands.
AID62577Inhibitory activity against constrictor response to electrical stimulation in the isolated perfused rabbit ear artery(REA) expressing dopamine receptor1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist.
AID446406Reversal of reserpine-induced hypolocomotion in Sprague-Dawley rat Parkinson's disease model at 10 umol/kg, sc measured after 6 hrs administered 18 hrs after reserpine challenge2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID310686Agonist activity at human recombinant dopamine D2 receptor expressed in rat pituitary cells assessed as inhibition of forskolin-stimulated cAMP accumulation2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
AID1448008Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID62165Displacement of [3H]spiroperidol from homogenized bovine pituitary Dopamine receptor D21987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID446400Agonist activity at human dopamine D2L receptor expressed in CHO cells assessed as stimulation of [35S]GTPgamma binding2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
AID1464189Bias factor, ratio of agonist activity at human D2SR expressed in HEK293 cell membranes co-expressing PTX insensitive variant by [35S]GTP-gammaS binding assay to human D2SR expressed in HEK293 cells by by beta-Arrestin 2 recruitment assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID461565Agonist activity at human dopamine D3 receptor expressed in CHO cells by [35S]GTPgammaS binding assay relative to dopamine2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID1464185Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay relative to quinpirole2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID513745Agonist activity at human dopamine D3 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to dopamine2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.
AID167710Ability to stimulate peripheral prejunctional dopaminergic receptors by 50% inhibition of vasoconstrictor response to field stimulation in isolated perfused rabbit ear artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Syntheses and in vitro evaluation of 4-(2-aminoethyl)-2(3H)-indolones and related compounds as peripheral prejunctional dopamine receptor agonists.
AID1448006Agonist activity at human D2S receptor expressed in HEK293T cell membranes coexpressing Galphao1 assessed as induction of nucleotide exchange at 0.1 pM to 100 uM preincubated for 30 mins followed by addition of [35S]GTPgammaS measured after 30 mins by [352017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1464184Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID461566Selectivity ratio of EC50 for human dopamine D2 receptor to EC50 for human dopamine D3 receptor2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
AID773369Selectivity ratio of Ki for dopamine D2 receptor (unknown origin) to Ki for dopamine D3 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and binding affinity of new 1,4-disubstituted triazoles as potential dopamine D(3) receptor ligands.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID750045Selectivity ratio of Ki for rat cloned dopamine D2L receptor to Ki for rat cloned dopamine D3 receptor2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
AID310687Agonist activity at human recombinant dopamine D3 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
AID1075432Antiparkinsonian activity in 6-OHDA-lesioned Sprague-Dawley rat assessed as stimulation of rotational activity at 10 umol/kg measured up to 12 hrs2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.
AID1189845Agonist activity at human dopamine D2L receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay relative to 100 uM quinelorane2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID1464187Agonist activity at human D2SR expressed in HEK293 cell membranes co-expressing PTX insensitive variant of Galphao1 incubated for 30 mins by [35S]GTP-gammaS binding assay relative to quinpirole2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation.
AID167274Ability to relax the electrically stimulated rabbit ear artery was determined1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID750047Displacement of [3H]spiperone from rat cloned dopamine D2L receptor expressed in HEK293 cells after 1 hr2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1345833Human D3 receptor (Dopamine receptors)1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID1345788Human D2 receptor (Dopamine receptors)1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (600)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (1.50)18.7374
1990's59 (9.83)18.2507
2000's256 (42.67)29.6817
2010's233 (38.83)24.3611
2020's43 (7.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 104.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index104.08 (24.57)
Research Supply Index6.64 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index189.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (104.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials129 (20.25%)5.53%
Reviews105 (16.48%)6.00%
Case Studies80 (12.56%)4.05%
Observational2 (0.31%)0.25%
Other321 (50.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (61)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda [NCT01371682]Phase 150 participants (Actual)Interventional2009-09-18Completed
An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa [NCT03250117]Phase 1/Phase 26 participants (Actual)Interventional2017-10-10Terminated(stopped due to This study was terminated for reasons not related to efficacy or safety)
A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Pati [NCT00256854]Phase 3135 participants (Actual)Interventional2005-11-14Completed
A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Sev [NCT00329602]Phase 4404 participants (Actual)Interventional2006-03-31Completed
Gait Pattern Analysis in Neurological Disease [NCT02994719]120 participants (Anticipated)Observational2016-03-01Active, not recruiting
Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis [NCT03176966]Phase 431 participants (Actual)Interventional2016-09-02Completed
The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fasting Conditions. [NCT00829504]Phase 144 participants (Actual)Interventional2004-10-31Completed
An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease [NCT00986245]Phase 482 participants (Actual)Interventional2009-09-30Completed
Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafil [NCT00996944]Phase 234 participants (Actual)Interventional2009-11-30Terminated(stopped due to Because GSK concluded that it was impossible to recruit sufficient participants within a reasonable timeframe.)
Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory [NCT00530790]Phase 235 participants (Actual)Interventional2007-08-23Completed
Randomized, Placebo-controlled, Double-blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke [NCT00221390]Phase 252 participants (Anticipated)Interventional2003-10-31Completed
A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions [NCT00674310]29 participants (Actual)Interventional2004-02-29Completed
Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists [NCT01007864]Phase 380 participants (Actual)Interventional2010-01-31Completed
Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type [NCT00639119]Phase 216 participants (Anticipated)Interventional2007-08-31Enrolling by invitation
Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease [NCT00823836]Phase 3302 participants (Actual)Interventional2009-03-31Completed
101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164 [NCT00650104]Phase 376 participants (Actual)Interventional2002-05-31Completed
A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany [NCT00357097]Phase 3240 participants (Actual)Interventional2006-06-30Completed
AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY [NCT01714856]Phase 112 participants (Actual)Interventional2008-09-30Completed
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study - [NCT00434304]Phase 262 participants (Actual)Interventional2007-04-09Completed
AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY [NCT01712568]Phase 112 participants (Actual)Interventional2008-09-30Completed
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stab [NCT00605683]Phase 3679 participants (Actual)Interventional2007-11-30Completed
A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS) [NCT00355641]Phase 3450 participants (Actual)Interventional2005-10-31Completed
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions [NCT00673088]30 participants (Actual)Interventional2004-02-29Completed
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa [NCT01154166]Phase 3347 participants (Actual)Interventional2010-02-15Completed
An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets. [NCT00460148]Phase 228 participants (Actual)Interventional2007-04-30Completed
An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information [NCT01327339]755 participants (Actual)Observational2006-04-01Completed
A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) Durin [NCT00373542]Phase 439 participants (Actual)Interventional2006-10-31Completed
An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628) [NCT00422994]Phase 148 participants (Actual)Interventional2006-04-30Completed
Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression [NCT00285727]60 participants Interventional2006-01-31Completed
An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease. [NCT00275275]Phase 361 participants (Actual)Interventional2006-01-31Completed
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder [NCT00314821]Phase 440 participants (Anticipated)Interventional2005-09-30Completed
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Synd [NCT00314860]Phase 3568 participants (Actual)Interventional2006-02-28Completed
Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants [NCT00334048]Phase 49 participants (Actual)Interventional2006-06-30Completed
A Study to Determine the Tolerability and Pharmacokinetics for Ropinirole in Paediatric / Adolescent Patients With RLS (Type 2) [NCT00140712]Phase 19 participants (Actual)Interventional2005-06-10Completed
An Open Label, Repeat Dose, Dose Escalation Study Conducted in RLS Patients to Characterize Pharmacokinetics and Food Effect of Ropinirole Controlled Release for RLS [NCT00419692]Phase 132 participants (Actual)Interventional2006-08-24Completed
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease. [NCT00036218]Phase 3600 participants Interventional2001-12-31Completed
A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome [NCT00197080]Phase 3380 participants Interventional2005-06-30Completed
A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS) [NCT00225862]Phase 3140 participants (Actual)Interventional2005-01-31Completed
A Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Efficacy of Controlled-release Ropinirole (CR) (1-24 mg) Administered Once Daily for 12 Weeks in Subjects With Fibromyalgia [NCT00256893]Phase 2164 participants Interventional2004-11-30Completed
Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease [NCT00260793]Phase 320 participants Interventional2005-11-30Recruiting
A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. [NCT00335205]Phase 460 participants Interventional2003-04-30Recruiting
Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole) 2 [NCT01627834]Phase 148 participants (Actual)Interventional2009-10-31Completed
Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole Hy [NCT01627847]Phase 148 participants (Actual)Interventional2009-10-31Completed
AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY [NCT01717235]Phase 112 participants (Actual)Interventional2008-09-30Completed
Effectiveness of Ropinirole and Gabapentin for the Treatment of Restless Legs Syndrom in Patients on Maintenance Hemodialysis: a Randomized, Blinded, Placebo-Controlled Trial [NCT03708237]Phase 23 participants (Actual)Interventional2019-02-19Terminated(stopped due to Recruitment suspended due to COVID-19 pandemic and will not resume.)
A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects [NCT01435915]Phase 124 participants (Actual)Interventional2010-06-28Completed
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability [NCT03038308]Phase 1/Phase 216 participants (Actual)Interventional2016-09-16Completed
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa [NCT00381472]Phase 3393 participants Interventional2003-06-30Completed
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease [NCT01485172]Phase 4186 participants (Actual)Interventional2012-01-31Completed
Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) [NCT00367822]Phase 3300 participants InterventionalCompleted
An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169 [NCT00632736]Phase 3419 participants (Actual)Interventional2004-02-29Completed
A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Pa [NCT00363727]Phase 3209 participants (Actual)Interventional2003-12-31Completed
A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are [NCT00331149]Phase 3343 participants (Actual)Interventional2006-06-20Completed
A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS) [NCT00363857]Phase 3360 participants (Actual)Interventional2003-08-31Completed
DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS Trial): A Randomized Controlled Trial [NCT03806530]Phase 352 participants (Actual)Interventional2019-05-01Completed
A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa [NCT01628926]Phase 3420 participants (Actual)Interventional2009-06-30Completed
A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease. [NCT01929317]Phase 381 participants (Actual)Interventional2013-08-28Terminated
Cognitive-enhancing DA Medications for Cocaine Dependence [NCT01393457]Phase 2119 participants (Actual)Interventional2011-06-30Completed
The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions [NCT00830219]Phase 146 participants (Actual)Interventional2004-11-30Completed
A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease [NCT01494532]Phase 4352 participants (Actual)Interventional2012-04-02Completed
An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528 [NCT01536574]Phase 3295 participants (Actual)Interventional2010-09-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00256854 (14) [back to overview]Number of Participants With pre-and One Week Post-conversion Values of Vital Signs of Potential Clinical Concern (PCC)
NCT00256854 (14) [back to overview]Change From Pre-conversion in International RLS (IRLS) Rating Scale Total Score to One Week Post-conversion
NCT00256854 (14) [back to overview]Change From Pre-conversion in Pulse Rate to One Week Post-conversion
NCT00256854 (14) [back to overview]Change From Pre-conversion in Systolic and Diastolic Orthostatic SBP and DBP to One Week Post-conversion
NCT00256854 (14) [back to overview]Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure
NCT00256854 (14) [back to overview]Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure
NCT00256854 (14) [back to overview]Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure
NCT00256854 (14) [back to overview]Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure
NCT00256854 (14) [back to overview]Number of Participants Discontinuing the Drug Due to AEs Post Conversion From Ropinirole IR to Ropinirole CR-RLS
NCT00256854 (14) [back to overview]Number of Participants With Adverse Events (AEs) Post-conversion From Ropinirole IR to Ropinirole CR Over Period
NCT00256854 (14) [back to overview]Number of Participants With Positive Scores (Improved) on Clinical Global Impression Improvement Scale (CGI-I) Pre-conversion and One Week Post-conversion
NCT00256854 (14) [back to overview]Number of Participants With pre-and One Week Post-conversion Values of Vital Signs of Potential Clinical Concern (PCC)
NCT00256854 (14) [back to overview]Number of Participants With pre-and One Week Post-conversion Values of Vital Signs of Potential Clinical Concern (PCC)
NCT00256854 (14) [back to overview]Number of Participants With SAEs and Severity of AEs
NCT00275275 (2) [back to overview]Number of Dose Adjustments
NCT00275275 (2) [back to overview]Adverse Effects Experienced
NCT00329602 (15) [back to overview]Post-hoc Analysis of Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26, Exploring the Impact of Center Group on Treatment Effect
NCT00329602 (15) [back to overview]Post-hoc Analysis of Percentage of Participants With a Score of Much/Very Much Improved on the Clinical Global Impression-Global Improvement (CGI-I) Scale at Weeks 12 and 26, Exploring the Impact of Center Group on Treatment Effect
NCT00329602 (15) [back to overview]Number of Participants Withdrawing Due to Lack of Efficacy During the First 26 Weeks of the Study
NCT00329602 (15) [back to overview]Mean Change From Baseline in the IRLS Rating Scale Total Score at Week 67
NCT00329602 (15) [back to overview]Median Time to First CGI-I Response of Much/Very Much Improved During the Double-blind Phase
NCT00329602 (15) [back to overview]Number of Participants Rated as Normal or Borderline Ill on the CGI Severity of Illness (CGI-S) Scale at Week 26
NCT00329602 (15) [back to overview]Number of Participants With a Score of Much/Very Much Improved on the CGI-I Scale at Week 67
NCT00329602 (15) [back to overview]Change From Baseline in Sleep Quantity, a Domain of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale, at Weeks 12 and 26
NCT00329602 (15) [back to overview]Change From Baseline in the Domains of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale at Weeks 12 and 26
NCT00329602 (15) [back to overview]Change From Baseline in the Domains of the MOS 36-item Short Form Health Survey (SF-36) at Weeks 12 and 26
NCT00329602 (15) [back to overview]Change From Baseline in the Johns Hopkins RLS Quality of Life (RLS QoL) Questionnaire Overall Life Impact Score at Weeks 12 and 26
NCT00329602 (15) [back to overview]Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26
NCT00329602 (15) [back to overview]Mean Change From Baseline in the International RLS (IRLS) Rating Scale Total Score at Weeks 1, 4, 8, 16, and 20
NCT00329602 (15) [back to overview]Number of Participants With Clinically Meaningful Augmentation and Early Morning Rebound (EMR) Cases
NCT00329602 (15) [back to overview]Percentage of Participants With a Score of Much/Very Much Improved on the Clinical Global Impression-Global Improvement (CGI-I) Scale at Weeks 1, 12 and 26
NCT00357097 (20) [back to overview]"Change From Average Baseline Scores of Subscale Sleep Disturbance of the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks"
NCT00357097 (20) [back to overview]Average Change of the HAM-D (Hamilton Depression Rating Scale, 17-item-Version) Total Score From Baseline to Final Visit After 12 Weeks of Treatment
NCT00357097 (20) [back to overview]Average Change of the Beck Depression Inventory (BDI) Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of an at Least Mild-moderate Depression (BDI >= 21) at Baseline
NCT00357097 (20) [back to overview]Percentage of Participants With a Decrease of International Restless Legs Scale (IRLS) Scores of at Least 6 Points After 1, 4 and 12 Weeks
NCT00357097 (20) [back to overview]Average Change of the Beck Depression Inventory (BDI) Total Score From Baseline to Final Visit After 12 Weeks of Treatment
NCT00357097 (20) [back to overview]"Percentage of Participants (Responder) With a Decrease of MADRS Total Score of at Least 6 Points After 12 Weeks Compared to Baseline"
NCT00357097 (20) [back to overview]= 18)"-NCT00357097">"Percentage of Participants (Responder) With a Decrease of MADRS Total Score of at Least 6 Points After 12 Weeks Compared to Baseline in Subjects With Signs of at Least Moderate Depression at Baseline (MADRS Score >= 18)"
NCT00357097 (20) [back to overview]"Change From Average Baseline Scores of Subscale Sleep Quantity (Hours) of the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks"
NCT00357097 (20) [back to overview]Average Change of the HAM-D Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of an at Least Moderate Depression (HAM-D Score >= 15) at Baseline
NCT00357097 (20) [back to overview]Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment
NCT00357097 (20) [back to overview]Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of at Least Moderate Depression (MADRS Score: >=18)
NCT00357097 (20) [back to overview]Change in Average International Restless Legs Scale for Severity (IRLS) Scores in All Participants From Baseline to After 1, 4, and 12 Weeks
NCT00357097 (20) [back to overview]Change in Average BDI Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)
NCT00357097 (20) [back to overview]Change in Average HAM-D Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)
NCT00357097 (20) [back to overview]Change in Average MADRS Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)
NCT00357097 (20) [back to overview]Percentage of Participants With at Least Moderate Depression (HAM-D >= 15) at Baseline and in Week 12
NCT00357097 (20) [back to overview]Percentage of Participants With at Least Moderate Depression (MADRS Score >= 18) at Baseline and in Week 12
NCT00357097 (20) [back to overview]"Percentage of Participants With Much Improved or Very Much Improved on the Clinical Global Impression-Global Improvement Scale After 1, 4 and 12 Weeks"
NCT00357097 (20) [back to overview]"Change From Average Baseline Score of Subscale of Somnolence in the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks"
NCT00357097 (20) [back to overview]"Change From Average Baseline Scores of Subscale Sleep Adequacy of the Medical Outcomes Study Sleep Scale (MOS-SS)to Final Visit After 12 Weeks"
NCT00434304 (32) [back to overview]Change From Baseline in Supine and Standing Pulse Rate at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Red Blood Cell Count at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Prolactin at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Platelet Count and White Blood Cell Count at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Hematocrit at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Supine and Standing Systolic and Diastolic Blood Pressure at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Albumin, Total Protein, and Hemoglobin at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Blood Urea Nitrogen, Cholesterol, Chloride, Potassium, and Sodium at Weeks 16 and 52
NCT00434304 (32) [back to overview]Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Weeks 16 and 52
NCT00434304 (32) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part II
NCT00434304 (32) [back to overview]Change From Baseline in the Japanese UPDRS Part I
NCT00434304 (32) [back to overview]Percentage of Participants Who Remained in the Study on the Indicated Days
NCT00434304 (32) [back to overview]Change From Baseline in the Japanese UPDRS Part III
NCT00434304 (32) [back to overview]Change From Baseline in the Japanese UPDRS Part IV
NCT00434304 (32) [back to overview]Change From Baseline in Total Bilirubin, Blood Urea Nitrogen, and Creatinine at Weeks 16 and 52
NCT00434304 (32) [back to overview]Food Effects on AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites
NCT00434304 (32) [back to overview]Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites
NCT00434304 (32) [back to overview]Number of Participants Scored as Responders on the Clinician's Global Impression (CGI) Scale
NCT00434304 (32) [back to overview]Number of Participants With the Indicated Shift From Baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52
NCT00434304 (32) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part I
NCT00434304 (32) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part III
NCT00434304 (32) [back to overview]Change From Baseline in the Japanese UPDRS Part II
NCT00434304 (32) [back to overview]Percentage of Responders of the Total Score in the Japanese UPDRS Total Score in Part III
NCT00434304 (32) [back to overview]Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites
NCT00434304 (32) [back to overview]Summary of the Modified Hoehn & Yahr Criteria Stages
NCT00434304 (32) [back to overview]Total Score in the Japanese UPDRS Part I
NCT00434304 (32) [back to overview]Total Score in the Japanese UPDRS Part II
NCT00434304 (32) [back to overview]Total Score in the Japanese UPDRS Part III
NCT00434304 (32) [back to overview]Total Score in the Japanese UPDRS Part IV
NCT00434304 (32) [back to overview]Urinalysis Data
NCT00434304 (32) [back to overview]Food Effects on Tmax of SKF101468 (Ropinirole) and Its Metabolites
NCT00434304 (32) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part IV
NCT00530790 (17) [back to overview]Change From Baseline to Week 12/EW in Pittsburgh Sleep Quality Index (PSQI) Total Score by Domains
NCT00530790 (17) [back to overview]Clinical Global Impression Global Improvement (CGI-GI)
NCT00530790 (17) [back to overview]Clinical Global Impression Scale - Severity of Illness (CGI-S)
NCT00530790 (17) [back to overview]Drug Related Adverse Events-On-Therapy
NCT00530790 (17) [back to overview]Pharmacokinetic Analysis: Plasma Concentrations of SK&F104557, a Circulating Metabolite of Ropinirole.
NCT00530790 (17) [back to overview]Haematology Clinical Lab Values Change From Baseline
NCT00530790 (17) [back to overview]Pharmacokinetic Analysis: Plasma Concentrations of SK&F101468, an Unchanged Form of Ropinirole.
NCT00530790 (17) [back to overview]12-Lead Electrocardiogram (ECG) Findings Transitions From Baseline
NCT00530790 (17) [back to overview]Pharmacokinetic Analysis: Plasma Concentrations of SK&F89124, a Circulating Metabolite of Ropinirole.
NCT00530790 (17) [back to overview]Urinalysis Clinical Lab Values
NCT00530790 (17) [back to overview]Vital Signs and Body Weight Change From Baseline
NCT00530790 (17) [back to overview]Blood Chemistry Clinical Lab Values Change From Baseline
NCT00530790 (17) [back to overview]Change From Baseline at Week 12/Early Withdrawal (EW) in Hospital Anxiety and Depression Scale (HADS)
NCT00530790 (17) [back to overview]Change From Baseline at Week 12/Early Withdrawal (EW) in Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLSQOL) on the Overall Life Impact Score
NCT00530790 (17) [back to overview]Change From Baseline at Week 12/Early Withdrawal (EW) in Pittsburgh Sleep Quality Index (PSQI) Total Score
NCT00530790 (17) [back to overview]Change From Baseline at Week 12/Early Withdrawal (EW) in Profile of Mood Status (POMS)
NCT00530790 (17) [back to overview]Change From Baseline to Week 12 in International Restless Leg Syndrome (IRLS) Rating Scale Total Score
NCT00632736 (2) [back to overview]Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00632736 (2) [back to overview]Number of Participants With the Indicated Response to the Patient Preference Question at Week 4 and Week 26
NCT00650104 (10) [back to overview]Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Responder Population)
NCT00650104 (10) [back to overview]Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (ITT Population)
NCT00650104 (10) [back to overview]Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)
NCT00650104 (10) [back to overview]Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Maintained Responder Population)
NCT00650104 (10) [back to overview]Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (ITT Population)
NCT00650104 (10) [back to overview]Number of Participants With the Indicated Number of Adverse Events (AEs)
NCT00650104 (10) [back to overview]Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Scores (Maintained Responder Population)
NCT00650104 (10) [back to overview]Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Score (Responder Population)
NCT00650104 (10) [back to overview]Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Reponder Population)
NCT00650104 (10) [back to overview]Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Maintained Responder Population)
NCT00823836 (62) [back to overview]Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Mean Change From Week 0 in the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase
NCT00823836 (62) [back to overview]Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Mean Change From Week 24 (Period Baseline) in the Japanese UPDRS Part I Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase
NCT00823836 (62) [back to overview]Mean Change From Week 24 in the Japanese UPDRS Part III Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase
NCT00823836 (62) [back to overview]Mean Change From Week 24 in the Japanese UPDRS Part IV Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase
NCT00823836 (62) [back to overview]Percentage of Responders on the CGI-I at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Responders on the Clinical Global Impression-Improvement (CGI-I) at FAP (up to Week 24) in the Non-Inferiority Verification Phase
NCT00823836 (62) [back to overview]"Japanese UPDRS Part II (at Off) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Japanese UPDRS Part II (at Off) Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Japanese UPDRS Part II (at On) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Japanese UPDRS Part II (at On) Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Japanese UPDRS Part II (at On) Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at Off) at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at Off) at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at Off) at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at On) at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at On) at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at On) at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase
NCT00823836 (62) [back to overview]Japanese UPDRS Part I Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase
NCT00823836 (62) [back to overview]Japanese UPDRS Part III Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase
NCT00823836 (62) [back to overview]Japanese UPDRS Part III Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase
NCT00823836 (62) [back to overview]Japanese UPDRS Part III Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Japanese UPDRS Part IV Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase
NCT00823836 (62) [back to overview]Japanese UPDRS Part IV Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase
NCT00823836 (62) [back to overview]Japanese UPDRS Part IV Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Participants Remaining in the Study on the Indicated Days During the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole IR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole IR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase
NCT00823836 (62) [back to overview]Percentage of Responders on the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Awake Time Spent Off at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Awake Time Spent On at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Awake Time Spent On With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Awake Time Spent On With Troublesome Dyskinesias at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Percentage of Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Percentage of Awake Time Spent Off at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]Japanese UPDRS Part I Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Percentage of Awake Time Spent On at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in Percentage of Awake Time Spent On With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in the Japanese UPDRS Part II (at Off) Total Score at Week 24 in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in the Japanese UPDRS Part II (at Off) Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in the Japanese UPDRS Part II (at On) Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 0 in the Japanese UPDRS Part II (at On) Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Japanese UPDRS Part II (at Off) Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 24 in Awake Time Spent Off at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 24 in Awake Time Spent On With Troublesome Dyskinesias at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 24 in Percentage of Awake Time Spent Off at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 24 in the Japanese UPDRS Part II (at Off) Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Mean Change From Week 24 in the Japanese UPDRS Part II (at On) Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"
NCT00823836 (62) [back to overview]"Mean Percent Change From Week 0 in Percentage of Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Percentage of Responders in Change From Week 0 in Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Percentage of Responders in Change From Week 0 in Awake Time Spent Off at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"
NCT00823836 (62) [back to overview]"Percentage of Responders in Percent Change From Week 0 in Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"
NCT00823836 (62) [back to overview]"Percentage of Responders in Percent Change From Week 0 in Awake Time Spent Off at Week 54 in the Long-term Phase"
NCT00823836 (62) [back to overview]Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase
NCT00823836 (62) [back to overview]Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase
NCT00829504 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00829504 (3) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT00829504 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00830219 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00830219 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00830219 (3) [back to overview]Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT00986245 (14) [back to overview]Hoehn and Yahr Stage
NCT00986245 (14) [back to overview]Nocturnal Off-symptoms
NCT00986245 (14) [back to overview]Overall Quality of Sleep
NCT00986245 (14) [back to overview]Patient Preference
NCT00986245 (14) [back to overview]Patients Who Have Global Impression for Improvement
NCT00986245 (14) [back to overview]Patients Who Have Global Impression for Improvement to Duration of Dyskinesia
NCT00986245 (14) [back to overview]Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation
NCT00986245 (14) [back to overview]Patients Who Have Global Impression for Improvement to Severity of Dyskinesia
NCT00986245 (14) [back to overview]Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation
NCT00986245 (14) [back to overview]Unified Parkinson's Disease Rating Scale, Part 3
NCT00986245 (14) [back to overview]Early Morning Off Symptoms
NCT00986245 (14) [back to overview]Adverse Events
NCT00986245 (14) [back to overview]Compliance
NCT00986245 (14) [back to overview]Epworth Sleep Scale
NCT00996944 (18) [back to overview]Number of Participants With the Indicated CGI-I Scores for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)
NCT00996944 (18) [back to overview]Mean Daily Number of Hours of RLS Symptoms by Timeframe for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)
NCT00996944 (18) [back to overview]Mean Daily Number of Hours of RLS Symptoms by Timeframe for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)
NCT00996944 (18) [back to overview]Mean Daily Number of Hours of RLS Symptoms by Timeframe at Week 0 and Week 12
NCT00996944 (18) [back to overview]Johns Hopkins Restless Legs Syndrome Quality of Life (RLSQOL) Questionnaire Overall Life Impact Score at Week 0 and Week 12
NCT00996944 (18) [back to overview]International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 0 and Week 12
NCT00996944 (18) [back to overview]The PSQI Total Score for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)
NCT00996944 (18) [back to overview]The PSQI Total Score for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)
NCT00996944 (18) [back to overview]Johns Hopkins RLSQOL Questionnaire Overall Life Impact Score for Participants Who Withdrew in the Long-term Treatment Period (LONG WD)
NCT00996944 (18) [back to overview]Johns Hopkins RLSQOL Questionnaire Overall Life Impact Score for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)
NCT00996944 (18) [back to overview]IRLS Rating Scale Total Score for Participants Who Withdrew in the Long-term Treatment Period (LONG WD)
NCT00996944 (18) [back to overview]IRLS Rating Scale Total Score for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)
NCT00996944 (18) [back to overview]Number of Participants With the Indicated Responses to the Patient Satisfaction Question at Week 0 and Week 12
NCT00996944 (18) [back to overview]Number of Participants With the Indicated Responses to the Patient Satisfaction Question for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)
NCT00996944 (18) [back to overview]Number of Participants With the Indicated Responses to the Patient Satisfaction Question for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)
NCT00996944 (18) [back to overview]Number of Participants With the Indicated CGI-I Scores for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)
NCT00996944 (18) [back to overview]Number of Participants With the Indicated Clinical Global Impression-Improvement (CGI-I) Scores at Week 12
NCT00996944 (18) [back to overview]The Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 0 and Week 12
NCT01154166 (13) [back to overview]"Mean Change From Baseline in Total Awake Time on Without Troublesome Dyskinesias (TD) at Week 24 Using LOCF"
NCT01154166 (13) [back to overview]"Mean Change From Baseline in Total Awake Time Spent Off at Week 24 Using Last Observation Carried Forward (LOCF)"
NCT01154166 (13) [back to overview]"Mean Change From Baseline in Total Awake Time Spent on at Week 24 Using LOCF"
NCT01154166 (13) [back to overview]Mean Change From Baseline (BL) in the Parkinson's Disease Sleep Scale (PDSS) Total Score Using LOCF
NCT01154166 (13) [back to overview]Mean Change From Baseline (BL) in the Unified Parkinson Disease Rating Scale (UPDRS) Total Motor Score at Week 24 Using LOCF
NCT01154166 (13) [back to overview]Mean Change From Baseline in the Depression Scores on the Hamilton Depression Rating Scale (HAMD-17) Using LOCF
NCT01154166 (13) [back to overview]Mean Change From Baseline in the UPDRS Activities of Daily Living (ADL) Score at Week 24 Using LOCF
NCT01154166 (13) [back to overview]Number of Participants Requiring Reinstatement of L-dopa Following a Dose Reduction Using LOCF
NCT01154166 (13) [back to overview]Number of Responders Based on the Clinical Global Impression (CGI) Global Improvement Scale Using LOCF
NCT01154166 (13) [back to overview]Number of Responders to Study Treatment Using LOCF
NCT01154166 (13) [back to overview]Time to Reinstatement of L-dopa Following a Reduction in Dose Using LOCF
NCT01154166 (13) [back to overview]Mean Change From Baseline in the Parkinson's Disease Quality of Life Scores (PDQ39) Using LOCF
NCT01154166 (13) [back to overview]"Mean Change From Baseline in the Percentage of Awake Time Spent Off (ATSO) at Week 24 Using LOCF"
NCT01327339 (3) [back to overview]Number of Participants With Any Serious Adverse Event
NCT01327339 (3) [back to overview]Number of Participants With the Indicated Unexpected Adverse Events
NCT01327339 (3) [back to overview]Number of Participants With Any Adverse Event
NCT01393457 (2) [back to overview]Number of Participants Who Completed the 10 Week Trial
NCT01393457 (2) [back to overview]Cocaine Use Based on Urine Drug Screening
NCT01485172 (11) [back to overview]Responder Rate Defined as Participants With a >=30% Reduction in Baseline UPDRS Motor Score
NCT01485172 (11) [back to overview]Change From Baseline (BL) in Unified Parkinson Disease (PD) Rating Scale (UPDRS) Motor Score
NCT01485172 (11) [back to overview]Change From Baseline in the Total UPDRS Score (Parts I-III)
NCT01485172 (11) [back to overview]Change From Baseline in the UPDRS Part I (Mentation)
NCT01485172 (11) [back to overview]Change From Baseline in UPDRS Activities of Daily Living
NCT01485172 (11) [back to overview]Change From Baseline in UPDRS Parts II and III Combined
NCT01485172 (11) [back to overview]Number of Participants With a >=10 Points Reduction From Baseline in UPDRS Motor Score
NCT01485172 (11) [back to overview]Number of Participants With a >=10 Points Reduction From Baseline in UPDRS Parts II and III Combined
NCT01485172 (11) [back to overview]Number of Participants With a >=5 Points Reduction From Baseline in UPDRS Motor Score
NCT01485172 (11) [back to overview]Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy
NCT01485172 (11) [back to overview]Responder Rate According to the Clinical Global Impression - Global Improvement (CGI-I) Scale
NCT01494532 (24) [back to overview]"Change From Baseline in the Percent Awake Time Spent on Without TD at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in the Percent of a 24- Hour Day Spent on Without TD at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in the Percent of a 24-hour Day Spent Off at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in the Percent of a 24-hour Day Spent on at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in Unified Parkinson Disease Rating Scale (UPDRS) Motor Score With Participants in an on State, at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in UPDRS Activities of Daily Living (ADL) Score With Participants in an on State, at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in UPDRS ADL Score With Participants in an Off State, at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Percent Change From Baseline in Awake Time Spent Off at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Percent Change From Baseline in Awake Time Spent on at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period"-NCT01494532">"Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]=2 Hours Reduction in Baseline Off Time at Week 4 of the Maintenance Period"-NCT01494532">"Percentage of Participants With a >=2 Hours Reduction in Baseline Off Time at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period"
NCT01494532 (24) [back to overview]Change From Baseline for Total Sleep Time During the Night Time Hours of Sleep at Week 4 of the Maintenance Period
NCT01494532 (24) [back to overview]Change From Baseline in Total Sleep Time During the Night Time Hours of Sleep as a Percentage of a 24-hour Day, at Week 4 of the Maintenance Period
NCT01494532 (24) [back to overview]Change From Baseline in UPDRS Part I at Week 4 of the Maintenance Period
NCT01494532 (24) [back to overview]Percent Change From Baseline in Total Sleep Time During the Night Time Hours of Sleep, at Week 4 of the Maintenance Period
NCT01494532 (24) [back to overview]Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy
NCT01494532 (24) [back to overview]Responder Rate According to the Clinical Global Impression-global Improvement (CGI-I) Scale at Week 4 of the Maintenance Period
NCT01494532 (24) [back to overview]"Percent Change From Baseline in Awake Time Spent on Without TD at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in Absolute Awake Time Spent on at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in Absolute Awake Time Spent on Without Troublesome Dyskinesia (TD) at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in the Percent Awake Time Spent Off at Week 4 of the Maintenance Period"
NCT01494532 (24) [back to overview]"Change From Baseline in the Percent Awake Time Spent on at Week 4 of the Maintenance Period"
NCT01536574 (7) [back to overview]Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase
NCT01536574 (7) [back to overview]Number of Participants With the Indicated Adverse Events Related to Investigational Product During the Follow-up Phase
NCT01536574 (7) [back to overview]Number of Participants With the Indicated Adverse Events During the Follow-up Phase
NCT01536574 (7) [back to overview]Number of Participants With an Adverse Event During the Follow-up Phase
NCT01536574 (7) [back to overview]Mean Gambling Symptom Assessment Scale (G-SAS) Score at Week 24
NCT01536574 (7) [back to overview]Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase)
NCT01536574 (7) [back to overview]Mean Change From Baseline in the Gambling Symptom Assessment Scale (G-SAS) Score at Week 24
NCT01628926 (14) [back to overview]UPDRS Part 2 Sum Score
NCT01628926 (14) [back to overview]UPDRS Part 3 Sum Score
NCT01628926 (14) [back to overview]Effective Rate in UPDRS Part 3 Sum Score
NCT01628926 (14) [back to overview]On Time
NCT01628926 (14) [back to overview]On Time With Dyskinesia Disturbing Daily Activities
NCT01628926 (14) [back to overview]On Time Without Dyskinesia Disturbing Daily Activities
NCT01628926 (14) [back to overview]Parkinson's Disease Sleep Scale-2 (PDSS-2)
NCT01628926 (14) [back to overview]Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score
NCT01628926 (14) [back to overview]Clinical Global Impression (CGI)
NCT01628926 (14) [back to overview]Dystonia (at an Early Hour)
NCT01628926 (14) [back to overview]Dystonia (in the Daytime)
NCT01628926 (14) [back to overview]Effective Rate in UPDRS Part 2 Sum Score
NCT01628926 (14) [back to overview]Off Time
NCT01628926 (14) [back to overview]Effective Rate in Off Time
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Long-term Phase
NCT01929317 (31) [back to overview]"Change From Baseline in Actual Hours of Awake Time Spent On at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 3 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 3 Total Score at the Indicated Visits in the Long Term Phase
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Long-term Phase
NCT01929317 (31) [back to overview]Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at Week 12 in the CR High-dose Group
NCT01929317 (31) [back to overview]Number of Participants With an Improvement (Responder) in the Clinical Global Impression (CGI) Global Improvement Scale at Week 12
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Long Term Phase
NCT01929317 (31) [back to overview]"Change From Baseline in Actual Hours of Awake Time Spent On at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"
NCT01929317 (31) [back to overview]"Change From Baseline in Actual Hours of Awake Time Spent On Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"
NCT01929317 (31) [back to overview]"Change From Baseline in Actual Hours of Awake Time Spent OnWithout Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"
NCT01929317 (31) [back to overview]"Change From Baseline in Percentage of Awake Time Spent On at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"
NCT01929317 (31) [back to overview]"Change From Baseline in Percentage of Awake Time Spent On Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"
NCT01929317 (31) [back to overview]"Change From Baseline in the Actual Hours of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"
NCT01929317 (31) [back to overview]"Change From Baseline in the Actual Hours of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"
NCT01929317 (31) [back to overview]"Change From Baseline in the Percentage of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"
NCT01929317 (31) [back to overview]"Change From Baseline in the Percentage of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"
NCT01929317 (31) [back to overview]Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Long-term Phase
NCT01929317 (31) [back to overview]Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Number of Participants Remaining in the Study
NCT01929317 (31) [back to overview]Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Long Term Phase
NCT01929317 (31) [back to overview]Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Long Term Phase
NCT01929317 (31) [back to overview]Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits
NCT01929317 (31) [back to overview]Mean Change From Baseline in UPDRS Part 3 Total Score at the Indicated Visits for Long Term Phase
NCT01929317 (31) [back to overview]Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in Long Term Phase.
NCT01929317 (31) [back to overview]Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase
NCT01929317 (31) [back to overview]Percent Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
NCT03038308 (2) [back to overview]Number of Subjects With Unchanged Tumor Size
NCT03038308 (2) [back to overview]Percentage of Subjects That Achieved Stable PRL Normalization
NCT03176966 (2) [back to overview]Frequency of Muscle Cramps as Assessed by Patient Survey
NCT03176966 (2) [back to overview]Muscle Cramp Severity as Assessed by Patient Survey
NCT03250117 (4) [back to overview]Total Number of Adverse Events Across Participants
NCT03250117 (4) [back to overview]"Mean Change From Baseline of Awake Time Off"
NCT03250117 (4) [back to overview]"Mean Change From Baseline of Awake Time On"
NCT03250117 (4) [back to overview]Mean Change From Baseline in MDS-UPDRS Total Score

Number of Participants With pre-and One Week Post-conversion Values of Vital Signs of Potential Clinical Concern (PCC)

The number of participants with pre- and post- conversion orthostatic systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate values of PCC were summarized. Both conversions (drug and dummy) were considered. High and low values of only orthostatic SBP and DBP of PCC are presented. (NCT00256854)
Timeframe: Up to 5 weeks

InterventionParticipants (Count of Participants)
4 mg IR to 4 mg IR, SBP, PCC high, pre-conversion4 mg IR to 6 mg CR, DBP, PCC high, post-conversion4 mg IR to 4 mg IR, DBP, PCC high, pre-conversion4 mg IR to 4 mg IR, DBP, PCC high, post-conversion
Ropinirole Cohort C1412

[back to top]

Change From Pre-conversion in International RLS (IRLS) Rating Scale Total Score to One Week Post-conversion

"The IRLS Rating Scale was developed to measure disease severity for clinical assessment, research, and therapeutic studies an also to show relationship between responses and overall RLS severity. The IRLS Rating Scale is a disease-specific 10-item scale that is based on the IRLSSG consensus of clinical features and associated sleep problems. The investigator asked the participant to rate his/her symptoms for each of the ten questions contained in the IRLS Rating Scale from 0 to 4, with 0 representing the absence of a problem and 4 a very severe problem. The best and worst possible scores are 0 and 40, respectively; higher scores represent a greater severity of symptoms. Changes from pre- to one-week post-conversion in the IRLS rating scale total score was obtained by subtracting the Week 1 total score from the Week 2 total score for the first conversion and the Week 3 total score from the Week 4 total score for the second conversion." (NCT00256854)
Timeframe: Up to 5 weeks

,,,,,
InterventionScores on a scale (Mean)
Post-Conversion 1Post-Conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR-5.1-2.9
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS-0.1-4.8
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR-1.5-1.6
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS-1.3-5.2
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR-5.80.6
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS1.2-2.2

[back to top]

Change From Pre-conversion in Pulse Rate to One Week Post-conversion

"Both conversions 1 and 2 (drug and dummy) were considered for analysis. High and low values of only orthostatic pulse of PCC are presented. Change from pre-conversion in pulse rate is the value of pulse rate at post-conversion minus the value at pre-conversion. For orthostatic changes (standing minus semi-supine vital signs values), pre-conversion measurements were compared with the post-conversion measurements. Positive values are indicative of less orthostatic decrease in pulse. The first conversion relates to the Week 1 visit, with pre- to post-conversion changes computed as Week 2 values minus the Week 1 values, and the second conversion relates to the Week 3 visit with pre- to post-conversion changes computed as the Week 4 values minus the Week 3 values." (NCT00256854)
Timeframe: Up to 5 weeks

,,,,,
InterventionBeats per minute (bpm) (Mean)
Semi-supine pulse, Conversion 1Standing pulse, Conversion 1Semi-supine pulse, Conversion 2Standing pulse, Conversion 2Post-Conversion 1Post-Conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR-0.12.4-0.7-0.42.50.3
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS-0.40.30.30.30.70.0
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR1.00.00.21.4-1.01.2
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS-0.90.70.30.91.60.6
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR-1.5-0.80.60.90.70.3
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS1.2-0.8-0.81.5-2.02.2

[back to top]

Change From Pre-conversion in Systolic and Diastolic Orthostatic SBP and DBP to One Week Post-conversion

"Both conversions 1 and 2 (drug and dummy) were considered for analysis. High and low values of only orthostatic SBP and DBP of PCC are presented. Change from pre-conversion in BP is the value of BP at post-conversion minus the value at pre-conversion. For orthostatic changes (standing minus semi-supine vital signs values), pre-conversion measurements were compared with the post-conversion measurements. Positive values are indicative of less orthostatic decrease in blood pressure. The first conversion relates to the Week 1 visit, with pre- to post-conversion changes computed as Week 2 values minus the Week 1 values, and the second conversion relates to the Week 3 visit with pre- to post-conversion changes computed as the Week 4 values minus the Week 3 values." (NCT00256854)
Timeframe: Up to 5 weeks

,,,,,
InterventionMillimeters of mercury (mm of Hg) (Mean)
Semi-supine SBP, conversion 1Standing SBP, conversion 1Semi-supine SBP, conversion 2Standing SBP, conversion 2Orhostatic SBP, post-conversion 1Orthostatic SBP, post-conversion 2Semi-supine DBP, conversion 1Standing DBP, conversion 1Semi-supine DBP, conversion 2Standing DBP, conversion 2Orthostatic DBP, post-conversion 1Orthostatic DBP, post-conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR-0.82.31.6-0.33.2-1.91.33.3-0.5-2.72.0-2.2
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS-3.9-2.90.63.11.02.5-2.5-3.42.82.8-0.90.0
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR4.0-0.20.33.6-4.23.32.24.11.30.31.9-1.1
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS-7.7-4.12.11.03.4-1.0-3.5-3.2-0.70.70.51.4
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR-1.20.7-2.60.41.93.0-1.30.60.0-0.31.9-0.3
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS-5.3-3.9-6.2-4.91.41.3-1.2-0.8-0.71.80.42.5

[back to top]

Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure

"Blood pressure (both systolic and diastolic) measurements were made just prior to the first dose of study medication ('evening' dose, ropinirole CR-RLS or matching placebo) and then every hour afterwards up to bedtime (when the device was removed). The changes for the first conversion were calculated as the post evening dose values minus the pre evening dose values at the Week 1 visit and the changes for the second conversion were the post evening dose values minus the pre evening dose values at the Week 3 visit." (NCT00256854)
Timeframe: Up to 5 weeks

InterventionmmHg (Mean)
SBP, conversion 1, 1 hourSBP, conversion 1, 2 hoursSBP, conversion 1, 3 hoursSBP, conversion 1, 4 hoursSBP, conversion 1, 5 hoursSBP, conversion 1, 6 hoursSBP, conversion 2, <30 minutesSBP, conversion 2, 1 hourSBP, conversion 2, 2 hoursSBP, conversion 2, 3 hoursSBP, conversion 2, 4 hoursSBP, conversion 2, 5 hoursDBP, conversion 1, 1 hourDBP, conversion 1, 2 hoursDBP, conversion 1, 3 hoursDBP, conversion 1, 4 hoursDBP, conversion 1, 5 hoursDBP, conversion 1, 6 hoursDBP, conversion 2, <30 minutesDBP, conversion 2, 1 hourDBP, conversion 2, 2 hoursDBP, conversion 2, 3 hoursDBP, conversion 2, 4 hoursDBP, conversion 2, 5 hours
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS-5.07.5-4.53.514.00.012.0-2.8-5.0-4.3-7.39.0-5.06.0-5.04.00.08.020.03.8-10.5-4.5-7.88.0

[back to top]

Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure

"Blood pressure (both systolic and diastolic) measurements were made just prior to the first dose of study medication ('evening' dose, ropinirole CR-RLS or matching placebo) and then every hour afterwards up to bedtime (when the device was removed). The changes for the first conversion were calculated as the post evening dose values minus the pre evening dose values at the Week 1 visit and the changes for the second conversion were the post evening dose values minus the pre evening dose values at the Week 3 visit." (NCT00256854)
Timeframe: Up to 5 weeks

InterventionmmHg (Mean)
SBP, conversion 1, 1 hourSBP, conversion 1, 2 hoursSBP, conversion 1, 3 hoursSBP, conversion 1, 4 hoursSBP, conversion 1, 5 hoursSBP, conversion 2, <30 minutesSBP, conversion 2, 1 hourSBP, conversion 2, 2 hoursSBP, conversion 2, 3 hoursSBP, conversion 2, 4 hoursSBP, conversion 2, 5 hoursSBP, conversion 2, 6 hoursDBP, conversion 1, 1 hourDBP, conversion 1, 2 hoursDBP, conversion 1, 3 hoursDBP, conversion 1, 4 hoursDBP, conversion 1, 5 hoursDBP, conversion 2, <30 minutesDBP, conversion 2, 1 hourDBP, conversion 2, 2 hoursDBP, conversion 2, 3 hoursDBP, conversion 2, 4 hoursDBP, conversion 2, 5 hoursDBP, conversion 2, 6 hours
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR-6.3-8.0-7.4-12.8-15.5-5.50.6-0.3-5.00.3-18.0-20.5-5.4-3.4-5.4-4.0-14.5-4.50.2-4.4-7.2-3.8-17.0-15.0

[back to top]

Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure

"Blood pressure (both systolic and diastolic) measurements were made just prior to the first dose of study medication ('evening' dose, ropinirole CR-RLS or matching placebo) and then every hour afterwards up to bedtime (when the device was removed). The changes for the first conversion were calculated as the post evening dose values minus the pre evening dose values at the Week 1 visit and the changes for the second conversion were the post evening dose values minus the pre evening dose values at the Week 3 visit." (NCT00256854)
Timeframe: Up to 5 weeks

,,
InterventionmmHg (Mean)
SBP, conversion 1, <30 minutesSBP, conversion 1, 1 hourSBP, conversion 1, 2 hoursSBP, conversion 1, 3 hoursSBP, conversion 1, 4 hoursSBP, conversion 1, 5 hoursSBP, conversion 1, 6 hoursSBP, conversion 2, 1 hourSBP, conversion 2, 2 hoursSBP, conversion 2, 3 hoursSBP, conversion 2, 4 hoursSBP, conversion 2, 5 hoursSBP, conversion 2, 6 hoursDBP, conversion 1, <30 minutesDBP, conversion 1, 1 hourDBP, conversion 1, 2 hoursDBP, conversion 1, 3 hoursDBP, conversion 1, 4 hoursDBP, conversion 1, 5 hoursDBP, conversion 1, 6 hoursDBP, conversion 2, 1 hourDBP, conversion 2, 2 hoursDBP, conversion 2, 3 hoursDBP, conversion 2, 4 hoursDBP, conversion 2, 5 hoursDBP, conversion 2, 6 hours
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR-20.0-8.0-12.9-10.8-11.0-8.6-14.3-5.42.6-12.01.0-9.0-8.0-6.0-4.9-9.0-4.9-5.3-1.2-9.0-0.44.62.40.8-8.0-7.0
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR-20.0-10.6-9.1-15.9-12.8-15.5-9.0-1.62.0-3.3-2.6-0.5-0.6-2.0-1.6-0.4-8.1-8.4-10.0-3.3-1.9-3.3-10.5-4.6-7.5-5.8
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS-6.0-1.0-4.3-3.0-10.3-8.3-11.0-1.3-0.60.76.43.7-7.0-2.0-1.5-4.8-9.2-5.1-5.8-6.00.90.9-1.4-1.02.0-15.0

[back to top]

Change From Pre-conversion to Post-conversion in Ambulatory Blood Pressure

"Blood pressure (both systolic and diastolic) measurements were made just prior to the first dose of study medication ('evening' dose, ropinirole CR-RLS or matching placebo) and then every hour afterwards up to bedtime (when the device was removed). The changes for the first conversion were calculated as the post evening dose values minus the pre evening dose values at the Week 1 visit and the changes for the second conversion were the post evening dose values minus the pre evening dose values at the Week 3 visit." (NCT00256854)
Timeframe: Up to 5 weeks

InterventionmmHg (Mean)
SBP, conversion 1, 1 hourSBP, conversion 1, 2 hoursSBP, conversion 1, 3 hoursSBP, conversion 1, 4 hoursSBP, conversion 1, 5 hoursSBP, conversion 1, 6 hoursSBP, conversion 2, <30 minutesSBP, conversion 2, 1 hourSBP, conversion 2, 2 hoursSBP, conversion 2, 3 hoursSBP, conversion 2, 4 hoursSBP, conversion 2, 5 hoursSBP, conversion 2, 6 hoursDBP, conversion 1, 1 hourDBP, conversion 1, 2 hoursDBP, conversion 1, 3 hoursDBP, conversion 1, 4 hoursDBP, conversion 1, 5 hoursDBP, conversion 1, 6 hoursDBP, conversion 2, <30 minutesDBP, conversion 2, 1 hourDBP, conversion 2, 2 hoursDBP, conversion 2, 3 hoursDBP, conversion 2, 4 hoursDBP, conversion 2, 5 hoursDBP, conversion 2, 6 hours
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS-6.40.11.3-9.9-10.6-11.0-15.0-1.5-10.6-4.6-6.8-11.03.0-4.7-2.9-1.9-9.7-8.4-23.0-10.0-5.1-9.6-5.8-8.3-2.3-10.0

[back to top]

Number of Participants Discontinuing the Drug Due to AEs Post Conversion From Ropinirole IR to Ropinirole CR-RLS

AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. Onset of an AE was pre-Conversion 1 and discontinuation for the same AE occurred post-Conversion 1. Serious adverse event (SAE) is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above. (NCT00256854)
Timeframe: Up to 5 weeks

,,,,,
InterventionParticipants (Count of Participants)
Post-conversion 1Post-conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR00
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS00
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR10
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS10
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR00
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS00

[back to top]

Number of Participants With Adverse Events (AEs) Post-conversion From Ropinirole IR to Ropinirole CR Over Period

AE is an unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain time period after the study has ended. This change may or may not be caused by the intervention being studied. In each of the 6 cohorts, there were 2 conversions, one of which was IR to CR-RLS and the other one IR to IR. Two populations were defined: the first conversion population and the second conversion population. The first conversion population consisted of all participants receiving at least one dose of randomized drug during the pre-conversion 1 period and during the post-conversion 1 period. The second conversion population consisted of all participants receiving at least one dose of randomized drug during the pre-conversion 2 period and during the post-conversion 2 period. (NCT00256854)
Timeframe: Up to 5 weeks

,,,,,
InterventionParticipants (Count of Participants)
Post-conversion 1Post-conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR96
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS148
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR107
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS116
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR75
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS56

[back to top]

Number of Participants With Positive Scores (Improved) on Clinical Global Impression Improvement Scale (CGI-I) Pre-conversion and One Week Post-conversion

"Global Improvement Scale (CGI-I) allows the Investigator to rate the participants' global improvement or worsening compared with the condition at Baseline (Day 0), whether or not the change is thought to be due to treatment with study drug. The scale is rated from 1 to 7 (1=Very much improved to 7=Very much worse). Typically, a participant with a score of 1 were considered as Very much improved and 2 as Much improved responder. Positive response was given in terms of worsen to stable or stable to improved." (NCT00256854)
Timeframe: Up to 4 weeks

,,,,,
InterventionParticipants (Count of Participants)
Post Coversion 1Post Conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR1411
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS1214
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR1013
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS914
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR65
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS67

[back to top]

Number of Participants With pre-and One Week Post-conversion Values of Vital Signs of Potential Clinical Concern (PCC)

The number of participants with pre- and post- conversion orthostatic systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate values of PCC were summarized. Both conversions (drug and dummy) were considered. High and low values of only orthostatic SBP and DBP of PCC are presented. (NCT00256854)
Timeframe: Up to 5 weeks

InterventionParticipants (Count of Participants)
1 mg IR to 2 mg CR, SBP, PCC low, pre-conversion1 mg IR to 1 mg IR, SBP, PCC high, post-conversion1 mg IR to 2 mg CR, DBP, PCC high, pre-conversion1 mg IR to 2 mg CR, DBP, PCC high, post-conversion1 mg IR to 1 mg IR, DBP, PCC high, pre-conversion1 mg IR to 1 mg IR, DBP, PCC high, post-conversion1 mg IR to 1 mg IR, pulse, PCC low,post-conversion
Ropinirole Cohort A1123421

[back to top]

Number of Participants With pre-and One Week Post-conversion Values of Vital Signs of Potential Clinical Concern (PCC)

The number of participants with pre- and post- conversion orthostatic systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate values of PCC were summarized. Both conversions (drug and dummy) were considered. High and low values of only orthostatic SBP and DBP of PCC are presented. (NCT00256854)
Timeframe: Up to 5 weeks

InterventionParticipants (Count of Participants)
2 mg IR to 3 mg CR, SBP, PCC high, pre-conversion2 mg IR to 2 mg IR,SBP, PCC high, post-conversion2 mg IR to 3 mg CR, DBP, PCC high, pre-conversion2 mg IR to 3 mg CR, DBP, PCC high, post-conversion2 mg IR to 2 mg IR, DBP, PCC high, pre-conversion2 mg IR to 2 mg IR, DBP, PCC high, post-conversion2 mg IR to 3 mg CR, pulse, PCC high,pre-conversion2 mg IR to 2 mg IR, pulse,PCC high,post-conversion
Ropinirole Cohort B11162212

[back to top]

Number of Participants With SAEs and Severity of AEs

SAE is an adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above. Severity was measured in terms of grades mild, moderate, and severe. SAEs data only for post-conversion has been reported. (NCT00256854)
Timeframe: Up to 5 weeks

,,,,,
InterventionParticipants (Count of Participants)
Any SAE, post conversion 1Any SAE, post conversion 2Mild AE, post conversion 1Moderate AE, post conversion 1Severe AE, post conversion 1Mild AE, post conversion 2Moderate AE, post conversion 2Severe AE, post conversion 2
Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR00542322
Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS00975242
Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR00546133
Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS00662150
Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR00342240
Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS00241114

[back to top]

Number of Dose Adjustments

Outcome measures the number of times a dose needed to be adjusted to compensate for adverse effects experienced. (NCT00275275)
Timeframe: Week 4

Interventionnumber of adjustments (Mean)
Preferred Requip PR0.6
Preferred Mirapex1.3

[back to top]

Adverse Effects Experienced

Number of adverse effect experienced by participants in the different conversion ratio groups. (NCT00275275)
Timeframe: Week 4

Interventionnumber of events (Number)
Preferred Requip PR29
Preferred Mirapex43

[back to top]

Post-hoc Analysis of Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26, Exploring the Impact of Center Group on Treatment Effect

A post-hoc analysis of the primary outcome measure, exploring the variation in treatment effects across center groups by excluding those with the most extreme treatment effects, was conducted. Centers were grouped into five center groups. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

,
InterventionPoints on a scale (Least Squares Mean)
Week 12, n=136, 134Week 26, n=103, 105
Double-blind Placebo-12.2-14.0
Double-blind Ropinirole IR-13.8-15.7

[back to top]

Post-hoc Analysis of Percentage of Participants With a Score of Much/Very Much Improved on the Clinical Global Impression-Global Improvement (CGI-I) Scale at Weeks 12 and 26, Exploring the Impact of Center Group on Treatment Effect

A post-hoc analysis of CGI-I, exploring the variation in treatment effects across center groups by excluding the same two center groups as in the IRLS post-hoc analysis, was conducted. Centers were grouped into five center groups. (NCT00329602)
Timeframe: Weeks 12 and 26

,
InterventionNumber of responders (Number)
Week 12, n=136, 134Week 26, n=99, 96
Double-blind Placebo7563
Double-blind Ropinirole IR9382

[back to top]

Number of Participants Withdrawing Due to Lack of Efficacy During the First 26 Weeks of the Study

Lack of efficacy is defined as up to a 10% improvement in the IRLS Rating Scale total score from the participant's Baseline value and at least 12 weeks of treatment during the double-blind phase. (NCT00329602)
Timeframe: Baseline to Week 26

Interventionparticipants (Number)
Double-blind Placebo2
Double-blind Ropinirole IR3

[back to top]

Mean Change From Baseline in the IRLS Rating Scale Total Score at Week 67

A 10-item, participant-reported scale covering different symptoms of the condition. Each item is scored from 0 to 4, with 0 representing the absence of a problem and 4 reflecting a very severe problem. The best and worst possible scores are 0 and 40, respectively. The primary assessment was made by calculating the difference in the average score obtained at Baseline with score at Week 67. (NCT00329602)
Timeframe: Baseline and Week 67

Interventionpoints on a scale (Mean)
Open-label Ropinirole IR-20.4

[back to top]

Median Time to First CGI-I Response of Much/Very Much Improved During the Double-blind Phase

The median time to first CGI-I response of much/very much improved was calculated. The CGI-I is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-I allows the investigator to rate the participant's global improvement or worsening compared with the condition at Baseline (Day 0). The scale is rated from 1-7 (1 = very much improved; 7 = very much worse). Typically, a participant with a score of 1 or 2 (much improved) is considered a responder. (NCT00329602)
Timeframe: Baseline to Week 26

Interventiondays (Median)
Double-blind Placebo28
Double-blind Ropinirole IR21

[back to top]

Number of Participants Rated as Normal or Borderline Ill on the CGI Severity of Illness (CGI-S) Scale at Week 26

The CGI-S scale is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-S allows the investigator to rate the severity of the participant's illness considering their total clinical experience with the subject population being studied and on all information available at the time of rating. The scale is rated from 1-7 (1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severly ill; 7 = among the most extremely ill participants). (NCT00329602)
Timeframe: Week 26

Interventionparticipants (Number)
Double-blind Placebo50
Double-blind Ropinirole IR50

[back to top]

Number of Participants With a Score of Much/Very Much Improved on the CGI-I Scale at Week 67

The CGI-I is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-I allows the investigator to rate the participant's global improvement or worsening compared with the condition at Baseline (Day 0). The scale is rated from 1-7 (1 = very much improved; 7 = very much worse). Typically, a participant with a score of 1 or 2 (much improved) is considered a responder. (NCT00329602)
Timeframe: Week 67

Interventionparticipants (Number)
Open-label Ropinirole IR184

[back to top]

Change From Baseline in Sleep Quantity, a Domain of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale, at Weeks 12 and 26

The MOS-12 Sleep Scale is a comprehensive battery, which measures specific aspects of sleep in participants that may have varying co-morbidities, and, as a result, is appropriate for a medically diverse participant population.Scores were adjusted for baseline MOS sleep scale domain value, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

,
Interventionhours (Least Squares Mean)
Week 12, n=153, 143Week 26, n=105, 97
Double-blind Placebo0.50.5
Double-blind Ropinirole IR0.70.7

[back to top]

Change From Baseline in the Domains of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale at Weeks 12 and 26

The MOS-12 Sleep Scale is a comprehensive battery, which measures specific aspects of sleep in participants that may have varying co-morbidities, and, as a result, is appropriate for a medically diverse participant population. Domain values are presented on a 0-100 scale, where a higher score means a greater degree of the attribute implied by the scale name. Scores were adjusted for baseline MOS sleep scale domain value, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

,
Interventionpoints on a scale (Least Squares Mean)
Sleep disturbance, Week 12, n=153, 143Sleep disturbance, Week 26, n=105, 97Sleep adequacy, Week 12, n=153, 143Sleep adequacy, Week 26, n=105, 97Daytime somnolence, Week 12, n=153, 143Daytime somnolence, Week 26, n=105, 97
Double-blind Placebo-15.0-16.415.014.9-7.5-9.1
Double-blind Ropinirole IR-24.0-24.622.826.0-11.4-11.4

[back to top]

Change From Baseline in the Domains of the MOS 36-item Short Form Health Survey (SF-36) at Weeks 12 and 26

The MOS SF-36 is a generic QoL instrument measuring functional status and well-being. Positive change from baseline for all domains indicates improvement. For all MOS SF-36 domains, the minimum and maximum scores are 0 and 100, respectively, for the transformed scale. Scores were adjusted for baseline domain score, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

,
Interventionpoints on a scale (Least Squares Mean)
Bodily pain, Week 12, n=149, 142Bodily pain, Week 26, n=104, 94General health, Week 12, n=149, 142General health, Week 26, n=104, 94Mental health, Week 12, n=149, 142Mental health, Week 26, n=104, 94Physical functioning, Week 12, n=149, 142Physical functioning, Week 26, n=104, 94Role emotional, Week 12, n=149, 142Role emotional, Week 26, n=104, 94Role physical, Week 12, n=149, 142Role physical, Week 26, n=104, 94Social functioning, Week 12, n=149, 142Social functioning, Week 26, n=104, 94Vitality, Week 12, n=149, 142Vitality, Week 26, n=104, 94
Double-blind Placebo12.313.33.02.65.04.62.43.55.15.95.27.56.37.18.06.0
Double-blind Ropinirole IR14.414.04.54.17.66.25.52.67.06.67.76.79.88.89.39.2

[back to top]

Change From Baseline in the Johns Hopkins RLS Quality of Life (RLS QoL) Questionnaire Overall Life Impact Score at Weeks 12 and 26

The Johns Hopkins RLS QoL Questionnaire is a disease-specific instrument that assesses the impact of RLS on the daily life, emotional well-being, social life, and work life of participants. The overall life impact score for the John Hopkins RLS QoL scale ranges from a lowest possible score of 0 to a highest possible score of 100. Higher scores represent better quality of life. Scores were adjusted for baseline RLS Quality of Life score, treatment group, visit, visit by treatment interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

,
Interventionpoints on a scale (Least Squares Mean)
Week 12, n=149, 141Week 26, n=103, 94
Double-blind Placebo14.016.5
Double-blind Ropinirole IR18.018.5

[back to top]

Mean Change From Baseline in the International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 12 and Week 26

A 10-item, participant-reported scale covering different symptoms of the condition. Each item is scored from 0 to 4; 0 represents the absence of a problem and 4 reflects a very severe problem. The best and worst possible scores are 0 and 40, respectively; higher scores represent a greater severity of symptoms. A negative change from baseline indicates improvement, and a negative treatment difference indicates a benefit of Ropinirole IR over placebo. The primary assessment was made by calculating the difference in the average score obtained at Baseline with scores at Week 12 and then Week 26. (NCT00329602)
Timeframe: Baseline and Weeks 12 and 26

,
Interventionpoints on a scale (Least Squares Mean)
Week 12, n=165, 164Week 26, n=119, 123
Double-blind Placebo-12.1-13.4
Double-blind Ropinirole IR-14.2-15.9

[back to top]

Mean Change From Baseline in the International RLS (IRLS) Rating Scale Total Score at Weeks 1, 4, 8, 16, and 20

A 10-item, participant-reported scale covering different RLS symptoms. Each item is scored from 0 to 4; 0 represents the absence of a problem and 4 reflects a very severe problem. The best and worst possible scores are 0 and 40, respectively; higher scores represent a greater severity of symptoms. The primary assessment from this study was made by calculating the difference in the average score obtained at Baseline with scores at Weeks 1, 4, 8, 16, and 20. Scores were adjusted for baseline IRLS total score, treatment group, visit, visit by treatment group interaction, and center group. (NCT00329602)
Timeframe: Baseline and Weeks 1, 4, 8, 16, and 20

,
Interventionpoints on a scale (Least Squares Mean)
Week 1, n=198, 194Week 4, n=183, 180Week 8, n=168, 170Week 16, n=137, 144Week 20, n=125, 132
Double-blind Placebo-5.5-10.5-13.0-12.6-12.3
Double-blind Ropinirole IR-7.8-13.6-15.3-15.0-15.7

[back to top]

Number of Participants With Clinically Meaningful Augmentation and Early Morning Rebound (EMR) Cases

Clinically meaningful augmentation and early morning rebound (EMR) were assessed and confirmed by an independent Adjudication Board. EMR describes the development of RLS symptoms during the early morning, following therapeutic intervention. EMR is differentiated from augmentation, in which the earlier onset of symptoms occurs in the evening. (NCT00329602)
Timeframe: During 15-month study duration at scheduled (Weeks 16, 20, 26, or early withdrawal for DB phase; Weeks 39, 47, 55, 63, 67, or early withdrawal for the OL phase) and unscheduled (26-week DB phase and 40-week OL phase) visits

,,,
Interventionparticipants (Number)
Confirmed augmentationClinically meaningful augmentationConfirmed EMR
Double-blind Placebo111
Double-blind Ropinirole IR754
Open-label Ropinirole IR852
Overall Study15117

[back to top]

Percentage of Participants With a Score of Much/Very Much Improved on the Clinical Global Impression-Global Improvement (CGI-I) Scale at Weeks 1, 12 and 26

The CGI-I is a psychometric instrument that is used to measure general clinical status in a variety of disease states. The CGI-I allows the investigator to rate the participant's global improvement or worsening compared with the condition at Baseline (Day 0). The scale is rated from 1-7 (1 = very much improved; 7 = very much worse). Typically, a participant with a score of 1 or 2 (much improved) is considered a responder. (NCT00329602)
Timeframe: Weeks 1, 12 and 26

,
Interventionpercentage of participants (Number)
Week 1, n=192, 192Week 12, n=165, 160Week 26, n=112, 108
Double-blind Placebo398672
Double-blind Ropinirole IR5010991

[back to top]

"Change From Average Baseline Scores of Subscale Sleep Disturbance of the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks"

Medical Outcome Study Sleep Scale (MOS-SS)-is a 12 item questionaire assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache. 10 question score from 1-6, 1 question scores 1-5 and 1 question asks average number of hours sleep each night. (NCT00357097)
Timeframe: Baseline and after Week 12

InterventionScore on a Scale (Mean)
Ropinirole-30.5
Placebo-15.8

[back to top]

Average Change of the HAM-D (Hamilton Depression Rating Scale, 17-item-Version) Total Score From Baseline to Final Visit After 12 Weeks of Treatment

The Hamilton Rating Scale for Depression contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAMD score range from 0 (not ill) to 54 (severely ill). (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-8.2
Placebo-5.5

[back to top]

Average Change of the Beck Depression Inventory (BDI) Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of an at Least Mild-moderate Depression (BDI >= 21) at Baseline

Becks Depression Inventory (BDI) is a 21 item self inventory evaluating symptoms of depression, cognition, and physical symptoms of fatigue, weight loss, and lack of interest in sex. The Higher the score represents most severely depressed participants. Score range for each items is 0-3 and total score 0-63. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-10.9
Placebo-9.9

[back to top]

Percentage of Participants With a Decrease of International Restless Legs Scale (IRLS) Scores of at Least 6 Points After 1, 4 and 12 Weeks

International Restless Legs Scale for Severity (IRLS)is a series of 10 questions which rate severity from 0-4 points for various questions and total score ranks: Very severe=31-40 points, Severe=21-30 points, Moderate=11-20 points, and Mild=1-10 points, None=0 points (NCT00357097)
Timeframe: Week 1, Week 4, Week 12

,
InterventionPercentage of Participants (Number)
1 Week4 Weeks12 Weeks
Placebo28.358.361.7
Ropinirole52.680.784.8

[back to top]

Average Change of the Beck Depression Inventory (BDI) Total Score From Baseline to Final Visit After 12 Weeks of Treatment

Becks Depression Inventory (BDI) is a 21 item self inventory evaluating symptoms of depression, cognition, and physical symptoms of fatigue, weight loss, and lack of interest in sex. The Higher the score represents most severely depressed participants. Score range for each items is 0-3 and Total score 0-63. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-8.6
Placebo-6.5

[back to top]

"Percentage of Participants (Responder) With a Decrease of MADRS Total Score of at Least 6 Points After 12 Weeks Compared to Baseline"

Montgomery-Asberg Depression Rating Scale (MADRS)is a 10 item questionaire preformed during a clinical interview asking broad to detailed questions about symptoms which allows a precise rating of severity of symptoms of the past week. Questions are scored 0-6. Total Score 0-60, the higher the score indicates the most severely depressed patients. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionPercentage of Participants (Number)
Ropinirole74.9
Placebo48.3

[back to top]
= 18)"-NCT00357097">

"Percentage of Participants (Responder) With a Decrease of MADRS Total Score of at Least 6 Points After 12 Weeks Compared to Baseline in Subjects With Signs of at Least Moderate Depression at Baseline (MADRS Score >= 18)"

Montgomery-Asberg Depression Rating Scale (MADRS)is a 10 item questionaire preformed during a clinical interview asking broad to detailed questions about symptoms which allows a precise rating of severity of symptoms of the past week. Questions are scored 0-6. Total Score 0-60, the higher the score indicates the most severely depressed patients. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionPercentage of Participants (Number)
Ropinirole80.2
Placebo58.6

[back to top]

"Change From Average Baseline Scores of Subscale Sleep Quantity (Hours) of the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks"

(NCT00357097)
Timeframe: Baseline and after Week 12

InterventionScore on a Scale (Mean)
Ropinirole1.3
Placebo0.5

[back to top]

Average Change of the HAM-D Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of an at Least Moderate Depression (HAM-D Score >= 15) at Baseline

The Hamilton Rating Scale for Depression contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAMD score range from 0 (not ill) to 54(severely ill). (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-9.6
Placebo-7.2

[back to top]

Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment

Montgomery-Asberg Depression Rating Scale (MADRS)is a 10 item questionaire preformed during a clinical interview asking broad to detailed questions about symptoms which allows a precise rating of severity of symptoms of the past week. Questions are scored 0-6. Total Score 0-60, the higher the score indicates the most severely depressed patients. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-10.1
Placebo-6.5

[back to top]

Average Change of the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score From Baseline to Final Visit After 12 Weeks of Treatment in Participants With Signs of at Least Moderate Depression (MADRS Score: >=18)

Montgomery-Asberg Depression Rating Scale (MADRS)is a 10 item questionaire preformed during a clinical interview asking broad to detailed questions about symptoms which allows a precise rating of severity of symptoms of the past week. Questions are scored 0-6. Total Score 0-60, the higher the score indicates the most severely depressed patients. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-12.5
Placebo-8.8

[back to top]

Change in Average International Restless Legs Scale for Severity (IRLS) Scores in All Participants From Baseline to After 1, 4, and 12 Weeks

International Restless Legs Scale for Severity (IRLS)is a series of 10 questions which rate severity from 0-4 points for various questions and total score ranks: Very severe=31-40 points, Severe=21-30 points, Moderate=11-20 points, and Mild=1-10 points, None=0 points (NCT00357097)
Timeframe: Baseline, Week 1, Week 4, Week 12

,
InterventionScore on a Scale (Mean)
Change from Baseline after 1 WeekChange from Baseline after 4 WeeksChange from Baseline after 12 Weeks
Placebo-4.1-8.6-10.2
Ropinirole-7.7-14.0-14.6

[back to top]

Change in Average BDI Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)

Becks Depression Inventory (BDI) is a 21 item self inventory evaluating symptoms of depression, cognition, and physical symptoms of fatigue, weight loss, and lack of interest in sex. The Higher the score represents most severely depressed participants. Score range for each items is 0-3 and Total score 0-63. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-10.4
Placebo-7.2

[back to top]

Change in Average HAM-D Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)

The Hamilton Rating Scale for Depression contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAMD score range from 0 (not ill) to 54 (severely ill). (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-9.2
Placebo-6.5

[back to top]

Change in Average MADRS Score From Baseline to Final Visit (Week 12) in Participants With Major Depressive Episodes (Diagnosed by MINI Interview Modules A, B and C / DSM Criteria)

Montgomery-Asberg Depression Rating Scale (MADRS)is a 10 item questionaire preformed during a clinical interview asking broad to detailed questions about symptoms which allows a precise rating of severity of symptoms of the past week. Questions are scored 0-6. Total Score 0-60, the higher the score indicates the most severely depressed patients. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionScore on a Scale (Mean)
Ropinirole-11.6
Placebo-7.6

[back to top]

Percentage of Participants With at Least Moderate Depression (HAM-D >= 15) at Baseline and in Week 12

The Hamilton Rating Scale for Depression contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAMD score range from 0 (not ill) to 54 (severely ill). (NCT00357097)
Timeframe: Baseline and Week 12

InterventionPercentage of Participants (Number)
Ropinirole10.7
Placebo26.8

[back to top]

Percentage of Participants With at Least Moderate Depression (MADRS Score >= 18) at Baseline and in Week 12

Montgomery-Asberg Depression Rating Scale (MADRS)is a 10 item questionaire preformed during a clinical interview asking broad to detailed questions about symptoms which allows a precise rating of severity of symptoms of the past week. Questions are scored 0-6. Total Score 0-60, the higher the score indicates the most severely depressed patients. (NCT00357097)
Timeframe: Baseline and Week 12

InterventionPercentage of Participants (Number)
Ropinirole11.7
Placebo23.3

[back to top]

"Percentage of Participants With Much Improved or Very Much Improved on the Clinical Global Impression-Global Improvement Scale After 1, 4 and 12 Weeks"

The CGI-I assesses the investigator's impression of the patient's current illness. The time span is the week before the rating and the score range: 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5- minimally worse, 6-much worse, to 7-very much worse. (NCT00357097)
Timeframe: Week 1, Week 4, Week 12

,
InterventionPercentage of Participants (Number)
Week 1Week 4Week 12
Placebo15.040.046.7
Ropinirole35.166.764.3

[back to top]

"Change From Average Baseline Score of Subscale of Somnolence in the Medical Outcomes Study Sleep Scale (MOS-SS) to Final Visit After 12 Weeks"

Medical Outcome Study Sleep Scale (MOS-SS)-is a 12 item questionaire assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache. 10 question score from 1-6, 1 question scores 1-5 and 1 question asks average number of hours sleep each night. (NCT00357097)
Timeframe: Baseline and after Week 12

InterventionScore on a Scale (Mean)
Ropinirole-12.5
Placebo-10.2

[back to top]

"Change From Average Baseline Scores of Subscale Sleep Adequacy of the Medical Outcomes Study Sleep Scale (MOS-SS)to Final Visit After 12 Weeks"

Medical Outcome Study Sleep Scale (MOS-SS)-is a 12 item questionaire assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache. 10 question score from 1-6, 1 question scores 1-5 and 1 question asks average number of hours sleep each night. (NCT00357097)
Timeframe: Baseline and after Week 12

InterventionScore on a Scale (Mean)
Ropinirole34.0
Placebo15.6

[back to top]

Change From Baseline in Supine and Standing Pulse Rate at Weeks 16 and 52

Change from baseline was calculated as Week 16 and Week 52 values minus baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionbeats per minute (bpm) (Mean)
Supine Heart Rate - Week 16Supine Heart Rate - Week 52Standing Heart Rate - Week 16Standing Heart Rate - Week 52
Ropinirole PR/XR0.2-2.30.20.0

[back to top]

Change From Baseline in Red Blood Cell Count at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventiontera per Liter (TI/L) (Mean)
Week 16Week 52
Ropinirole PR/XR-0.1-0.2

[back to top]

Change From Baseline in Prolactin at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionmicrograms per Liter (MCG/L) (Mean)
Week 16Week 52
Ropinirole PR/XR-7.22-8.18

[back to top]

Change From Baseline in Platelet Count and White Blood Cell Count at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventiongiga per Liter (GI/L) (Mean)
Platelet count, Week 16Platelet count, Week 52White Blood Cell Count, Week 16White Blood Cell Count, Week 52
Ropinirole PR/XR-6.81-8.07-0.6-0.5

[back to top]

Change From Baseline in Hematocrit at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionproportion of 1 (SI) (Mean)
Week 16Week 52
Ropinirole PR/XR-0.01-0.01

[back to top]

Change From Baseline in Supine and Standing Systolic and Diastolic Blood Pressure at Weeks 16 and 52

Change from baseline was calculated as Week 16 and Week 52 values minus baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionmillimeters of mercury (mmHg) (Mean)
Supine Systolic BP - Week 16Supine Systolic BP - Week 52Supine Diastolic BP - Week 16Supine Diastolic BP - Week 52Standing Systolic BP - Week 16Standing Systolic BP - Week 52Standing Diastolic BP - Week 16Standing Diastolic BP - Week 52
Ropinirole PR/XR-0.0-1.20.6-1.2-0.70.0-0.72.1

[back to top]

Change From Baseline in Albumin, Total Protein, and Hemoglobin at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventiongrams per Liter (G/L) (Mean)
Albumin, Week 16Albumin, Week 52Total Protein, Week 16Total Protein, Week 52Hemoglobin, Week 16Hemoglobin, Week 52
Ropinirole PR/XR-0.66-1.68-1.71-2.32-4.44-4.00

[back to top]

Change From Baseline in Blood Urea Nitrogen, Cholesterol, Chloride, Potassium, and Sodium at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionmillimoles per Liter (MMOL/L) (Mean)
Blood Urea Nitrogen, Week 16Blood Urea Nitrogen, Week 52Cholesterol, Week 16Cholesterol, Week 52Chloride, Week 16Chloride, Week 52Potassium, Week 16Potassium, Week 52Sodium, Week 16Sodium, Week 52
Ropinirole PR/XR0.020.19-0.3-0.3-0.10.4-0.01-0.03-0.1-0.1

[back to top]

Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventioninternational units per Liter (IU/L) (Mean)
Alkaline Phosphatase, Week 16Alkaline Phosphatase, Week 52Alanine Amino Transferase, Week 16Alanine Amino Transferase, Week 52Aspartate Amino Transferase, Week 16Aspartate Amino Transferase, Week 52Creatine Kinase, Week 16Creatine Kinase, Week 52Gamma Glutamyl transferase, Week 16Gamma Glutamyl transferase, Week 52Lactate Dehydrogenase, Week 16Lactate Dehydrogenase, Week 52
Ropinirole PR/XR16.52.51.12.30.32.05.744.0-0.2-3.6-2.98.7

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part II

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpercent change (Mean)
Week 1, n=60Week 2, n=58Week 3, n=58Week 4, n=56Week 6, n=55Week 8, n=54Week 10, n=55Week 12, n=54Week 16, n=52Final Assessment Point (Up to Week 16), n=60Week 20, n=51Week 24, n=49Week 28, n=46Week 32, n=45Week 36, n=45Week 40, n=43Week 44, n=43Week 48, n=42Week 52, n=42
Ropinirole PR/XR-11.01-23.04-33.09-44.30-48.89-53.88-52.52-51.51-50.78-49.03-50.10-54.29-51.15-50.91-51.05-48.31-47.48-49.28-41.48

[back to top]

Change From Baseline in the Japanese UPDRS Part I

The UPDRS (Unified Parkinson's Disease Rating Scale) assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpoints on a scale (Mean)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR-0.3-0.5-0.5-0.5-0.5-0.5-0.3-0.5-0.6-0.5-0.5-0.5-0.5-0.5-0.4-0.4-0.4-0.4-0.4

[back to top]

Percentage of Participants Who Remained in the Study on the Indicated Days

The percentage of participants remaining in the study was examined using the Kaplan-Meier method, in which a premature discontinuation will be considered as an event. (NCT00434304)
Timeframe: Days 0-364

Interventionpercentage of participants (Number)
Day 0Day 10Day 14Day 21Day 28Day 70Day 84Day 96Day 112Day 140Day 168Day 175Day 183Day 196Day 239Day 252Day 315Day 359Day 364
Ropinirole PR/XR100989794929089878584827977767473716967

[back to top]

Change From Baseline in the Japanese UPDRS Part III

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpoints on a scale (Mean)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR-3.1-5.8-7.7-9.7-10.5-11.5-12.4-12.3-12.2-11.3-12.1-11.6-11.5-11.7-11.7-11.5-11.2-11.9-11.4

[back to top]

Change From Baseline in the Japanese UPDRS Part IV

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpoints on a scale (Mean)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR0.20.40.30.30.30.20.20.20.20.20.30.20.30.20.30.10.20.30.2

[back to top]

Change From Baseline in Total Bilirubin, Blood Urea Nitrogen, and Creatinine at Weeks 16 and 52

Change from baseline was calculated as the Week 16 and 52 values minus the baseline values. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionmicromoles per Liter (UMOL/L) (Mean)
Total Bilirubin, Week 16Total Bilirubin, Week 52Creatinine, Week 16Creatinine, Week 52
Ropinirole PR/XR0.190.122.2811.266

[back to top]

Food Effects on AUC0-24 of SKF101468 (Ropinirole) and Its Metabolites

The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours (hr) post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. AUC0-24: area under the drug concentration 24 hr curve. (NCT00434304)
Timeframe: Weeks 5-16

Interventionhours*pg/mL (Geometric Mean)
SKF101468 (ropinirole), fedSKF101468 (ropinirole), fastedSKF104557 (metabolite), fedSKF104557 (metabolite), fastedSKF89124 (metabolite), fedSKF89124 (metabolite), fasted
Ropinirole PR/XR27206.10327191.80423090.15024478.7971044.8771092.635

[back to top]

Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites

The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. Cmax: maximum concentration, Cmin: trough plasma concentration. (NCT00434304)
Timeframe: Weeks 5-16

Interventionpicograms/milliliter (pg/mL) (Geometric Mean)
SKF101468 (ropinirole), Cmax, fedSKF101468 (ropinirole), Cmax, fastedSKF101468 (ropinirole), Cmin, fedSKF101468 (ropinirole), Cmin, fastedSKF104557 (metabolite), Cmax, fedSKF104557 (metabolite), Cmax, fastedSKF104557 (metabolite), Cmin, fedSKF104557 (metabolite), Cmin, fastedSKF89124 (metabolite), Cmax, fedSKF89124 (metabolite), Cmax, fastedSKF89124 (metabolite), Cmin, fedSKF89124 (metabolite), Cmin, fasted
Ropinirole PR/XR1563.7841542.182728.404725.1031159.1201250.554798.871786.09755.28260.74234.28134.599

[back to top]

Number of Participants Scored as Responders on the Clinician's Global Impression (CGI) Scale

"CGI is measured on a 7-point scale. 1: Very much improved, 2: Much Improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse, 7: Very much worse. Responders are defined as those participants scored as very much improved or much improved." (NCT00434304)
Timeframe: Weeks 1-52

Interventionparticipants (Number)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR8162539404547484144434038353533353735

[back to top]

Number of Participants With the Indicated Shift From Baseline in 12-Lead Electrocardiogram (ECG) Findings at Weeks 16 and 52

Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS. (NCT00434304)
Timeframe: Baseline (Screening) and Weeks 16 and 52

Interventionparticipants (Number)
Baseline: N; Week 16: NBaseline: N; Week 16: ANCSBaseline: N; Week 16: ACSBaseline: ANCS; Week 16: NBaseline: ANCS; Week 16: ANCSBaseline: ANCS; Week 16: ACSBaseline: ACS; Week 16: NBaseline: ACS; Week 16: ANCSBaseline: ACS; Week 16: ACSBaseline: N; Week 52: NBaseline: N; Week 52: ANCSBaseline: N; Week 52: ACSBaseline: ANCS; Week 52: NBaseline: ANCS; Week 52: ANCSBaseline: ANCS; Week 52: ACSBaseline: ACS; Week 52: NBaseline: ACS; Week 52: ANCSBaseline: ACS; Week 52: ACS
Ropinirole PR/XR3210051300022630590001

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part I

The UPDRS (Unified Parkinson's Disease Rating Scale) assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpercent change (Mean)
Week 1, n=30Week 2, n=29Week 3, n=29Week 4, n=28Week 6, n=27Week 8, n=27Week 10, n=27Week 12, n=26Week 16, n=24Final Assessment Point (Up to Week 16), n=30Week 20, n=23Week 24, n=22Week 28, n=20Week 32, n=19Week 36, n=19Week 40, n=17Week 44, n=17Week 48, n=16Week 52, n=16
Ropinirole PR/XR-34.17-54.60-63.79-60.71-69.44-54.94-48.46-62.50-77.08-68.89-71.74-65.91-71.67-67.54-55.26-69.61-52.94-59.38-53.13

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part III

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. A maximum total score is 108 points.The higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpercent change (Mean)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR-14.14-27.14-35.13-45.03-48.35-51.34-56.63-56.24-53.78-49.38-52.61-51.56-50.25-51.67-51.36-50.58-49.51-53.05-51.11

[back to top]

Change From Baseline in the Japanese UPDRS Part II

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpoints on a scale (Mean)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR-1.0-1.9-2.6-3.4-3.7-4.2-4.1-4.0-4.1-3.9-4.1-4.4-4.0-4.2-4.1-3.9-3.8-4.0-3.7

[back to top]

Percentage of Responders of the Total Score in the Japanese UPDRS Total Score in Part III

A responder is defined as a participant with a 30% or more reduction at baseline. The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpercentage of responders (Number)
Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR12.938.358.370.771.982.184.289.381.575.881.178.479.276.676.677.877.881.881.8

[back to top]

Plasma Trough Concentrations of SKF101468 (Ropinirole) and Its Metabolites

Blood sampling in the fixed titration phase will be performed at 24 hour post dose of the last dose of 2, 4, and 8 mg (immediately before the morning dose). Blood sampling in the maintenance dose phase will be performed at 24 hour post dose of 10 mg or more for one week or longer (immediately before the morning dose), as sampling needs to be conducted at steady state. (NCT00434304)
Timeframe: Weeks 1-16

Interventionpg/mL (Mean)
SKF101468 (ropinirole), 2 mg, n=61SKF101468 (ropinirole), 4 mg, n=58SKF101468 (ropinirole), 6 mg, n=1SKF101468 (ropinirole), 8 mg, n=61SKF101468 (ropinirole), 10 mg, n=17SKF101468 (ropinirole), 12 mg, n=12SKF101468 (ropinirole), 14 mg, n=9SKF101468 (ropinirole), 16 mg, n=12SKF104557 (metabolite), 2 mg, n=61SKF104557 (metabolite), 4 mg, n=58SKF104557 (metabolite), 6 mg, n=1SKF104557 (metabolite), 8 mg, n=61SKF104557 (metabolite), 10 mg, n=17SKF104557 (metabolite), 12 mg, n=12SKF104557 (metabolite), 14 mg, n=9SKF104557 (metabolite), 16 mg, n=12SKF89124 (metabolite), 2 mg, n=61SKF89124 (metabolite), 4 mg, n=58SKF89124 (metabolite), 6 mg, n=1SKF89124 (metabolite), 8 mg, n=61SKF89124 (metabolite), 10 mg, n=17SKF89124 (metabolite), 12 mg, n=12SKF89124 (metabolite), 14 mg, n=9SKF89124 (metabolite), 16 mg, n=12
Ropinirole PR/XR1804.873529.593820.207598.909772.2311971.4912575.4115467.011564.523224.534172.106353.307944.7011814.2811579.7912753.8366.14139.84157.40281.36318.82479.36564.57628.76

[back to top]

Summary of the Modified Hoehn & Yahr Criteria Stages

Hoehn & Yahr criteria were measured on an 8-point scale. 0: No signs of disease, 1: Unilateral disease, 1.5: Unilateral plus axial involvement, 2: Bilateral disease, 2.5: Mild bilateral disease, 3: Mild to moderate bilateral disease. No subjects evaluated had a score of 4 (severe disability) or 5 (wheelchair bound or bedridden unless aided). (NCT00434304)
Timeframe: Screening-Week 52

Interventionpoints on a scale (Number)
Screening, Stage 0Screening, Stage 1Screening, Stage 1.5Screening, Stage 2Screening, Stage 2.5Screening, Stage 3Week 0, Stage 0Week 0, Stage 1Week 0, Stage 1.5Week 0, Stage 2Week 0, Stage 2.5Week 0, Stage 3Week 1, Stage 0Week 1, Stage 1Week 1, Stage 1.5Week 1, Stage 2Week 1, Stage 2.5Week 1, Stage 3Week 2, Stage 0Week 2, Stage 1Week 2, Stage 1.5Week 2, Stage 2Week 2, Stage 2.5Week 2, Stage 3Week 3, Stage 0Week 3, Stage 1Week 3, Stage 1.5Week 3, Stage 2Week 3, Stage 2.5Week 3, Stage 3Week 4, Stage 0Week 4, Stage 1Week 4, Stage 1.5Week 4, Stage 2Week 4, Stage 2.5Week 4, Stage 3Week 6, Stage 0Week 6, Stage 1Week 6, Stage 1.5Week 6, Stage 2Week 6, Stage 2.5Week 6, Stage 3Week 8, Stage 0Week 8, Stage 1Week 8, Stage 1.5Week 8, Stage 2Week 8, Stage 2.5Week 8, Stage 3Week 10, Stage 0Week 10, Stage 1Week 10, Stage 1.5Week 10, Stage 2Week 10, Stage 2.5Week 10, Stage 3Week 12, Stage 0Week 12, Stage 1Week 12, Stage 1.5Week 12, Stage 2Week 12, Stage 2.5Week 12, Stage 3Week 16, Stage 0Week 16, Stage 1Week 16, Stage 1.5Week 16, Stage 2Week 16, Stage 2.5Week 16, Stage 3Final Assessment Point (Up to Week 16), Stage 0Final Assessment Point (Up to Week 16), Stage 1Final Assessment Point (Up to Week 16), Stage 1.5Final Assessment Point (Up to Week 16), Stage 2Final Assessment Point (Up to Week 16), Stage 2.5Final Assessment Point (Up to Week 16), Stage 3Week 20, Stage 0Week 20, Stage 1Week 20, Stage 1.5Week 20, Stage 2Week 20, Stage 2.5Week 20, Stage 3Week 24, Stage 0Week 24, Stage 1Week 24, Stage 1.5Week 24, Stage 2Week 24, Stage 2.5Week 24, Stage 3Week 28, Stage 0Week 28, Stage 1Week 28, Stage 1.5Week 28, Stage 2Week 28, Stage 2.5Week 28, Stage 3Week 32, Stage 0Week 32, Stage 1Week 32, Stage 1.5Week 32, Stage 2Week 32, Stage 2.5Week 32, Stage 3Week 36, Stage 0Week 36, Stage 1Week 36, Stage 1.5Week 36, Stage 2Week 36, Stage 2.5Week 36, Stage 3Week 40, Stage 0Week 40, Stage 1Week 40, Stage 1.5Week 40, Stage 2Week 40, Stage 2.5Week 40, Stage 3Week 44, Stage 0Week 44, Stage 1Week 44, Stage 1.5Week 44, Stage 2Week 44, Stage 2.5Week 44, Stage 3Week 48, Stage 0Week 48, Stage 1Week 48, Stage 1.5Week 48, Stage 2Week 48, Stage 2.5Week 48, Stage 3Week 52, Stage 0Week 52, Stage 1Week 52, Stage 1.5Week 52, Stage 2Week 52, Stage 2.5Week 52, Stage 3
Ropinirole PR/XR07718121806523121608424121418522121201232681101252678117423391185217431972125318817553166204531862357416320373143224521441756214219552132196521221874216214561161164611521655

[back to top]

Total Score in the Japanese UPDRS Part I

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per each item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. (NCT00434304)
Timeframe: Weeks 0-52

Interventionpoints on a scale (Mean)
Week 0, n=62Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR1.00.70.60.50.40.50.50.60.40.40.40.30.40.30.30.40.30.30.30.3

[back to top]

Total Score in the Japanese UPDRS Part II

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per each item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Weeks 0-52

Interventionpoints on a scale (Mean)
Week 0, n=62Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR8.27.26.35.54.84.54.04.14.24.14.34.13.74.03.94.04.14.23.84.1

[back to top]

Total Score in the Japanese UPDRS Part III

The Unified Parkinson's Disease Rating Scale (UPDRS) assesses the status of Parkinson's Disease (PD) patients objectively. The Japanese UPDRS Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per each item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. (NCT00434304)
Timeframe: Weeks 0-52

Interventionpoints on a scale (Mean)
Week 0, n=62Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR22.419.316.814.513.012.111.110.210.110.311.110.410.610.610.710.711.011.310.210.7

[back to top]

Total Score in the Japanese UPDRS Part IV

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 0-52

Interventionpoints on a scale (Mean)
Week 0, n=62Week 1, n=62Week 2, n=60Week 3, n=60Week 4, n=58Week 6, n=57Week 8, n=56Week 10, n=57Week 12, n=56Week 16, n=54Final Assessment Point (Up to Week 16), n=62Week 20, n=53Week 24, n=51Week 28, n=48Week 32, n=47Week 36, n=47Week 40, n=45Week 44, n=45Week 48, n=44Week 52, n=44
Ropinirole PR/XR0.40.60.80.70.70.70.50.50.50.60.60.60.50.60.50.60.40.50.50.5

[back to top]

Urinalysis Data

The number of participants with the indicated dipstick test values were measured. Dipstick test values: Neg Value, Trace, +1, +2, +3, +4. No participants had a score of +5. (NCT00434304)
Timeframe: Screening, Week 16, and Week 52

Interventionparticipants (Number)
Urine Occult Blood - Screening: Neg ValueUrine Occult Blood - Screening: TraceUrine Occult Blood - Screening: +1Urine Occult Blood - Screening: +2Urine Occult Blood - Screening: +3Urine Occult Blood - Screening: +4Urine Occult Blood - Week 16: Neg ValueUrine Occult Blood - Week 16: TraceUrine Occult Blood - Week 16: +1Urine Occult Blood - Week 16: +2Urine Occult Blood - Week 16: +3Urine Occult Blood - Week 16: +4Urine Occult Blood - Week 52: Neg ValueUrine Occult Blood - Week 52: TraceUrine Occult Blood - Week 52: +1Urine Occult Blood - Week 52: +2Urine Occult Blood - Week 52: +3Urine Occult Blood - Week 52: +4Urine Glucose - Screening: Neg ValueUrine Glucose - Screening: TraceUrine Glucose - Screening: +1Urine Glucose - Screening: +2Urine Glucose - Screening: +3Urine Glucose - Screening: +4Urine Glucose - Week 16: Neg ValueUrine Glucose - Week 16: TraceUrine Glucose - Week 16: +1Urine Glucose - Week 16: +2Urine Glucose - Week 16: +3Urine Glucose - Week 16: +4Urine Glucose - Week 52: Neg ValueUrine Glucose - Week 52: TraceUrine Glucose - Week 52: +1Urine Glucose - Week 52: +2Urine Glucose - Week 52: +3Urine Glucose - Week 52: +4Urine Protein - Screening: Neg ValueUrine Protein - Screening: TraceUrine Protein - Screening: +1Urine Protein - Screening: +2Urine Protein - Screening: +3Urine Protein - Screening: +4Urine Protein - Week 16: Neg ValueUrine Protein - Week 16: TraceUrine Protein - Week 16: +1Urine Protein - Week 16: +2Urine Protein - Week 16: +3Urine Protein - Week 16: +4Urine Protein - Week 52: Neg ValueUrine Protein - Week 52: TraceUrine Protein - Week 52: +1Urine Protein - Week 52: +2Urine Protein - Week 52: +3Urine Protein - Week 52: +4Urine Urobilinogen - Screening: Neg ValueUrine Urobilinogen - Screening: TraceUrine Urobilinogen - Screening: +1Urine Urobilinogen - Screening: +2Urine Urobilinogen - Screening: +3Urine Urobilinogen - Screening: +4Urine Urobilinogen - Week 16: Neg ValueUrine Urobilinogen - Week 16: TraceUrine Urobilinogen - Week 16: +1Urine Urobilinogen - Week 16: +2Urine Urobilinogen - Week 16: +3Urine Urobilinogen - Week 16: +4Urine Urobilinogen - Week 52: Neg ValueUrine Urobilinogen - Week 52: TraceUrine Urobilinogen - Week 52: +1Urine Urobilinogen - Week 52: +2Urine Urobilinogen - Week 52: +3Urine Urobilinogen - Week 52: +4
Ropinirole PR/XR527111053450004112000570121159020014120001600200055331004301000062000006110000431000

[back to top]

Food Effects on Tmax of SKF101468 (Ropinirole) and Its Metabolites

The dose of SKF101468 and its metabolites was normalized to 1 mg. Blood sampling at steady state up to 24 hours post dose after receiving the maintenance dose was conducted. In order to investigate the effect of a meal on pharmacokinetics, blood was sampled twice (after a standard morning meal and at fasted state) from identical participants. Tmax: time of maximum concentration. Data are presented as the median difference between fed and fasted states for ropinirole and each metabolite. (NCT00434304)
Timeframe: Weeks 5-16

Interventionhours (Median)
SKF101468 (ropinirole)SKF104557 (metabolite)SKF89124 (metabolite)
Ropinirole PR/XR2.0003.9831.000

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part IV

The UPDRS assesses the status of PD patients objectively. The Japanese UPDRS Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per each item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. (NCT00434304)
Timeframe: Baseline (Week 0) and Weeks 1-52

Interventionpercent change (Mean)
Week 1, n=21Week 2, n=20Week 3, n=19Week 4, n=19Week 6, n=18Week 8, n=17Week 10, n=18Week 12, n=17Week 16, n=16Final Assessment Point (Up to Week 16), n=21Week 20, n=15Week 24, n=14Week 28, n=13Week 32, n=13Week 36, n=13Week 40, n=12Week 44, n=12Week 48, n=12Week 52, n=12
Ropinirole PR/XR-2.3817.5010.537.89-5.56-35.29-16.67-14.71-15.63-16.67-6.67-25.00-23.08-34.62-26.92-41.67-25.00-41.67-41.67

[back to top]

Change From Baseline to Week 12/EW in Pittsburgh Sleep Quality Index (PSQI) Total Score by Domains

The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0-21). A PSQI global score > 5 is considered to be suggestive of significant sleep disturbance. (NCT00530790)
Timeframe: Baseline - Week 12/EW

InterventionPoints on a scale (Mean)
Sleep Quality - BaselineSleep Quality - Week 12/EWSleep Quality - Change from BaselineDuration getting to sleep - BaselineDuration getting to sleep - Week 12/EWDuration getting to sleep - Change from BaselineSleep Duration - BaselineSleep Duration - Week 12/EWSleep Duration - Change from BaselineSleep Adequacy - BaselineSleep Adequacy - Week 12/EWSleep Adequacy - Change from BaselineSleep Disturbance - BaselineSleep Disturbance - Week 12/EWSleep Disturbance - Change from BaselineUse of Sleeping pill - BaselineUse of Sleeping pill - Week 12/EWUse of Sleeping pill - Change from BaselineSomnolence - BaselineSomnolence - Week 12/EWSomnolence - Change from Baseline
Ropinirole CR-RLS2.01.2-0.92.01.0-1.11.91.5-0.40.90.4-0.61.20.9-0.30.40.0-0.41.00.5-0.5

[back to top]

Clinical Global Impression Global Improvement (CGI-GI)

CGI-GI is a 7 point scale assessing Global Improvement. 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse (no patients scored a 5, 6, or 7). (NCT00530790)
Timeframe: Baseline - Final assessment point

InterventionParticipants (Number)
Week 1 - Very Much ImprovedWeek 1 - Much ImprovedWeek 1 - Minimally ImprovedWeek 1 - No ChangeWeek 2 - Very Much ImprovedWeek 2 - Much ImprovedWeek 2 - Minimally ImprovedWeek 2 - No ChangeWeek 3 - Very Much ImprovedWeek 3 - Much ImprovedWeek 3 - Minimally ImprovedWeek 3 - No ChangeWeek 4 - Very Much ImprovedWeek 4 - Much ImprovedWeek 4 - Minimally ImprovedWeek 4 - No ChangeWeek 5 - Very Much ImprovedWeek 5 - Much ImprovedWeek 5 - Minimally ImprovedWeek 5 - No ChangeWeek 6 - Very Much ImprovedWeek 6 - Much ImprovedWeek 6 - Minimally ImprovedWeek 6 - No ChangeWeek 8 - Very Much ImprovedWeek 8 - Much ImprovedWeek 8 - Minimally ImprovedWeek 8 - No ChangeWeek 10 - Very Much ImprovedWeek 10 - Much ImprovedWeek 10 - Minimally ImprovedWeek 10 - No ChangeWeek 12 - Very Much ImprovedWeek 12 - Much ImprovedWeek 12 - Minimally ImprovedWeek 12 - No ChangeFinal assessment point - Very Much ImprovedFinal assessment point - Much ImprovedFinal assessment point - Minimally ImprovedFinal assessment point - No Change
Ropinirole CR-RLS412136159922176121761216602274024620226202540127512

[back to top]

Clinical Global Impression Scale - Severity of Illness (CGI-S)

The CGI-S scale measures the overall severity of illness on a 7 point scale. Normal = 1, Borderline = 2, Mildly = 3, Moderately = 4, Markedly = 5, Severely = 6, Extremely Severe = 7(no subjects scored a 7). (NCT00530790)
Timeframe: Baseline - Final assessment point

InterventionParticipants (Number)
Baseline - NormalBaseline - BorderlineBaseline - MildlyBaseline - ModeratelyBaseline - MarkedlyBaseline - SeverelyWeek 1 - NormalWeek 1 - BorderlineWeek 1 - MildlyWeek 1 - ModeratelyWeek 1 - MarkedlyWeek 1 - SeverelyWeek 2 - NormalWeek 2 - BorderlineWeek 2 - MildlyWeek 2 - ModeratelyWeek 2 - MarkedlyWeek 2 - SeverelyWeek 3 - NormalWeek 3 - BorderlineWeek 3 - MildlyWeek 3 - ModeratelyWeek 3 - MarkedlyWeek 3 - SeverelyWeek 4 - NormalWeek 4 - BorderlineWeek 4 - MildlyWeek 4 - ModeratelyWeek 4 - MarkedlyWeek 4 - SeverelyWeek 5 - NormalWeek 5 - BorderlineWeek 5 - MildlyWeek 5 - ModeratelyWeek 5 - MarkedlyWeek 5 - SeverelyWeek 6 - NormalWeek 6 - BorderlineWeek 6 - MildlyWeek 6 - ModeratelyWeek 6 - MarkedlyWeek 6 - SeverelyWeek 8 - NormalWeek 8 - BorderlineWeek 8 - MildlyWeek 8 - ModeratelyWeek 8 - MarkedlyWeek 8 - SeverelyWeek 10 - NormalWeek 10 - BorderlineWeek 10 - MildlyWeek 10 - ModeratelyWeek 10 - MarkedlyWeek 10 - SeverelyWeek 12 - NormalWeek 12 - BorderlineWeek 12 - MildlyWeek 12 - ModeratelyWeek 12 - MarkedlyWeek 12 - SeverelyFinal assessment point - NormalFinal assessment point - BorderlineFinal assessment point - MildlyFinal assessment point - ModeratelyFinal assessment point - MarkedlyFinal assessment point - Severely
Ropinirole CR-RLS0001313903101642371210211178711991051111611410134114101010831015581101631001017312111

[back to top] [back to top]

Pharmacokinetic Analysis: Plasma Concentrations of SK&F104557, a Circulating Metabolite of Ropinirole.

Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&104557 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision. (NCT00530790)
Timeframe: Weeks 1 -12

Interventionpicograms/mL (Mean)
35 subjects who received 0.5 mg of Study drug27 subjects who received 1 mg of Study drug11 subjects who received 2 mg of Study drug2 subjects who received 3 mg of Study drug2 subjects who received 4 mg of Study drug
Ropinirole CR-RLS324.65615.911320.311666.652541.95

[back to top]

Haematology Clinical Lab Values Change From Baseline

Standard units of measure vary. Therefore, Mean Change is represented in Standard Units: Hematocrit = SI unit of GSK; Hemoglobin = G/L; Platelet count, White Blood Cell count = GI/L; Red Blood Cell count = TI/L. n = number of subjects evaluated. EW = Early Withdrawal. (NCT00530790)
Timeframe: Baseline - Week 13 (Follow-up)

InterventionVaried Standard Units of Measure (Mean)
Hemoglobin (G/L) - week 4Hemoglobin (G/L) - week 8Hemoglobin (G/L) - week 12Hemoglobin (G/L) - week 12/EWHemoglobin (G/L)- week 13Hematocrit (SI) - week 4Hematocrit (SI) - week 8Hematocrit (SI) - week 12Hematocrit (SI) - week 12/EWHematocrit (SI) - week 13Platelet Count (GI/L) - week 4Platelet Count (GI/L) - week 8Platelet Count (GI/L) - week 12Platelet Count (GI/L) - week 12/EWPlatelet Count (GI/L) - week 13Red Blood Cell Count (TI/L) - week 4Red Blood Cell Count (TI/L) - week 8Red Blood Cell Count (TI/L) - week 12Red Blood Cell Count (TI/L) - week 12/EWRed Blood Cell Count (TI/L) - week 13White Blood Cell Count (GI/L) - week 4White Blood Cell Count (GI/L) - week 8White Blood Cell Count (GI/L) - week 12White Blood Cell Count (GI/L) - week 12/EWWhite Blood Cell Count (GI/L) - week 13
Ropinirole CR-RLS-1.2-2.7-1.0-0.8-2.2-0.0033-0.0074-0.0021-0.0016-0.006314.511.78.58.810.7-0.043-0.084-0.015-0.011-0.050-0.191-0.268-0.577-0.516-0.624

[back to top]

Pharmacokinetic Analysis: Plasma Concentrations of SK&F101468, an Unchanged Form of Ropinirole.

Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&101468 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision. (NCT00530790)
Timeframe: Weeks 1-12

Interventionpicograms/mL (Mean)
35 subjects who received 0.5 mg of Study drug27subjects who received 1 mg of Study drug11 subjects who received 2 mg of Study drug2 subjects who received 3 mg of Study drug2 subjects who received 4 mg of Study drug
Ropinirole CR-RLS310.01500.97968.361294.551198.10

[back to top]

12-Lead Electrocardiogram (ECG) Findings Transitions From Baseline

Baseline Finding/Time Period Finding. Abbreviations: N = normal; A = abnormal; CS = clinically significant; NCS = not clinically significant. Options include N/N, N/ANCS, N/ACS, ANCS/N, ANCS/ANCS, ANCS/ACS, ACS/N, ACS/ANCS, and ACS/ACS. (NCT00530790)
Timeframe: Baseline, Week 4, 8, 12, 13 (Follow-up)

InterventionParticipants (Number)
Baseline: N; Baseline: NBaseline: N; Baseline: ANCSBaseline: N; Baseline: ACSBaseline: ANCS; Baseline: NBaseline: ANCS; Baseline: ANCSBaseline: ANCS; Baseline: ACSBaseline: ACS; Baseline: NBaseline; ACS; Baseline: ANCSBaseline: ACS ; Baseline: ACSBaseline: N; Week 4: NBaseline: N; Week 4: ANCSBaseline: N; Week 4: ACSBaseline: ANCS; Week 4: NBaseline: ANCS; Week 4: ANCSBaseline: ANCS; Week 4: ACSBaseline: ACS; Week 4: NBaseline: ACS; Week 4: ANCSBaseline: ACS; Week 4: ACSBaseline: N; Week 8: NBaseline: N; Week 8: ANCSBaseline: N; Week 8: ACSBaseline: ANCS; Week 8: NBaseline: ANCS; Week 8: ANCSBaseline: ANCS; Week 8: ACSBaseline: ACS; Week 8: NBaseline: ACS; Week 8: ANCSBaseline: ACS; Week 8: ACSBaseline: N; Week 12/EW: NBaseline: N; Week 12/EW: ANCSBaseline: N; Week 12/EW: ACSBaseline: ANCS; Week 12/EW: NBaseline: ANCS; Week 12/EW: ANCSBaseline: ANCS; Week 12/EW: ACSBaseline: ACS; Week 12/EW: NBaseline: ACS; Week 12/EW: ANCSBaseline: ACS; Week 12/EW: ACSBaseline: N; Week 13: NBaseline: N; Week 13: ANCSBaseline: N; Week 13: ACSBaseline: ANCS; Week 13: NBaseline: ANCS; Week 13: ANCSBaseline: ANCS; Week 13: ACSBaseline: ACS; Week 13: NBaseline: ACS; Week 13: ANCSBaseline: ACS; Week 13: ACS
Ropinirole CR-RLS29000500012710211001242021101027004010012720221001

[back to top]

Pharmacokinetic Analysis: Plasma Concentrations of SK&F89124, a Circulating Metabolite of Ropinirole.

Plasma samples taken at 24 hours after dosing had been administered for 3 days or longer. This was repeated if the dose was escalated. Lower Limits of Quantitation (LLQ) for SK&89124 = 20 pg/mL. The lowest concentration of analyte can be measured with established acceptable accuracy and precision. (NCT00530790)
Timeframe: Weeks 1-12

Interventionpicograms/mL (Mean)
2 subjects who received 0.5 mg of Study drug11 subjects who received 1 mg of Study drug11 subjects who received 2 mg of Study drug2 subjects who received 3 mg of Study drug2 subjects who received 4 mg of Study drug
Ropinirole CR-RLS22.4530.3742.7546.8072.05

[back to top]

Urinalysis Clinical Lab Values

Dipstick test values: Neg Value, Trace, +1, +2, +3. No subjects tested higher than +3. (NCT00530790)
Timeframe: Baseline - Week 13 (Follow-up)

InterventionParticipants (Number)
Urine Urobilinogen - Baseline: Neg ValueUrine Urobilinogen - Baseline: TraceUrine Urobilinogen - Baseline: +1Urine Urobilinogen - Baseline: +2Urine Urobilinogen - Baseline: +3Urine Urobilinogen - week 4: Neg ValueUrine Urobilinogen - week 4: TraceUrine Urobilinogen - week 4: +1Urine Urobilinogen - week 4: +2Urine Urobilinogen - week 4: +3Urine Urobilinogen - week 8: Neg ValueUrine Urobilinogen - week 8: TraceUrine Urobilinogen - week 8: +1Urine Urobilinogen - week 8: +2Urine Urobilinogen - week 8: +3Urine Urobilinogen - week 12: Neg ValueUrine Urobilinogen - week 12: TraceUrine Urobilinogen - week 12: +1Urine Urobilinogen - week 12: +2Urine Urobilinogen - week 12: +3Urine Urobilinogen - week 12/EW: Neg ValueUrine Urobilinogen - week 12/EW: TraceUrine Urobilinogen - week 12/EW: +1Urine Urobilinogen - week 12/EW: +2Urine Urobilinogen - week 12/EW: +3Urine Urobilinogen - week 13: Neg ValueUrine Urobilinogen - week 13: TraceUrine Urobilinogen - week 13: +1Urine Urobilinogen - week 13: +2Urine Urobilinogen - week 13: +3Urine Protein - Baseline: Neg ValueUrine Protein - Baseline: TraceUrine Protein - Baseline: +1Urine Protein - Baseline: +2Urine Protein - Baseline: +3Urine Protein - Week 4: Neg ValueUrine Protein - Week 4: TraceUrine Protein - Week 4: +1Urine Protein - Week 4: +2Urine Protein - Week 4: +3Urine Protein - Week 8: Neg ValueUrine Protein - Week 8: TraceUrine Protein - Week 8: +1Urine Protein - Week 8: +2Urine Protein - Week 8: +3Urine Protein - Week 12: Neg ValueUrine Protein - Week 12: TraceUrine Protein - Week 12: +1Urine Protein - Week 12: +2Urine Protein - Week 12: +3Urine Protein - Week 12/EW: Neg ValueUrine Protein - Week 12/EW: TraceUrine Protein - Week 12/EW: +1Urine Protein - Week 12/EW: +2Urine Protein - Week 12/EW: +3Urine Protein - Week 13: Neg ValueUrine Protein - Week 13: TraceUrine Protein - Week 13: +1Urine Protein - Week 13: +2Urine Protein - Week 13: +3Urine Occult Blood - Baseline: Neg ValueUrine Occult Blood - Baseline: TraceUrine Occult Blood - Baseline: +1Urine Occult Blood - Baseline: +2Urine Occult Blood - Baseline: +3Urine Occult Blood - Week 4: Neg ValueUrine Occult Blood - Week 4: TraceUrine Occult Blood - Week 4: +1Urine Occult Blood - Week 4: +2Urine Occult Blood - Week 4: +3Urine Occult Blood - Week 8: Neg ValueUrine Occult Blood - Week 8: TraceUrine Occult Blood - Week 8: +1Urine Occult Blood - Week 8: +2Urine Occult Blood - Week 8: +3Urine Occult Blood - Week 12: Neg ValueUrine Occult Blood - Week 12: TraceUrine Occult Blood - Week 12: +1Urine Occult Blood - Week 12: +2Urine Occult Blood - Week 12: +3Urine Occult Blood - Week 12/EW: Neg ValueUrine Occult Blood - Week 12/EW: TraceUrine Occult Blood - Week 12/EW: +1Urine Occult Blood - Week 12/EW: +2Urine Occult Blood - Week 12/EW: +3Urine Occult Blood - Week 13: Neg ValueUrine Occult Blood - Week 13: TraceUrine Occult Blood - Week 13: +1Urine Occult Blood - Week 13: +2Urine Occult Blood - Week 13: +3Urine Glucose - Baseline: Neg ValueUrine Glucose - Baseline: TraceUrine Glucose - Baseline: +1Urine Glucose - Baseline: +2Urine Glucose - Baseline: +3Urine Glucose - Week 4: Neg ValueUrine Glucose - Week 4: TraceUrine Glucose - Week 4: +1Urine Glucose - Week 4: +2Urine Glucose - Week 4: +3Urine Glucose - Week 8: Neg ValueUrine Glucose - Week 8: TraceUrine Glucose - Week 8: +1Urine Glucose - Week 8: +2Urine Glucose - Week 8: +3Urine Glucose - Week 12: Neg ValueUrine Glucose - Week 12: TraceUrine Glucose - Week 12: +1Urine Glucose - Week 12: +2Urine Glucose - Week 12: +3Urine Glucose - Week 12/EW: Neg ValueUrine Glucose - Week 12/EW: TraceUrine Glucose - Week 12/EW: +1Urine Glucose - Week 12/EW: +2Urine Glucose - Week 12/EW: +3Urine Glucose - Week 13: Neg ValueUrine Glucose - Week 13: TraceUrine Glucose - Week 13: +1Urine Glucose - Week 13: +2Urine Glucose - Week 13: +3
Ropinirole CR-RLS035000035000032000030000033000035000341000350000311000300000330000350000275300207620253301234210255210263600350000340100311000291000321000350000

[back to top]

Vital Signs and Body Weight Change From Baseline

Units of Measure Vary: Weight = kg; Semi-supine and Standing Systolic and Diastolic BP = mmHg; Semi-supine and Standing Pulse Rate = bpm; EW = early withdrawal; Semi-supine = lying down; Orthostatic = lying, sitting, and standing. (NCT00530790)
Timeframe: Baseline to Week 12/EW

InterventionVaried Standard Units of Measure (Mean)
Weight (Kg)Semi-Supine Systolic BP (mmHg)Semi-Supine Diastolic BP (mmHg)Semi-Supine Pulse Rate (bpm)Standing Systolic BP (mmHg)Standing Diastolic BP (mmHg)Standing Pulse Rate (bpm)Orthostatic Systolic BP (mmHg)Orthostatic Diastolic BP (mmHg)Orthostatic Pulse Rate (bpm)
Ropinirole CR-RLS0.52.72.60.8-0.70.81.1-1.54.39.2

[back to top]

Blood Chemistry Clinical Lab Values Change From Baseline

Mean Change in Standard Units of Measure: Albumin, Total Protein=G/L; Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Lactate Dehydrogenase, Creatine Phosphokinase, Gamma Glutamyl Transferase=IU/L; Total Bilirubin, Creatinine=UMOL/L; Blood Urea Nitrogen, Cholesterol, Chloride, Sodium, Potassium=MMOL/L; Prolactin=MCG/L (NCT00530790)
Timeframe: Baseline - Week 13 (Follow-up)

InterventionVaried Standard Units of Measure (Mean)
Albumin (G/L) - week 4Albumin (G/L) - week 8Albumin (G/L) - week 12Albumin (G/L) - week 12/EWAlbumin (G/L) - week 13Alkaline Phosphatase (IU/L) - week 4Alkaline Phosphatase (IU/L) - week 8Alkaline Phosphatase (IU/L) - week 12Alkaline Phosphatase (IU/L) - week 12/EWAlkaline Phosphatase (IU/L) - week 13Alanine Amino Transferase (IU/L) - week 4Alanine Amino Transferase (IU/L) - week 8Alanine Amino Transferase (IU/L) - week 12Alanine Amino Transferase - week 12/EWAlanine Amino Transferase - week 13Aspartate Amino Transferase(IU/L) - week 4Aspartate Amino Transferase (IU/L) - week 8Aspartate Amino Transferase (IU/L) - week 12Aspartate Amino Transferase (IU/L) - week 12/EWAspartate Amino Transferase (IU/L) - week 13Total Bilirubin (UMOL/L) - week 4Total Bilirubin (UMOL/L) - week 8Total Bilirubin (UMOL/L) - week 12Total Bilirubin (UMOL/L) - week 12/EWTotal Bilirubin (UMOL/L) - week 13Blood Urea Nitrogen (MMOL/L) - week 4Blood Urea Nitrogen (MMOL/L) - week 8Blood Urea Nitrogen (MMOL/L) - week 12Blood Urea Nitrogen (MMOL/L) - week 12/EWBlood Urea Nitrogen (MMOL/L) - week 13Cholesterol (MMOL/L) - week 4Cholesterol (MMOL/L) - week 8Cholesterol (MMOL/L) - week 12Cholesterol (MMOL/L) - week 12/EWCholesterol - week 13Chloride(MMOL/L) - week 4Chloride (MMOL/L) - week 8Chloride (MMOL/L) - week 12Chloride (MMOL/L) - week 12/EWChloride (MMOL/L) - week 13Lactate Dehydrogenase (IU/L) - week 4Lactate Dehydrogenase (IU/L) - week 8Lactate Dehydrogenase (IU/L) - week 12Lactate Dehydrogenase (IU/L) - week 12/EWLactate Dehydrogenase (IU/L) - week 13Sodium (MMOL/L) - week 4Sodium (MMOL/L) - week 8Sodium (MMOL/L) - week 12Sodium (MMOL/L) - week 12/EWSodium (MMOL/L) - week 13Prolactin (MCG/L) - week 4Prolactin (MCG/L) - week 8Prolactin (MCG/L) - week 12Prolactin (MCG/L) - week 12/EWProlactin (MCG/L) - week 13Total Protein (G/L) - week 4Total Protein (G/L) - week 8Total Protein (G/L) - week 12Total Protein (G/L) - week 12/EWTotal Protein (G/L) - week 13Creatine Phosphokinase (IU/L) - week 4Creatine Phosphokinase (IU/L) - week 8Creatine Phosphokinase (IU/L) - week 12Creatine Phosphokinase (IU/L) - week 12/EWCreatine Phosphokinase (IU/L) - week 13Creatinine (UMOL/L) - week 4Creatinine (UMOL/L) - week 8Creatinine (UMOL/L) - week 12Creatinine (UMOL/L) - week 12/EWCreatinine (UMOL/L) - week 13Gamma Glutamyl Transferase (IU/L) - week 4Gamma Glutamyl Transferase (IU/L) - week 8Gamma Glutamyl Transferase (IU/L) - week 12Gamma Glutamyl Transferase (IU/L) - week 12/EWGamma Glutamyl Tranferase (IU/L) - week 13Potassium (MMOL/L) - week 4Potassium (MMOL/L) - week 8Potassium (MMOL/L) - week 12Potassium (MMOL/L) - week 12/EWPotassium (MMOL/L) - week 13
Ropinirole CR-RLS-1.0-1.4-0.7-0.6-1.35.24.213.213.416.0-0.3-0.71.71.81.40.4-0.21.31.50.60.147-0.5880.5130.311-1.173-0.14382-0.060240.257040.303990.32334-0.093835-0.1907170.1517120.146540-0.1078730.10.3-0.3-0.2-0.10.3-1.32.02.7-2.2-0.4-0.20.0-0.0-0.20.800.510.200.221.14-1.1-1.7-0.8-0.8-2.272.3-15.8-0.6-0.2-1.91.31340.58011.00191.04471.64171.5-1.41.92.60.10.070.050.090.100.06

[back to top]

Change From Baseline at Week 12/Early Withdrawal (EW) in Hospital Anxiety and Depression Scale (HADS)

"Self screening questionnaire that requires the first response to questions. Questionnaire consists of 14 questions, seven for anxiety 0-21 and seven for depression 0-21. Questions are answered on a four point scale from 0-3; Items 1, 3, 5, 6, 8, 10, 11, and 13 are reversed for summation." (NCT00530790)
Timeframe: Baseline - Week 12/EW

InterventionPoints on a scale (Mean)
Anxiety-HADS Anxiety Population - BaselineAnxiety-HADS Anxiety Population - Week 12/EWChange from Baseline for Anxiety PopulationDepression-HADS Depression Population -BaselineDepression-HADS Depression Population-Week 12/EWChange from Baseline for Depression Population
Ropinirole CR-RLS9.37.7-1.89.79.5-0.1

[back to top]

Change From Baseline at Week 12/Early Withdrawal (EW) in Johns Hopkins Restless Leg Syndrome Quality of Life Questionnaire (RLSQOL) on the Overall Life Impact Score

The RLSQOL scale consists of 18 items, 13 of which are scored on a 5-point scale. Ten of the items can be summed to the overall life impact score, which can be transformed to a 0-100 score. Mild = 84.48, Moderate = 62.93, or Severe = 37.47 (NCT00530790)
Timeframe: Baseline and Week 12/EW

InterventionPoints on a scale (Mean)
RLSQOL Overall Life Impact Score - BaselineRLSQOL Overall Life Impact Score - Week 12Change from Baseline
Ropinirole CR-RLS65.2989.0923.94

[back to top]

Change From Baseline at Week 12/Early Withdrawal (EW) in Pittsburgh Sleep Quality Index (PSQI) Total Score

The PSQI generates seven scores that correspond to different domains. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The domain scores are totaled to produce a global score (range of 0-21). A PSQI global score > 5 is considered to be suggestive of significant sleep disturbance. (NCT00530790)
Timeframe: Baseline - Week 12/EW

InterventionPoints on a scale (Mean)
PSQI Total Score at BaselinePSQI Total Score at Week 12/EWChange from Baseline at Week 12/EW
Ropinirole CR-RLS9.45.4-4.2

[back to top]

Change From Baseline at Week 12/Early Withdrawal (EW) in Profile of Mood Status (POMS)

"The POMS Standard form contains 65 items (0-232). The respondent rates each item on a 5-point scale, ranging from Not at all (0) to Extremely (4). The assessment measures six identified mood factors:~Tension-Anxiety~Depression-Dejection~Anger-Hostility~Vigor-Activity~Fatigue-Inertia~Confusion-Bewilderment" (NCT00530790)
Timeframe: Baseline and Week 12/EW

InterventionPoints on a scale (Mean)
POMS - BaselinePOMS - Week 12/EWChange from Baseline
Ropinirole CR-RLS59.248.0-10.4

[back to top]

Change From Baseline to Week 12 in International Restless Leg Syndrome (IRLS) Rating Scale Total Score

The IRLS Scale assesses the severity of sensory and motor symptoms, sleep disturbance, daytime somnolence, and impact on activities of daily living and mood. The questionnaire scores various questions and totals them using the following scale: Very severe=31-40 points, Severe=21-30 points, Moderate=11-20 points, Mild=1-10 points, None=0 points. (NCT00530790)
Timeframe: Baseline and after Week 12

InterventionPoints on a scale (Mean)
IRLS assessment Score - week 0IRLS assessment Score - week 12Change from Baseline at week 12
Ropinirole CR-RLS25.36.0-19.3

[back to top]

Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)

AEs, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, were collected to obtain data on the safety, tolerability, and benefit of ropinirole XL. SAEs, defined as AEs that are fatal, life threatening, disabling/incapacitating, resulting in hospitalization or prolongation of a hospital stay, a congenital abnormality/birth defect, or any important medical occurrence that the investigator regards as serious based on medical judgment, were also collected. st. med., study medication. (NCT00632736)
Timeframe: 13 February 2004 through 31 March 2010

Interventionparticipants (Number)
Participants (Par.) reporting at least one AEPar. reporting at least one SAEPar. with drug-related AEsPar. with AEs leading to withdrawal
Ropinirole XL365109213106

[back to top]

Number of Participants With the Indicated Response to the Patient Preference Question at Week 4 and Week 26

"The patient preference question assessed the participant's preference for either dosing regimen of study drug, once a day versus three times a day. Participants were asked to respond to the following question to assess preference: Please indicate whether you preferred taking your Parkinson's tablets 3 times a day or once a day. Wk, Week." (NCT00632736)
Timeframe: Week 4 and Week 26

Interventionparticipants (Number)
Very much preferred three times a day, Wk 4, n=74Much preferred three times a day, Week 4, n=74Preferred three times a day, Week 4, n=74Both regimens are about the same, Week 4, n=74Preferred once a day, Week 4, n=74Much preferred once a day, Week 4, n=74Very much preferred once a day, Week 4, n=74Very much preferred three times a day, Wk 26, n=87Much preferred three times a day, Week 26, n=87Preferred three times a day, Week 26, n=87Both regimens are about the same, Week 26, n=87Preferred once a day, Week 26, n=87Much preferred once a day, Week 26, n=87Very much preferred once a day, Week 26, n=87
Ropinirole XL20451718284124142042

[back to top]

Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Responder Population)

The Clinical Global Impression (CGI) scale comprises the following three components (CGI-Severity, CGI-Improvement, Index); where only the CGI-S and CGI-I were assessed in this study. CGI-I is a global improvement scale that scores the clinician's view of the participant's global functioning prior to and after initiating a study medication from 1 (very much improved) to 7 (very much worse). 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse. (NCT00650104)
Timeframe: Week 2, Month 12, Month 78

Interventionparticipants (Number)
Week 2 - Very Much Improved, n=49Week 2 - Much Improved, n=49Week 2 - Minimally Improved, n=49Week 2 - No Change, n=49Week 2 - Minimally Worse, n=49Week 2 - Much Worse, n=49Week 2 - Very Much Worse, n=49Month 12 - Very Much Improved, n=56Month 12 - Much Improved, n=56Month 12 - Minimally Improved, n=56Month 12 - No Change, n=56Month 12 - Minimally Worse, n=56Month 12 - Much Worse, n=56Month 12 - Very Much Worse, n=56Month 78 - Very Much Improved, n=13Month 78 - Much Improved, n=13Month 78 - Minimally Improved, n=13Month 78 - No Change, n=13Month 78 - Minimally Worse, n=13Month 78 - Much Worse, n=13Month 78 - Very Much Worse, n=13
Ropinirole XL0217272107251255101811100

[back to top]

Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (ITT Population)

Two of the six UPDRS sections (Part II, Activities of Daily Living (ADL); Part III, Motor Examination) were assessed in this study. The Motor Exam has 17 items, some of which are assessed in both the left and right extremities. Each item has a choice of 5 responses that are numerically scored 0-4 (0 as the least severe, 4 as the most severe). The final score is a sum of the 17 items, with some sections requiring multiple grades assigned to each extremity, and has a value ranging from 0 (no motor impairment) to 108 (severe motor impairment). (NCT00650104)
Timeframe: Screening and Month 78

Interventionpoints on a scale (Mean)
Screening, n=83Month 78, n=13
Ropinirole XL22.020.7

[back to top]

Unified Parkinson's Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)

The UPDRS is a clinician-based scale used to assess the longitudinal course of PD. Two of the six sections were assessed (Part II, Activities of Daily Living (ADL); Part III, Motor Examination). Both consist of a number of items (ADL, 13 items; Motor Exam., 17 items), and each item has a choice of 5 responses that are numerically scored 0-4, with 0 as the least severe response and 4 as the most severe response. ADL final score is a sum of the 13 items and may have a value between 0 (no impairment of overall activities) and 52 (severe impairment of overall activities). LTT, long-term treatment. (NCT00650104)
Timeframe: Screening; Week 4; Months 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, and 78

Interventionpoints on a scale (Mean)
Screening, n=83Up-titration (Week 4), n=64LTT, Month 3, n=76LTT, Month 9, n=72LTT, Month 15, n=67LTT, Month 21, n=63LTT, Month 27, n=58LTT, Month 33, n=53LTT, Month 39, n=19LTT, Month 45, n=18LTT, Month 51, n=19LTT, Month 57, n=20LTT, Month 63, n=19LTT, Month 69, n=20LTT, Month 75, n=16LTT, Month 78, n=13
Ropinirole XL9.48.98.28.19.08.69.310.310.59.310.110.411.910.812.611.5

[back to top]

Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Maintained Responder Population)

The Clinical Global Impression (CGI) scale comprises the following three components (CGI-Severity, CGI-Improvement, Index); where only the CGI-S and CGI-I were assessed in this study. CGI-I is a global improvement scale that scores the clinician's view of the participant's global functioning prior to and after initiating a study medication from 1 (very much improved) to 7 (very much worse). 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse. (NCT00650104)
Timeframe: Week 2, Month 12, Month 78

Interventionparticipants (Number)
Week 2 - Very Much Improved, n=37Week 2 - Much Improved, n=37Week 2 - Minimally Improved, n=37Week 2 - No Change, n=37Week 2 - Minimally Worse, n=37Week 2 - Much Worse, n=37Week 2 - Very Much Worse, n=37Month 12 - Very Much Improved, n=46Month 12 - Much Improved, n=46Month 12 - Minimally Improved, n=46Month 12 - No Change, n=46Month 12 - Minimally Worse, n=46Month 12 - Much Worse, n=46Month 12 - Very Much Worse, n=46Month 78 - Very Much Improved, n=13Month 78 - Much Improved, n=13Month 78 - Minimally Improved, n=13Month 78 - No Change, n=13Month 78 - Minimally Worse, n=13Month 78 - Much Worse, n=13Month 78 - Very Much Worse, n=13
Ropinirole XL021220210623744101811100

[back to top]

Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (ITT Population)

The Clinical Global Impression (CGI) scale comprises the following three components (CGI-Severity, CGI-Improvement, Index); where only the CGI-S and CGI-I were assessed in this study. CGI-I is a global improvement scale that scores the clinician's view of the participant's global functioning prior to and after initiating a study medication from 1 (very much improved) to 7 (very much worse). 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse. (NCT00650104)
Timeframe: Week 2, Month 12, Month 78

Interventionparticipants (Number)
Week 2 - Very Much Improved, n=70Week 2 - Much Improved, n=70Week 2 - Minimally Improved, n=70Week 2 - No Change, n=70Week 2 - Minimally Worse, n=70Week 2 - Much Worse, n=70Week 2 - Very Much Worse, n=70Month 12 - Very Much Improved, n=69Month 12 - Much Improved, n=69Month 12 - Minimally Improved, n=69Month 12 - No Change, n=69Month 12 - Minimally Worse, n=69Month 12 - Much Worse, n=69Month 12 - Very Much Worse, n=69Month 78 -Very Much Improved, n=13Month 78 - Much Improved, n=13Month 78 - Minimally Improved, n=13Month 78 - No Change, n=13Month 78 - Minimally Worse, n=13Month 78 - Much Worse, n=13Month 78 - Very Much Worse, n=13
Ropinirole XL0220434107252078101811100

[back to top]

Number of Participants With the Indicated Number of Adverse Events (AEs)

AEs, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, were collected to obtain data on the safety, tolerability, and benefit of ropinirole XL. Serious Adverse Events (SAEs), defined as AEs that are either fatal, life threatening, disabling/incapacitating, resulting in hospitalization or prolongation of a hospital stay, a congenital abnormality/birth defect, or any important medical occurrence that the investigator regards as serious based on medical judgment, were also collected. st. med., study medication. (NCT00650104)
Timeframe: Every study visit from baseline to market availability (Month 78)

Interventionparticipants (Number)
Participants (Par.) with at least one eventPar. with 0 eventsPar. with 1 eventPar. with 2 eventsPar. with ≥3 eventsPar. with mild AEs (by maximum intensity)Par. with moderate AEs (by maximum intensity)Par. with severe AEs (by maximum intensity)Par. with AEs not related to st. med.Par. with AEs not likely related to st. med.Par. with AEs suspected to be related to st. med.Par. with AEs probably related to st. med.Par. who withdrew study due to AEsPar. reporting SAEs
Ropinirole XL8121080338406636332035

[back to top]

Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Scores (Maintained Responder Population)

The UPDRS is a clinician-based scale used to assess the longitudinal course of PD. Two of the six sections were assessed (Part II, Activities of Daily Living (ADL); Part III, Motor Examination). Both consist of a number of items (ADL, 13 items; Motor Exam., 17 items), and each item has a choice of 5 responses that are numerically scored 0-4, with 0 as the least severe response and 4 as the most severe response. ADL final score is a sum of the 13 items and may have a value between 0 (no impairment of overall activities) and 52 (severe impairment of overall activities). LTT, long-term treatment. (NCT00650104)
Timeframe: Screening; Months 3, 9, 15, 27, and 78

Interventionpoints on a scale (Mean)
Screening, n=47LTT, Month 3, n=46LTT, Month 9, n= 46LTT, Month 15, n=44LTT, Month 27, n=37LTT, Month 78, n=13
Ropinirole XL9.07.77.78.68.411.5

[back to top]

Unified Parkinson's Disease Rating Scale (UPDRS) Total Activities of Daily Living Score (Responder Population)

The UPDRS is a clinician-based scale used to assess the longitudinal course of PD. Two of the six sections were assessed (Part II, Activities of Daily Living (ADL); Part III, Motor Examination). Both consist of a number of items (ADL, 13 items; Motor Exam., 17 items), and each item has a choice of 5 responses that are numerically scored 0-4, with 0 as the least severe response and 4 as the most severe response. ADL final score is a sum of the 13 items and may have a value between 0 (no impairment of overall activities) and 52 (severe impairment of overall activities). LTT, long-term treatment. (NCT00650104)
Timeframe: Screening; Months 3, 9, 15, 27, and 78

Interventionpoints on a scale (Mean)
Screening, n=60LTT, Month 3, n=59LTT, Month 9, n=58LTT, Month 15, n=55LTT, Month 27, n=47LTT, Month 78, n=13
Ropinirole XL9.18.07.88.78.811.5

[back to top]

Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Reponder Population)

Two of the six UPDRS sections (Part II, Activities of Daily Living (ADL); Part III, Motor Examination) were assessed in this study. The Motor Exam has 17 items, some of which are assessed in both the left and right extremities. Each item has a choice of 5 responses that are numerically scored 0-4 (0 as the least severe, 4 as the most severe). The final score is a sum of the 17 items, with some sections requiring multiple grades assigned to each extremity, and has a value ranging from 0 (no motor impairment) to 108 (severe motor impairment). (NCT00650104)
Timeframe: Screening and Month 78

Interventionpoints on a scale (Mean)
Screening, n=60Month 78, n=13
Ropinirole XL21.720.7

[back to top]

Unified Parkinson's Disease Rating Scale (UPDRS) Motor Examination Score (Maintained Responder Population)

Two of the six UPDRS sections (Part II, Activities of Daily Living (ADL); Part III, Motor Examination) were assessed in this study. The Motor Exam has 17 items, some of which are assessed in both the left and right extremities. Each item has a choice of 5 responses that are numerically scored 0-4 (0 as the least severe, 4 as the most severe). The final score is a sum of the 17 items, with some sections requiring multiple grades assigned to each extremity, and has a value ranging from 0 (no motor impairment) to 108 (severe motor impairment). (NCT00650104)
Timeframe: Screening and Month 78

Interventionpoints on a scale (Mean)
Screening, n=47Month 78, n=13
Ropinirole XL22.220.7

[back to top]

Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0. (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.4

[back to top]

Mean Change From Week 0 in the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0. (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-12.7

[back to top]

Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.6
Ropinirole IR-Ropinirole PR-0.2

[back to top]

Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0. (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.8

[back to top]

Mean Change From Week 24 (Period Baseline) in the Japanese UPDRS Part I Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included. (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.0
Ropinirole IR-Ropinirole PR0.1

[back to top]

Mean Change From Week 24 in the Japanese UPDRS Part III Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24. (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.2
Ropinirole IR-Ropinirole PR-0.7

[back to top]

Mean Change From Week 24 in the Japanese UPDRS Part IV Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24. (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.1
Ropinirole IR-Ropinirole PR-0.2

[back to top]

Percentage of Responders on the CGI-I at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The CGI-I assesses the participant's improvement or worsening of PD from baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Responders are defined as those participants with scores of very much improved or much improved. (NCT00823836)
Timeframe: Week 54

Interventionpercentage of participants (Number)
Ropinirole PR-Ropinirole PR65

[back to top]

Percentage of Responders on the Clinical Global Impression-Improvement (CGI-I) at FAP (up to Week 24) in the Non-Inferiority Verification Phase

The CGI-I assesses the participant's improvement or worsening of PD from Baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Responders are defined as those participants with scores of very much improved or much improved. (NCT00823836)
Timeframe: FAP (up to Week 24)

Interventionpercentage of participants (Number)
Ropinirole PR-Ropinirole PR63
Ropinirole IR-Ropinirole PR61

[back to top]

"Japanese UPDRS Part II (at Off) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionscores on a scale (Mean)
Week 0; n=86, 88FAP; n=66, 76
Ropinirole IR-Ropinirole PR13.18.7
Ropinirole PR-Ropinirole PR13.69.6

[back to top]

"Japanese UPDRS Part II (at Off) Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Week 0, n=44Week 54, n=32
Ropinirole PR-Ropinirole PR13.29.0

[back to top]

"Japanese UPDRS Part II (at On) Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. On state is defined as the state at which PD symptoms are well controlled by the drug." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionscores on a scale (Mean)
Week 0; n=156, 146FAP; n=151, 142
Ropinirole IR-Ropinirole PR7.64.6
Ropinirole PR-Ropinirole PR7.75.2

[back to top]

"Japanese UPDRS Part II (at On) Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. On state is defined as the state at which PD symptoms are well controlled by the drug." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionscores on a scale (Mean)
Week 24; n=127, 122FAP; n=126, 119
Ropinirole IR-Ropinirole PR4.14.3
Ropinirole PR-Ropinirole PR4.44.4

[back to top]

"Japanese UPDRS Part II (at On) Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. On state is defined as the state at which PD symptoms are well controlled by the drug." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Week 0, n=73Week 54, n=67
Ropinirole PR-Ropinirole PR6.94.3

[back to top]

"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at Off) at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionparticipants (Number)
Week 0; Stage 0; n=86, 88Week 0; Stage 1; n=86, 88Week 0; Stage 1.5; n=86, 88Week 0; Stage 2; n=86, 88Week 0; Stage 2.5; n=86, 88Week 0; Stage 3; n=86, 88Week 0; Stage 4; n=86, 88Week 0; Stage 5; n=86, 88FAP; Stage 0; n=66, 76FAP; Stage 1; n=66, 76FAP; Stage 1.5; n=66, 76FAP; Stage 2; n=66, 76FAP; Stage 2.5; n=66, 76FAP; Stage 3; n=66, 76FAP; Stage 4; n=66, 76FAP; Stage 5; n=66, 76
Ropinirole IR-Ropinirole PR00071437264021231122143
Ropinirole PR-Ropinirole PR0004133924605391319152

[back to top]

"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at Off) at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Only participants who had off state were included in the analysis." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionparticipants (Number)
Week 24; Stage 0; n=58, 63Week 24; Stage 1; n=58, 63Week 24; Stage 1.5; n=58, 63Week 24; Stage 2; n=58, 63Week 24; Stage 2.5; n=58, 63Week 24; Stage 3; n=58, 63Week 24; Stage 4; n=58, 63Week 24; Stage 5; n=58, 63FAP; Stage 0; n=56, 61FAP; Stage 1; n=56, 61FAP; Stage 1.5; n=56, 61FAP; Stage 2; n=56, 61FAP; Stage 2.5; n=56, 61FAP; Stage 3; n=56, 61FAP; Stage 4; n=56, 61FAP; Stage 5; n=56, 61
Ropinirole IR-Ropinirole PR0202111189203016151872
Ropinirole PR-Ropinirole PR05391314131043121311112

[back to top]

"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at Off) at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionparticipants (Number)
Week 0; Stage 0; n=44Week 0; Stage 1; n=44Week 0; Stage 1.5; n=44Week 0; Stage 2; n=44Week 0; Stage 2.5; n=44Week 0; Stage 3; n=44Week 0; Stage 4; n=44Week 0; Stage 5; n=44Week 54; Stage 0; n=32Week 54; Stage 1; n=32Week 54; Stage 1.5; n=32Week 54; Stage 2; n=32Week 54; Stage 2.5; n=32Week 54; Stage 3; n=32Week 54; Stage 4; n=32Week 54; Stage 5; n=32
Ropinirole PR-Ropinirole PR000282111203159671

[back to top]

"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at On) at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. On state is defined as the state at which PD symptoms are well controlled by the drug." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionparticipants (Number)
Week 0; Stage 0; n=156, 146Week 0; Stage 1; n=156, 146Week 0; Stage 1.5; n=156, 146Week 0; Stage 2; n=156, 146Week 0; Stage 2.5; n=156, 146Week 0; Stage 3; n=156, 146Week 0; Stage 4; n=156, 146Week 0; Stage 5; n=156, 146FAP; Stage 0; n=151, 142FAP; Stage 1; n=151, 142FAP; Stage 1.5; n=151, 142FAP; Stage 2; n=151, 142FAP; Stage 2.5; n=151, 142FAP; Stage 3; n=151, 142FAP; Stage 4; n=151, 142FAP; Stage 5; n=151, 142
Ropinirole IR-Ropinirole PR0013443571014181444292760
Ropinirole PR-Ropinirole PR000344764110220354313479

[back to top]

"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at On) at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. On state is defined as the state at which PD symptoms are well controlled by the drug." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionparticipants (Number)
Week 24; Stage 0; n=127, 122Week 24; Stage 1; n=127, 122Week 24; Stage 1.5; n=127, 122Week 24; Stage 2; n=127, 122Week 24; Stage 2.5; n=127,122Week 24; Stage 3; n=127, 122Week 24; Stage 4; n=127, 122Week 24; Stage 5; n=127, 122FAP; Stage 0; n=125, 119FAP; Stage 1; n=125, 119FAP; Stage 1.5; n=125, 119FAP; Stage 2; n=125, 119FAP; Stage 2.5; n=125, 119FAP; Stage 3; n=125, 119FAP; Stage 4; n=125, 119FAP; Stage 5; n=125, 119
Ropinirole IR-Ropinirole PR41612412423203191044202021
Ropinirole PR-Ropinirole PR220349252260317551232060

[back to top]

"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at On) at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"The Modified Hoehn & Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. On state is defined as the state at which PD symptoms are well controlled by the drug." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionparticipants (Number)
Week 0; Stage 0; n=73Week 0; Stage 1; n=73Week 0; Stage 1.5; n=73Week 0; Stage 2; n=73Week 0; Stage 2.5; n=73Week 0; Stage 3; n=73Week 0; Stage 4; n=73Week 0; Stage 5; n=73Week 54; Stage 0; n=67Week 54; Stage 1; n=67Week 54; Stage 1.5; n=67Week 54; Stage 2; n=67Week 54; Stage 2.5; n=67Week 54; Stage 3; n=67Week 54; Stage 4; n=67Week 54; Stage 5; n=67
Ropinirole PR-Ropinirole PR0001819351018329151100

[back to top]

Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionscores on a scale (Mean)
Week 0; n=156, 146FAP; n=151, 142
Ropinirole IR-Ropinirole PR1.10.8
Ropinirole PR-Ropinirole PR0.90.7

[back to top]

Japanese UPDRS Part I Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionscores on a scale (Mean)
Week 24; n=127, 122FAP; n=127, 120
Ropinirole IR-Ropinirole PR0.60.7
Ropinirole PR-Ropinirole PR0.50.4

[back to top]

Japanese UPDRS Part III Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionscores on a scale (Mean)
Week 0; n=156, 146FAP; n=151, 139
Ropinirole IR-Ropinirole PR24.312.7
Ropinirole PR-Ropinirole PR24.013.7

[back to top]

Japanese UPDRS Part III Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. One participant whose observation could not be obtained at Week 24 was not included in the analysis for Week 24. (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionscores on a scale (Mean)
Week 24; n=127, 121FAP; n=125, 118
Ropinirole IR-Ropinirole PR12.311.3
Ropinirole PR-Ropinirole PR11.911.7

[back to top]

Japanese UPDRS Part III Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Week 0, n=73Week 54, n=68
Ropinirole PR-Ropinirole PR24.611.9

[back to top]

Japanese UPDRS Part IV Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

,
Interventionscores on a scale (Mean)
Week 0; n=156, 146FAP; n=151, 141
Ropinirole IR-Ropinirole PR2.82.6
Ropinirole PR-Ropinirole PR2.72.1

[back to top]

Japanese UPDRS Part IV Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. One participant whose observation could not be obtained at Week 24 was not included in the analysis for Week 24. (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionscores on a scale (Mean)
Week 24; n=127, 121FAP; n=127, 119
Ropinirole IR-Ropinirole PR2.52.3
Ropinirole PR-Ropinirole PR1.91.9

[back to top]

Japanese UPDRS Part IV Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Week 0, n=73Week 54, n=68
Ropinirole PR-Ropinirole PR2.92.1

[back to top]

Percentage of Participants Remaining in the Study on the Indicated Days During the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 54) was the event, and participants who had completed the study were censored. (NCT00823836)
Timeframe: 0-385 days (up to Week 54)

Interventionpercentage of participants (Number)
0 days258 days261 days322 days329 days346 days385 days
Ropinirole PR-Ropinirole PR100999796959393

[back to top]

Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole IR-Ropinirole PR Group

The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 24) was the event, and participants who had completed the phase were censored. (NCT00823836)
Timeframe: 0-175 days (up to Week 24)

Interventionpercentage of participants (Number)
0 days7 days12 days14 days18 days21 days28 days30 days32 days42 days51 days55 days60 days86 days88 days119 days142 days168 days175 days
Ropinirole IR-Ropinirole PR100999997979694939290908888878686858484

[back to top]

Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole PR-Ropinirole PR Group

The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 24) was the event, and participants who had completed the phase were censored. (NCT00823836)
Timeframe: 0-175 days (up to Week 24)

Interventionpercentage of participants (Number)
0 days6 days9 days14 days17 days19 days20 days21 days25 days28 days34 days42 days43 days55 days62 days74 days119 days139 days142 days153 days154 days160 days168 days175 days
Ropinirole PR-Ropinirole PR1009999989796969392919090898888878685858483838282

[back to top]

Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole IR-Ropinirole PR Group

The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 32) was the event, and participants who had completed the phase were censored. (NCT00823836)
Timeframe: 0-89 days within the PR/XR Switching Phase (between Weeks 24 and 32)

Interventionpercentage of participants (Number)
0 days4 days7 days18 days28 days33 days89 days
Ropinirole IR-Ropinirole PR100999898979696

[back to top]

Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole PR-Ropinirole PR Group

The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 32) was the event, and participants who had completed the phase were censored. (NCT00823836)
Timeframe: 0-89 days within the PR/XR Switching Phase (between Weeks 24 and 32)

Interventionpercentage of participants (Number)
0 days28 days35 days89 days
Ropinirole PR-Ropinirole PR100999898

[back to top]

Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase

Thirty percent responders were defined as participants with a 30 percent or greater reduction from Week 0 in the Japanese UPDRS Part III total score. Twenty percent responders were defined as participants with a 20 percent or greater reduction from Week 0 in the Japanese UPDRS Part III total score. On-treatment last observations within the phase were carried forward as FAP values of the phase. FAP values do not include values of Weeks 0, 1, and 2; participants who withdrew before Week 2 and who had only one measurement for the part III total score were not included in the analysis. (NCT00823836)
Timeframe: FAP (up to Week 24)

,
Interventionpercentage of participants (Number)
30 percent responder20 percent responder
Ropinirole IR-Ropinirole PR6978
Ropinirole PR-Ropinirole PR6681

[back to top]

Percentage of Responders on the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

Thirty percent responders were defined as participants with a 30 percent or greater reduction from Week 0 (Baseline) in the Japanese UPDRS Part III total score. Twenty percent responders were defined as participants with a 20 percent or greater reduction from Week 0 in the Japanese UPDRS Part III total score. (NCT00823836)
Timeframe: Week 54

Interventionpercentage of participants (Number)
30 percent responders20 percent responders
Ropinirole PR-Ropinirole PR8476

[back to top]

"Mean Change From Week 0 in Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 in Off time (actual hours) was calculated as Off time (hours) at FAP minus Off time (hours) at Week 0." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR-2.88
Ropinirole IR-Ropinirole PR-2.59

[back to top]

"Mean Change From Week 0 in Awake Time Spent Off at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 in Off time (actual hours) was calculated as Off time (hours) at Week 54 minus Off time (hours) at Week 0." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR-2.87

[back to top]

"Mean Change From Week 0 in Awake Time Spent On at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Mean Change from Week 0 in On time (actual hours) was calculated as On time (hours) at FAP minus On time (hours) at Week 0. Participants who had only one observation for On time were not included in the analysis." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR1.65
Ropinirole IR-Ropinirole PR1.35

[back to top]

"Mean Change From Week 0 in Awake Time Spent On With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Troublesome dyskinesia is defined as dyskinesia that interferes with the participant's daily activity. Mean change from Week 0 in On time with troublesome dyskinesias (actual hours) was calculated as On time with troublesome dyskinesias (hours) at FAP minus On time with troublesome dyskinesias (hours) at Week 0. Participants who had only one observation for On time with troublesome dyskinesias were not included in the analysis." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR0.57
Ropinirole IR-Ropinirole PR0.87

[back to top]

"Mean Change From Week 0 in Awake Time Spent On With Troublesome Dyskinesias at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Troublesome dyskinesia is defined as dyskinesia that interferes with the participant's daily activity. Mean change from Week 0 in On time with troublesome dyskinesias (actual hours) was calculated as On time with troublesome dyskinesias (hours) at Week 54 minus On time with troublesome dyskinesias (hours) at Week 0." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR-0.33

[back to top]

"Mean Change From Week 0 in Percentage of Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Off time is measured as a proportion using the following formula: (Sum of two days off time [hours]/Sum of two days awake time [hours]) x 100. Change from Week 0 in Off time is measured using the following formula: Off time (proportion) at FAP minus Off time (proportion) at Week 0." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionpercentage of time (Mean)
Ropinirole PR-Ropinirole PR-18.39
Ropinirole IR-Ropinirole PR-16.81

[back to top]

"Mean Change From Week 0 in Percentage of Awake Time Spent Off at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Off time is measured as a proportion using the following formula: (Sum of two days off time [hours]/Sum of two days awake time [hours]) x 100. Change from Week 0 in Off time is measured using the following formula: Off time (proportion) at Week 54 minus Off time (proportion) at Week 0." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionpercentage of time (Mean)
Ropinirole PR-Ropinirole PR-18.55

[back to top]

Japanese UPDRS Part I Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group

The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Week 0, n=73Week 54, n=68
Ropinirole PR-Ropinirole PR1.10.6

[back to top]

"Mean Change From Week 0 in Percentage of Awake Time Spent On at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. On time is measured as a proportion using the following formula: (Sum of two days On time [hours]/Sum of two days awake time [hours]) x 100. Change from Week 0 in On time is measured using the following formula: On time (proportion) at FAP minus On time (proportion) at Week 0. Participants who had only one observation for On time were not included in the analysis." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionpercentage of time (Mean)
Ropinirole PR-Ropinirole PR9.03
Ropinirole IR-Ropinirole PR7.79

[back to top]

"Mean Change From Week 0 in Percentage of Awake Time Spent On With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"On time with troublesome dyskinesias is measured as a proportion using the following formula: (Sum of two days On time with troublesome dyskinesias [hours]/Sum of two days awake time [hours]) x 100. Change from Week 0 in On time with troublesome dyskinesias is measured using the following formula: On time with troublesome dyskinesias (proportion) at FAP minus On time with troublesome dyskinesias (proportion) at Week 0. Participants who had only one observation for On time with troublesome dyskinesias were not included in the analysis." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionpercentage of time (Mean)
Ropinirole PR-Ropinirole PR2.61
Ropinirole IR-Ropinirole PR5.39

[back to top]

"Mean Change From Week 0 in the Japanese UPDRS Part II (at Off) Total Score at Week 24 in the Non-Inferiority Verification Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. Particpants with only one observation for the part II (at Off) total score were not included in the analysis." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-4.7
Ropinirole IR-Ropinirole PR-3.8

[back to top]

"Mean Change From Week 0 in the Japanese UPDRS Part II (at Off) Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-4.6

[back to top]

"Mean Change From Week 0 in the Japanese UPDRS Part II (at On) Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. On state is defined as the state at which PD symptoms are well controlled by the drug. Mean change from Week 0 was calculated as the total score at FAP minus the score at Week 0." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-2.6
Ropinirole IR-Ropinirole PR-2.9

[back to top]

"Mean Change From Week 0 in the Japanese UPDRS Part II (at On) Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. On state is defined as the state at which PD symptoms are well controlled by the drug. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0." (NCT00823836)
Timeframe: Weeks 0 and 54

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-2.6

[back to top]

"Japanese UPDRS Part II (at Off) Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Only participants who had off state were included in the analysis." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

,
Interventionscores on a scale (Mean)
Week 24; n=58, 63FAP; n=57, 61
Ropinirole IR-Ropinirole PR7.87.5
Ropinirole PR-Ropinirole PR8.88.5

[back to top]

"Mean Change From Week 24 in Awake Time Spent Off at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 24 in Off time (actual hours) was calculated as Off time (hours) at FAP minus Off time (hours) at Week 24. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included in the analysis." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR-0.07
Ropinirole IR-Ropinirole PR-0.13

[back to top]

"Mean Change From Week 24 in Awake Time Spent On With Troublesome Dyskinesias at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Troublesome dyskinesia is defined as dyskinesia that interferes with the participant's daily activity. Mean change from Week 24 on On time with troublesome dyskinesias (actual hours) was calculated as On time with troublesome dyskinesias (hours) at FAP minus On time with troublesome dyskinesias (hours) at Week 24. Participants who had 0 hour as On time with troublesome dyskinesias at Week 24 were excluded from the analysis." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionhours (Mean)
Ropinirole PR-Ropinirole PR0.00
Ropinirole IR-Ropinirole PR-1.25

[back to top]

"Mean Change From Week 24 in Percentage of Awake Time Spent Off at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Off time is measured as a proportion using the following formula: (Sum of two days off time [hours]/Sum of two days awake time [hours]) x 100. Change from Week 24 in Off time is measured using the following formula: Off time (proportion) at FAP minus Off time (proportion) at Week 24. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included in the analysis." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionpercentage of time (Mean)
Ropinirole PR-Ropinirole PR-0.97
Ropinirole IR-Ropinirole PR-0.14

[back to top]

"Mean Change From Week 24 in the Japanese UPDRS Part II (at Off) Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. Off state is where PD symptoms are not adequately controlled by the drug. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included in the analysis." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.2
Ropinirole IR-Ropinirole PR-0.4

[back to top]

"Mean Change From Week 24 in the Japanese UPDRS Part II (at On) Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase"

"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. On state is defined as the state at which PD symptoms are well controlled by the drug. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24." (NCT00823836)
Timeframe: Week 24 and FAP (from Week 26 up to Week 32)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.0
Ropinirole IR-Ropinirole PR0.3

[back to top]

"Mean Percent Change From Week 0 in Percentage of Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Off time is measured as a proportion using the following formula: (Sum of two days off time [hours]/Sum of two days awake time [hours]) x 100. Percent change from Week 0 in Off time (proportion) is measured using the following formula: (Change from Week 0 in Off time [proportion]/Off time [proportion] at Week 0) x 100." (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionpercent change (Mean)
Ropinirole PR-Ropinirole PR-42.36
Ropinirole IR-Ropinirole PR-40.48

[back to top]

"Percentage of Responders in Change From Week 0 in Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction on change from Week 0 in Off time (percentage)." (NCT00823836)
Timeframe: FAP (up to Week 24)

Interventionpercentage of participants (Number)
Ropinirole PR-Ropinirole PR44
Ropinirole IR-Ropinirole PR40

[back to top]

"Percentage of Responders in Change From Week 0 in Awake Time Spent Off at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction in change from Week 0 in Off time (percentage)." (NCT00823836)
Timeframe: Week 54

Interventionpercentage of participants (Number)
Ropinirole PR-Ropinirole PR46

[back to top]

"Percentage of Responders in Percent Change From Week 0 in Awake Time Spent Off at FAP (up to Week 24) in the Non-Inferiority Verification Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction in percent change from Week 0 in Off time (percentage)." (NCT00823836)
Timeframe: FAP (up to Week 24)

Interventionpercentage of participants (Number)
Ropinirole PR-Ropinirole PR76
Ropinirole IR-Ropinirole PR69

[back to top]

"Percentage of Responders in Percent Change From Week 0 in Awake Time Spent Off at Week 54 in the Long-term Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction on percent change from Week 0 in Off time (percentage)." (NCT00823836)
Timeframe: Week 54

Interventionpercentage of participants (Number)
Ropinirole PR-Ropinirole PR79

[back to top]

Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase

The Japanese UPDRS assesses the status of Parkinson's Disease (PD) patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. Participants who withdrew before Week 2 and who had only one observation for the part III total score were not included in the analysis. (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-10.8
Ropinirole IR-Ropinirole PR-11.0

[back to top]

Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase

The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. (NCT00823836)
Timeframe: Week 0 and FAP (up to Week 24)

Interventionscores on a scale (Mean)
Ropinirole PR-Ropinirole PR-0.2
Ropinirole IR-Ropinirole PR-0.3

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00829504)
Timeframe: Blood samples collected over a 24 hour period.

Interventionpg*h/mL (Mean)
Test (Ropinirole HCl)4190.92
Reference (Requip®)4062.99

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax. (NCT00829504)
Timeframe: Blood samples collected over a 24 hour period.

Interventionpg/mL (Mean)
Test (Ropinirole HCl)552.1
Reference (Requip®)546.5

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00829504)
Timeframe: Blood samples collected over a 24 hour period.

Interventionpg*h/mL (Mean)
Test (Ropinirole HCl)4469
Reference (Requip®)4305.88

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00830219)
Timeframe: Blood samples collected over a 24 hour period.

Interventionpg*h/mL (Mean)
Test (Ropinirole HCl)4551.89
Reference (Requip®)4441.31

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00830219)
Timeframe: Blood samples collected over a 24 hour period.

Interventionpg*h/mL (Mean)
Test (Ropinirole HCl)4300.07
Reference (Requip®)4209.47

[back to top]

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax. (NCT00830219)
Timeframe: Blood samples collected over a 24 hour period.

Interventionpg/mL (Mean)
Test (Ropinirole HCl)564.09
Reference (Requip®)543.71

[back to top]

Hoehn and Yahr Stage

Hoehn and Yahr(HY) stage for parkinsonism after 8 weeks in each arm or at last visit for early completion Range: 0~5 Higher values represent more severe parkinsonism (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

InterventionScores on a scale (Mean)
Once-daily of Ropinirole PR2.1
Twice-daily of Ropinirole PR2.1

[back to top]

Nocturnal Off-symptoms

"Sleep questionnaire 2 for Nocturnal off-symptoms Visual analogue scale: 0~10 Higher values represent worse nocturnal off-symptoms." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Interventionunits on a scale (Mean)
Once-daily of Ropinirole PR2.9
Twice-daily of Ropinirole PR3.1

[back to top]

Overall Quality of Sleep

"Sleep questionnaire 1 for Overall quality of sleep Visual analogue scale: 0~10 Higher values represent worse overall sleep quality." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Interventionunits on a scale (Mean)
Once-daily of Ropinirole PR2.9
Twice-daily of Ropinirole PR3.2

[back to top]

Patient Preference

Patient preference between once-daily and twice-daily regimen (NCT00986245)
Timeframe: After 16 weeks or at last visit for early completion

Interventionparticipants (Number)
Once-daily17
Twice-daily31
No Preference13

[back to top]

Patients Who Have Global Impression for Improvement

Patients who have global impression for improvement for each dosing. (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Interventionparticipants (Number)
Once-daily of Ropinirole PR32
Twice-daily of Ropinirole PR42

[back to top]

Patients Who Have Global Impression for Improvement to Duration of Dyskinesia

Patients who have global impression for improvement to duration of dyskinesia compared (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Interventionparticipants (Number)
Once-daily of Ropinirole PR13
Twice-daily of Ropinirole PR16

[back to top]

Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation

Patients who have global impression for improvement to duration of motor fluctuation (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Interventionparticipants (Number)
Once-daily of Ropinirole PR27
Twice-daily of Ropinirole PR38

[back to top]

Patients Who Have Global Impression for Improvement to Severity of Dyskinesia

Patients who have Global Impression for Improvement to Severity of Dyskinesia compared (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Interventionparticipants (Number)
Once-daily of Ropinirole PR16
Twice-daily of Ropinirole PR15

[back to top]

Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation

Patients who have global impression for improvement to severity of motor fluctuation compared (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Interventionparticipants (Number)
Once-daily of Ropinirole PR28
Twice-daily of Ropinirole PR34

[back to top]

Unified Parkinson's Disease Rating Scale, Part 3

"Unified Parkinson's disease rating scale (UPDRS) motor scale after 8 weeks in each arm or at last visit for early completion.~UPDRS part 3 is motor scale for parkinson's disease. Range: 0~108 Higher values represent more severe motor symptoms of parkinsonism." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Interventionunits on a scale (Mean)
Once-daily of Ropinirole PR17.5
Twice-daily of Ropinirole PR17.1

[back to top]

Early Morning Off Symptoms

"Sleep questionnaire 3 for early morning off symptoms Visual analogue scale: 0~10 Higher values represent worse early morning off symptoms." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Interventionunits on a scale (Mean)
Once-daily of Ropinirole PR2.5
Twice-daily of Ropinirole PR2.9

[back to top]

Adverse Events

Patients who have adverse events (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Interventionparticipants (Number)
Once-daily of Ropinirole PR33
Twice-daily of Ropinirole PR28

[back to top]

Compliance

Compliances after 8 weeks in each arm or at last visit for early completion. Compliance was calcuated by the percentage of used medication. (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Interventionpercentage of used medication (Mean)
Once-daily of Ropinirole PR98.4
Twice-daily of Ropinirole PR97.6

[back to top]

Epworth Sleep Scale

"Epworth sleep scale after 8 weeks in each arm or at last visit for early completion.~Range: 0~24 Higher values represent worse daytime-sleepiness." (NCT00986245)
Timeframe: 8 weeks in each arm or at last visit for early completion

Interventionunits on a scale (Mean)
Once-daily of Ropinirole PR6.3
Twice-daily of Ropinirole PR6.4

[back to top]

Number of Participants With the Indicated CGI-I Scores for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)

The CGI-I assesses the participant's improvement or worsening of RLS from baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. (NCT00996944)
Timeframe: LONG WD (up to Week 64)

,
Interventionparticipants (Number)
Not AssessedVery Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Placebo-Ropinirole IR00220000
Ropinirole IR-Ropinirole IR03140300

[back to top]

Mean Daily Number of Hours of RLS Symptoms by Timeframe for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)

Participants recorded the onset time and total duration of RLS symptoms on their diary cards for 7 days from one week before each visit. Timeframes were defined as follows: daytime, 7:00AM to 4:59PM; evening, 5:00PM to 7:59PM; and nighttime, 8:00PM to 6:59AM. (NCT00996944)
Timeframe: DBT WD (up to Week 12)

,
Interventionhours (Mean)
Daytime, n=1, 2Evening, n=1, 1Nighttime, n=3, 2
Placebo-Ropinirole IR2.9002.5902.936
Ropinirole IR-Ropinirole IR9.5902.5901.802

[back to top]

Mean Daily Number of Hours of RLS Symptoms by Timeframe for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)

Participants recorded the onset time and total duration of RLS symptoms on their diary cards for 7 days from one week before each visit. Timeframes were defined as follows: daytime, 7:00AM to 4:59PM; evening, 5:00PM to 7:59PM; and nighttime, 8:00PM to 6:59AM. (NCT00996944)
Timeframe: LONG WD (up to Week 64)

,
Interventionhours (Mean)
Daytime, n=0, 2Evening, n=1, 2Nighttime, n=2, 1
Placebo-Ropinirole IR0.8831.9480.867
Ropinirole IR-Ropinirole IRNA0.2002.432

[back to top]

Mean Daily Number of Hours of RLS Symptoms by Timeframe at Week 0 and Week 12

Participants recorded the onset time and total duration of RLS symptoms on their diary cards for 7 days from one week before each visit. Timeframes were defined as follows: daytime, 7:00AM to 4:59PM; evening, 5:00PM to 7:59PM; and nighttime, 8:00PM to 6:59AM. (NCT00996944)
Timeframe: Week 0 and Week 12

,
Interventionhours (Mean)
Daytime, Week 0, n=16, 9Daytime, Week 12, n=7, 3Evening, Week 0, n=11, 9Evening, Week 12, n=6, 2Nighttime, Week 0, n=21, 12Nighttime, Week 12, n=9, 4
Placebo-Ropinirole IR1.8570.7351.1480.7832.3181.688
Ropinirole IR-Ropinirole IR1.7941.4821.2961.0972.2561.726

[back to top]

Johns Hopkins Restless Legs Syndrome Quality of Life (RLSQOL) Questionnaire Overall Life Impact Score at Week 0 and Week 12

The RLSQOL questionnaire is a participant-rated questionnaire designed to assess the impact of RLS on the lives of participants. It consists of 18 items, 10 of which contribute to a single summary score (overall life impact). The response for each item is coded from 1 to 5, with 1 representing the best quality of life and 5 representing the worst quality of life. The lowest possible overall life impact score is 0, and the highest possible overall life impact score is 100. The score of 100 represents the best possible quality of life. (NCT00996944)
Timeframe: Week 0 and Week 12

,
Interventionunits on a scale (Mean)
Week 0, n=22, 12Week 12, n=12, 5
Placebo-Ropinirole IR73.1390.50
Ropinirole IR-Ropinirole IR77.5085.63

[back to top]

International Restless Legs Syndrome (IRLS) Rating Scale Total Score at Week 0 and Week 12

The IRLS rating scale is an investigator-rated scale consisting of 10 questions with a choice of 5 responses each. These responses are numerically scored from 0 (the least severe response) to 4 (the most severe response). The IRLS rating scale total score is calculated by summing the individual response scores. The highest possible score is 40, which represents the most severe RLS; the lowest possible score is 0, which represents an absence of RLS. A total of 17 participants were prematurely withdrawn from the study before Week 12. (NCT00996944)
Timeframe: Week 0 and Week 12

,
Interventionunits on a scale (Mean)
Week 0, n=22, 12Week 12, n=12, 5
Placebo-Ropinirole IR24.09.2
Ropinirole IR-Ropinirole IR26.015.9

[back to top]

The PSQI Total Score for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)

The PSQI consists of the following 7 domains: sleep quality, duration getting to sleep, sleep duration, sleep adequacy, sleep disturbance, use of sleeping pill, and somnolence. These domains are numerically scored from 0 to 3, with 0 representing the least severe response and 3 representing the most severe response. The PSQI total score is calculated by summing the individual domain scores. The highest possible score is 21, which represents the most disturbances in sleep quality; the lowest possible score is 0, which represents an absence of disturbances in sleep quality. (NCT00996944)
Timeframe: DBT WD (up to Week 12)

Interventionunits on a scale (Mean)
Ropinirole IR-Ropinirole IR7.8
Placebo-Ropinirole IR7.3

[back to top]

The PSQI Total Score for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)

The PSQI consists of the following 7 domains: sleep quality, duration getting to sleep, sleep duration, sleep adequacy, sleep disturbance, use of sleeping pill, and somnolence. These domains are numerically scored from 0 to 3, with 0 representing the least severe response and 3 representing the most severe response. The PSQI total score is calculated by summing the individual domain scores. The highest possible score is 21, which represents the most disturbances in sleep quality; the lowest possible score is 0, which represents an absence of disturbances in sleep quality. (NCT00996944)
Timeframe: LONG WD (up to Week 64)

Interventionunits on a scale (Mean)
Ropinirole IR-Ropinirole IR8.8
Placebo-Ropinirole IR9.3

[back to top]

Johns Hopkins RLSQOL Questionnaire Overall Life Impact Score for Participants Who Withdrew in the Long-term Treatment Period (LONG WD)

The RLSQOL questionnaire is a participant-rated questionnaire designed to assess the impact of RLS on the lives of participants. It consists of 18 items, 10 of which contribute to a single summary score (overall life impact). The response for each item is coded from 1 to 5, with 1 representing the best quality of life and 5 representing the worst quality of life. The lowest possible overall life impact score is 0, and the highest possible overall life impact score is 100. The score of 100 represents the best possible quality of life. (NCT00996944)
Timeframe: LONG WD (up to Week 64)

Interventionunits on a scale (Mean)
Ropinirole IR-Ropinirole IR79.32
Placebo-Ropinirole IR87.50

[back to top]

Johns Hopkins RLSQOL Questionnaire Overall Life Impact Score for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)

The RLSQOL questionnaire is a participant-rated questionnaire designed to assess the impact of RLS on the lives of participants. It consists of 18 items, 10 of which contribute to a single summary score (overall life impact). The response for each item is coded from 1 to 5, with 1 representing the best quality of life and 5 representing the worst quality of life. The lowest possible overall life impact score is 0, and the highest possible overall life impact score is 100. The score of 100 represents the best possible quality of life. (NCT00996944)
Timeframe: DBT WD (up to Week 12)

Interventionunits on a scale (Mean)
Ropinirole IR-Ropinirole IR75.00
Placebo-Ropinirole IR84.64

[back to top]

IRLS Rating Scale Total Score for Participants Who Withdrew in the Long-term Treatment Period (LONG WD)

The IRLS rating scale is an investigator-rated scale consisting of 10 questions with a choice of 5 responses each. These responses are numerically scored from 0 (the least severe response) to 4 (the most severe response). The IRLS rating scale total score is calculated by summing the individual response scores. The highest possible score is 40, which represents the most severe RLS; the lowest possible score is 0, which represents an absence of RLS. (NCT00996944)
Timeframe: LONG WD (up to Week 64)

Interventionunits on a scale (Mean)
Ropinirole IR-Ropinirole IR18.0
Placebo-Ropinirole IR16.5

[back to top]

IRLS Rating Scale Total Score for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)

The IRLS rating scale is an investigator-rated scale consisting of 10 questions with a choice of 5 responses each. These responses are numerically scored from 0 (the least severe response) to 4 (the most severe response). The IRLS rating scale total score is calculated by summing the individual response scores. The highest possible score is 40, which represents the most severe RLS; the lowest possible score is 0, which represents an absence of RLS. A total of 17 participants were prematurely withdrawn from the study before Week 12, and 2 participants had missing DBT WD data. (NCT00996944)
Timeframe: DBT WD (up to Week 12)

Interventionunits on a scale (Mean)
Ropinirole IR-Ropinirole IR20.3
Placebo-Ropinirole IR16.3

[back to top]

Number of Participants With the Indicated Responses to the Patient Satisfaction Question at Week 0 and Week 12

Participants responded to a question about their satisfaction with the IP on the following 1 to 7 scale: 1 = very much satisfied; 2 = satisfied; 3 = somewhat satisfied; 4 = neither satisfied nor dissatisfied; 5 = somewhat dissatisfied; 6 = dissatisfied; and 7 = very dissatisfied. At Week 0, participants responded to a question about their satisfaction with their prior medications. (NCT00996944)
Timeframe: Week 0 and Week 12

,
Interventionparticipants (Number)
Week 0, n=22,12; Very satisfiedWeek 0, n=22, 12; SatisfiedWeek 0, n=22, 12; Somewhat satisfiedWeek 0, n=22, 12; Neither satisfied/dissatisfiedWeek 0, n=22, 12; Somewhat dissatisfiedWeek 0, n=22, 12; DissatisfiedWeek 0, n=22, 12; Very dissatisfiedWeek 12, n=12, 5; Very satisfiedWeek 12, n=12, 5; SatisfiedWeek 12, n=12, 5; Somewhat satisfiedWeek 12, n=12, 5; Neither satisfied/dissatisfiedWeek 12, n=12, 5; Somewhat dissatisfiedWeek 12, n=12, 5; DissatisfiedWeek 12, n=12, 5, Very dissatisfied
Placebo-Ropinirole IR16221000311000
Ropinirole IR-Ropinirole IR034101310403131

[back to top]

Number of Participants With the Indicated Responses to the Patient Satisfaction Question for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)

Participants responded to a question about their satisfaction with the IP on the following 1 to 7 scale: 1 = very much satisfied; 2 = satisfied; 3 = somewhat satisfied; 4 = neither satisfied nor dissatisfied; 5 = somewhat dissatisfied; 6 = dissatisfied; and 7 = very dissatisfied. At Week 0, participants responded to a question about their satisfaction with their prior medications. (NCT00996944)
Timeframe: DBT WD (up to Week 12)

,
Interventionparticipants (Number)
Very satisfiedSatisfiedSomewhat satisfiedNeither satisfied/dissatisfiedSomewhat dissatisfiedDissatisfiedVery dissatisfied
Placebo-Ropinirole IR2102101
Ropinirole IR-Ropinirole IR2013101

[back to top]

Number of Participants With the Indicated Responses to the Patient Satisfaction Question for Participants Who Withdrew fn the Long-term Treatment Period (LONG WD)

Participants responded to a question about their satisfaction with the IP on the following 1 to 7 scale: 1 = very much satisfied; 2 = satisfied; 3 = somewhat satisfied; 4 = neither satisfied nor dissatisfied; 5 = somewhat dissatisfied; 6 = dissatisfied; and 7 = very dissatisfied. At Week 0, participants responded to a question about their satisfaction with their prior medications. (NCT00996944)
Timeframe: LONG WD (up to Week 64)

,
Interventionparticipants (Number)
Very satisfiedSatisfiedSomewhat satisfiedNeither satisfied/dissatisfiedSomewhat dissatisfiedDissatisfiedVery dissatisfied
Placebo-Ropinirole IR1011100
Ropinirole IR-Ropinirole IR0232022

[back to top]

Number of Participants With the Indicated CGI-I Scores for Participants Who Withdrew From the Double-Blind Treatment Period (DBT WD)

The CGI-I assesses the participant's improvement or worsening of RLS from baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. (NCT00996944)
Timeframe: DBT WD (up to Week 12)

,
Interventionparticipants (Number)
Not AssessedVery Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Placebo-Ropinirole IR01230001
Ropinirole IR-Ropinirole IR00322010

[back to top]

Number of Participants With the Indicated Clinical Global Impression-Improvement (CGI-I) Scores at Week 12

The CGI-I assesses the participant's improvement or worsening of RLS from baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. (NCT00996944)
Timeframe: Week 12

,
Interventionparticipants (Number)
Not AssessedVery Much ImprovedMuch ImprovedMinimally ImprovedNo ChangeMinimally WorseMuch WorseVery Much Worse
Placebo-Ropinirole IR03110000
Ropinirole IR-Ropinirole IR02342100

[back to top]

The Pittsburgh Sleep Quality Index (PSQI) Total Score at Week 0 and Week 12

The PSQI consists of the following 7 domains: sleep quality, duration getting to sleep, sleep duration, sleep adequacy, sleep disturbance, use of sleeping pill, and somnolence. These domains are numerically scored from 0 to 3, with 0 representing the least severe response and 3 representing the most severe response. The PSQI total score is calculated by summing the individual domain scores. The highest possible score is 21, which represents the most disturbances in sleep quality; the lowest possible score is 0, which represents an absence of disturbances in sleep quality. (NCT00996944)
Timeframe: Week 0 and Week 12

,
Interventionunits on a scale (Mean)
Week 0, n=22, 12Week 12, n=12, 5
Placebo-Ropinirole IR10.58.6
Ropinirole IR-Ropinirole IR10.37.3

[back to top]

"Mean Change From Baseline in Total Awake Time on Without Troublesome Dyskinesias (TD) at Week 24 Using LOCF"

"Dyskinesias are involuntary twisting, turning movements caused by medication during on time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Participants were asked to record the number of awake hours spent on without TD in 24-hour diary cards prior to each visit on the same two days of each relevant week. The total number of awake hours spentonwithout TD per 24-hour period was the sum of the hours recorded on the two 24-hour diary cards. Change from Baseline is calculated as the value at Week 24 minus the Baseline value." (NCT01154166)
Timeframe: Baseline and Week 24

Interventionhours (Mean)
Placebo0.3
Ropinirole PR1.7

[back to top]

"Mean Change From Baseline in Total Awake Time Spent Off at Week 24 Using Last Observation Carried Forward (LOCF)"

"The off state is defined as the state in which Parkinson's Disease (PD) symptoms (lack of mobility, tremor, or rigidity) are not adequately controlled by the drug. Participants were asked to record the duration of their off periods in 24-hour diary cards prior to each visit on two days of each relevant week. The total number of awake hours spent off per 24-hour period was the sum of the hours recorded on the two 24-hour diary cards. Change from Baseline is calculated as the value at Week 24 minus the Baseline value." (NCT01154166)
Timeframe: Baseline and Week 24 (Visit 13)

Interventionhours (Mean)
Placebo-0.4
Ropinirole PR-2.1

[back to top]

"Mean Change From Baseline in Total Awake Time Spent on at Week 24 Using LOCF"

"The on state is defined as the state in which the PD symptoms (lack of mobility, tremor, or rigidity) are adequately controlled by the drug. Participants were asked to record the duration of their on periods in 24-hour diary cards prior to each visit on the same two days of each relevant week. The total number of awake hours spent on per 24-hour period was the sum of the hours recorded on the two 24-hour diary cards. Change from Baseline is calculated as the value at Week 24 minus the Baseline value." (NCT01154166)
Timeframe: Baseline and Week 24

Interventionhours (Mean)
Placebo0.1
Ropinirole PR1.9

[back to top]

Mean Change From Baseline (BL) in the Parkinson's Disease Sleep Scale (PDSS) Total Score Using LOCF

The PDSS uses a series of 15 questions to assess sleep disturbance associated with PD. Participants completed the assessments based on their experiences in the past week by marking a cross on each 10 centimeter (cm) scale (labelled from worst to best state). Responses were quantified by measuring the distance along each line where the cross was placed. The scores for each item ranged from 0 (symptom severe and always experienced) to 10 (symptom free). The maximum cumulative score for the PDSS was thus 150 (free of all symptoms). Change from BL=value at Week 24 minus the BL value. (NCT01154166)
Timeframe: Baseline and Week 24

Interventionscores on a scale (Mean)
Placebo-1.7
Ropinirole PR0.5

[back to top]

Mean Change From Baseline (BL) in the Unified Parkinson Disease Rating Scale (UPDRS) Total Motor Score at Week 24 Using LOCF

The UPDRS, a clinician-based rating scale, assesses 6 features of PD impairment: (1) mentation, behavior, and mood; (2) activities of daily living; (3) motor examination; (4) complications of therapy; (5) modified Hoehn and Yahr stage; (6) Schwab and England activities of daily living scale. Assessments were conducted when participants had benefit in regard to mobility, tremor, and rigidity. The total motor score (sum of motor examination) ranges from 0 to 108: 0=normal/no symptoms; 108=worst possible case. Change from BL was calculated as the value at Week 24 minus the value at BL. (NCT01154166)
Timeframe: Baseline and Week 24 (Visit 13)

Interventionscores on a scale (Mean)
Placebo-0.7
Ropinirole PR-6.3

[back to top]

Mean Change From Baseline in the Depression Scores on the Hamilton Depression Rating Scale (HAMD-17) Using LOCF

The HAMD-17 is a 17-item scale that is completed by the investigator. Each item was evaluated and scored using either a 5-point scale (e.g., absent, mild, moderate, severe, very severe) or a 3-point scale (e.g., absent, mild, marked). The total HAMD-17 score (sum of the scores of all 17 items) may range from 0 (least severe) to 52 (most severe). Change from Baseline is calculated as the value at Week 24 minus the Baseline value. (NCT01154166)
Timeframe: Baseline and Week 24

Interventionscores on a scale (Mean)
Placebo-0.6
Ropinirole PR-1.6

[back to top]

Mean Change From Baseline in the UPDRS Activities of Daily Living (ADL) Score at Week 24 Using LOCF

The UPDRS assesses six features of PD impairment, including Activities of Daily Living (ADL). The total ADL score ranges from 0 to 52, where 0= normal/no symptoms and 52= worst possible case. Change from Baseline is calculated as the value at Week 24 minus the Baseline value. (NCT01154166)
Timeframe: Baseline and Week 24

Interventionscores on a scale (Mean)
Placebo-0.2
Ropinirole PR-2.2

[back to top]

Number of Participants Requiring Reinstatement of L-dopa Following a Dose Reduction Using LOCF

In the event of unacceptable side effects relative to Baseline (e.g., dyskinesias, dystonias [neurological movement disorder]) the dosage of L-dopa was reduced. If there was reduction in the side effects and there was loss of symptom control, the dose of study medication was again increased (reinstated) at subsequent visits. If symptoms could still not be controlled, then L-dopa was reinstated; however, the dose could not exceed the baseline dose. (NCT01154166)
Timeframe: Week 24

Interventionparticipants (Number)
Placebo23
Ropinirole PR13

[back to top]

Number of Responders Based on the Clinical Global Impression (CGI) Global Improvement Scale Using LOCF

The CGI global improvement scale allows the investigator to rate the participant's total improvement since the beginning of treatment (Baseline). Scores on the scale range from 1 to 7 (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse). Participants with a CGI global improvement score of <=2 (representing much improved or very much improved) were considered to be responders. (NCT01154166)
Timeframe: Week 24

Interventionparticipants (Number)
Placebo16
Ropinirole PR77

[back to top]

Number of Responders to Study Treatment Using LOCF

"The off state is defined as the state in which PD symptoms (lack of mobility, tremor, or rigidity) are not adequately controlled by the drug. Responders are defined as participants who had at least a 20% reduction from Baseline in awake time spent off and at least a 20% reduction from Baseline in the L-dopa dose." (NCT01154166)
Timeframe: Baseline to Week 24

Interventionparticipants (Number)
Placebo4
Ropinirole PR39

[back to top]

Time to Reinstatement of L-dopa Following a Reduction in Dose Using LOCF

The mean number of days after which the dose of L-dopa was readministered after the reduction in dose was recorded. (NCT01154166)
Timeframe: Baseline to Week 24

Interventiondays (Mean)
Placebo114.3
Ropinirole PR162.9

[back to top]

Mean Change From Baseline in the Parkinson's Disease Quality of Life Scores (PDQ39) Using LOCF

"The PDQ39 is a 39 item self-administered questionnaire. The questionnaire covers eight domains of health that are reported as adversely affected by patients with PD. Participants were asked to rate responses on a scale from 0 to 4 (never to always). The overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem). Change from Baseline is calculated as the value at Week 24 minus the Baseline value." (NCT01154166)
Timeframe: Baseline and Week 24

,
Interventionscores on a scale (Mean)
Mobility Domain; n=160, 170Activities of Daily Living Domain; n=160, 170Emotional Wellbeing Domain; n=160, 170Stigma Domain; n=160, 170Social Support Domain; n=157, 167Cognitive Impairment Domain; n=160, 170Communication Domain; n=160, 170Bodily Discomfort Domain; n=160, 170
Placebo2.5-0.3-0.8-1.1-0.7-0.82.60.7
Ropinirole PR-5.7-5.9-4.8-5.1-0.4-1.1-1.1-3.5

[back to top]

"Mean Change From Baseline in the Percentage of Awake Time Spent Off (ATSO) at Week 24 Using LOCF"

"The off state is defined as the state in which PD symptoms (lack of mobility, tremor, or rigidity) are not adequately controlled by the drug. Participants were asked to record the duration of their off periods in 24-hour diary cards prior to each visit on the same 2 days of each relevant week. The total number of awake hours spent off per 24-hour period was the sum of the hours recorded on the two 24-hour diary cards. The percentage of ATSO=ATSO divided by (ATSO + awake time spent on) * 100. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline." (NCT01154166)
Timeframe: Baseline and Week 24

InterventionPercentage of time (Mean)
Placebo-1.8
Ropinirole PR-13.5

[back to top]

Number of Participants With Any Serious Adverse Event

"A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening , requires hospitalization or results in prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. For a list of all serious adverse events occurring during the course of the study, see the table entitled Serious Adverse Events in the Adverse Event section of the results record." (NCT01327339)
Timeframe: one month

Interventionparticipants (Number)
Requip 0.25 mg, 1 mg, 2 mg3

[back to top]

Number of Participants With the Indicated Unexpected Adverse Events

An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unexpected adverse events include those not listed in the approved product information and not described as precautions or warnings. (NCT01327339)
Timeframe: one month

Interventionparticipants (Number)
Weight DecreaseThirstyEye PainSaliva IncreasedMelenaAmnesiaAppendicitis
Requip 0.25 mg, 1 mg, 2 mg2111111

[back to top]

Number of Participants With Any Adverse Event

An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT01327339)
Timeframe: one month

Interventionparticipants (Number)
Requip 0.25 mg, 1 mg, 2 mg44

[back to top]

Number of Participants Who Completed the 10 Week Trial

(NCT01393457)
Timeframe: 10 weeks

Interventionparticipants (Number)
Ldopa + Ropinirole Low Dose14
Ldopa + Ropinirole High Dose14
Ldopa16
Placebo15

[back to top]

Cocaine Use Based on Urine Drug Screening

The mean of the predicted probabilities (derived from generalized linear mixed models) of negative drug screens over all 10 weeks is reported, as per the analysis proposed in the protocol. (NCT01393457)
Timeframe: 10 weeks

Interventionnumber of negative drug screens (Mean)
Ldopa + Ropinirole Low Dose20.36
Ldopa + Ropinirole High Dose15.57
Ldopa22.3
Placebo27.8

[back to top]

Responder Rate Defined as Participants With a >=30% Reduction in Baseline UPDRS Motor Score

The responder rate is defined as the percentage of participants with a greater than or equal to (>=)30% reduction in their individual Baseline UPDRS motor score at Week 4 of the Maintenance Period (Study Week 17). Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values. (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionPercentage of Participants (Number)
Treatment Group A: Placebo18
Treatment Group B: 2 mg/Day31
Treatment Group C: 4 mg/Day23
Treatment Group D: 8 mg/Day30
Treatment Group E: 12 mg/Day38
Treatment Group F: 24 mg/Day31

[back to top]

Change From Baseline (BL) in Unified Parkinson Disease (PD) Rating Scale (UPDRS) Motor Score

The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the participant. One of the six features include the Part III - Motor Examination where scores can range 0-108 where the maximum score indicates the worse condition. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the individual post-randomization values. The least squares(LS) means were estimated using the mixed model repeated measures(MMRM) adjusting for BL UPDRS motor score and race(white versus other) or by using the non-parametric rank analysis of covariance(ANCOVA). (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on a scale (Least Squares Mean)
Treatment Group A: Placebo-1.91
Treatment Group B: 2 mg/Day-1.58
Treatment Group C: 4 mg/Day-2.76
Treatment Group D: 8 mg/Day-4.31
Treatment Group E: 12 mg/Day-4.07
Treatment Group F: 24 mg/Day-2.83

[back to top]

Change From Baseline in the Total UPDRS Score (Parts I-III)

"The total UPDRS score was calculated by the sum of the values for each component (Part I + Part II + Part III) as determined by the physician. The UPDRS Part I scores mentation, behavior and mood and scores can range from 0-16. The UPDRS Part II is the Activities of Daily Living (ADL) score and can range from 0-52. The UPDRS Part III is the Motor Examination (Total Motor Score [TMS]) and scores range from 0-108. The total UPDRS (Part I + II + III) scores can range from 0-176 with the higher score indicating the worse condition. Tests were performed when the participant is in the on state of Parkinson's. Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values." (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on a scale (Least Squares Mean)
Treatment Group A: Placebo-2.74
Treatment Group B: 2 mg/Day-2.18
Treatment Group C: 4 mg/Day-3.83
Treatment Group D: 8 mg/Day-5.93
Treatment Group E: 12 mg/Day-6.68
Treatment Group F: 24 mg/Day-3.40

[back to top]

Change From Baseline in the UPDRS Part I (Mentation)

"The UPDRS Part I scores mentation, behavior and mood as determined by a physician and participants were tested during the on phase of Parkinson's. This component of the UPDRS is the total score for 4 items (the items 1- 4 include intellectual impairment, thought disorder, motivation/initiative, and depression) and may have a value ranging from 0 to 16 as determined by a physician where 16 indicates the maximum score and the worse condition. All 4 items have to be present for a total score to be calculated. If one or more items are missing, the total score for the component will also be missing. Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values." (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on a scale (Least Squares Mean)
Treatment Group A: Placebo0.05
Treatment Group B: 2 mg/Day-0.34
Treatment Group C: 4 mg/Day-0.01
Treatment Group D: 8 mg/Day-0.26
Treatment Group E: 12 mg/Day-0.02
Treatment Group F: 24 mg/Day0.50

[back to top]

Change From Baseline in UPDRS Activities of Daily Living

"The UPDRS Part II is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The higher score indicates the worse condition. Tests were performed when the participant is in the on state of Parkinson's. Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values." (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on a scale (Least Squares Mean)
Treatment Group A: Placebo-0.26
Treatment Group B: 2 mg/Day0.91
Treatment Group C: 4 mg/Day-0.73
Treatment Group D: 8 mg/Day-1.13
Treatment Group E: 12 mg/Day-1.27
Treatment Group F: 24 mg/Day-0.99

[back to top]

Change From Baseline in UPDRS Parts II and III Combined

"The UPDRS Part II is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The UPDRS Part III is the Motor Examination (Total Motor Score [TMS]) and is defined as the total score, ranging from 0-108 as determined by the physician, of the tests given in the motor examination section. The combined scores of Parts II and III can range from 0-160 with the higher score indicating the worse condition. Tests were performed when the participant is in the on state of Parkinson's. Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values." (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScores on a scale (Least Squares Mean)
Treatment Group A: Placebo-2.88
Treatment Group B: 2 mg/Day-1.81
Treatment Group C: 4 mg/Day-3.81
Treatment Group D: 8 mg/Day-5.63
Treatment Group E: 12 mg/Day-6.62
Treatment Group F: 24 mg/Day-3.87

[back to top]

Number of Participants With a >=10 Points Reduction From Baseline in UPDRS Motor Score

The UPDRS motor scores can range from 0-108 where the maximum score indicates the worse condition. Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values. (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionParticipants (Number)
Treatment Group A: Placebo5
Treatment Group B: 2 mg/Day3
Treatment Group C: 4 mg/Day7
Treatment Group D: 8 mg/Day7
Treatment Group E: 12 mg/Day9
Treatment Group F: 24 mg/Day2

[back to top]

Number of Participants With a >=10 Points Reduction From Baseline in UPDRS Parts II and III Combined

"The UPDRS Part II is the Activities of Daily Living (ADL) score and can range from 0-52 as determined by the physician. The UPDRS Part III is the Motor Examination (Total Motor Score [TMS]) and is defined as the total score, ranging from 0-108 as determined by the physician, of the tests given in the motor examination section. The combined scores of Parts II and III can range from 0-160 with the higher score indicating the worse condition. Tests were performed when the participant is in the on state of Parkinson's. Baseline is defined as the last non-missing assessment measured on or before the first dose date." (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionParticipants (Number)
Treatment Group A: Placebo6
Treatment Group B: 2 mg/Day3
Treatment Group C: 4 mg/Day7
Treatment Group D: 8 mg/Day10
Treatment Group E: 12 mg/Day12
Treatment Group F: 24 mg/Day5

[back to top]

Number of Participants With a >=5 Points Reduction From Baseline in UPDRS Motor Score

The UPDRS motor scores can range from 0-108 where the maximum score indicates the worse condition. Baseline is defined as the last non-missing assessment measured on or before the first dose date. The change from Baseline will be calculated by subtracting the Baseline values from the individual post-randomization values. (NCT01485172)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionParticipants (Number)
Treatment Group A: Placebo9
Treatment Group B: 2 mg/Day6
Treatment Group C: 4 mg/Day14
Treatment Group D: 8 mg/Day16
Treatment Group E: 12 mg/Day19
Treatment Group F: 24 mg/Day5

[back to top]

Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy

The percentage of participants who withdrew from the study due to lack of efficacy as defined by either the participant or the investigator is presented here. (NCT01485172)
Timeframe: Up to Week 4 of the Maintenance Period (Study Week 17)

InterventionPercentage of participants (Number)
Treatment Group A: Placebo5
Treatment Group B: 2 mg/Day0
Treatment Group C: 4 mg/Day0
Treatment Group D: 8 mg/Day0
Treatment Group E: 12 mg/Day0
Treatment Group F: 24 mg/Day0

[back to top]

Responder Rate According to the Clinical Global Impression - Global Improvement (CGI-I) Scale

"The CGI-I scale allows the investigator to rate the participant's total improvement since the beginning of treatment (Baseline). Baseline is defined as the last non-missing assessment measured on or before the first dose date. The scale is rated from 1-7 where 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The responder rate is defined as the percentage of participants with a score of 1 or 2." (NCT01485172)
Timeframe: Week 4 of the Maintenance Period (Study Week 17)

InterventionPercentage of participants (Number)
Treatment Group A: Placebo20
Treatment Group B: 2 mg/Day15
Treatment Group C: 4 mg/Day28
Treatment Group D: 8 mg/Day45
Treatment Group E: 12 mg/Day56
Treatment Group F: 24 mg/Day23

[back to top]

"Change From Baseline in the Percent Awake Time Spent on Without TD at Week 4 of the Maintenance Period"

"Dyskinesias are involuntary twisting, turning movements caused by medication during on time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hr diary cards for the 2 days preceding each visit of the study. The total number of awake hr spent on without TD per 24-hr period was the average across the 2 diary cards of the sum of awake hr spent on without TD in each 24-hr diary card. Percentage of awake time spent onwithout TD= Awake time spent on without TD divided by(Awake time spent on + Awake time spent off) × 100. BL is defined as the last non-missing assessment measured on or before the first dose date, change from BL was calculated by subtracting BL values from MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of on time in hours" (Least Squares Mean)
Treatment Group A: Placebo12.89
Treatment Group B: 4 mg/Day11.58
Treatment Group C: 8 mg/Day18.34
Treatment Group D: 12 mg/Day14.99
Treatment Group E: 16 mg/Day17.05
Treatment Group F: 24 mg/Day14.56

[back to top]

"Change From Baseline in the Percent of a 24- Hour Day Spent on Without TD at Week 4 of the Maintenance Period"

"Dyskinesias are involuntary twisting, turning movements caused by medication during on time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hr diary cards for the 2 days preceding each visit. The total number of day awake hr spent on without TD per 24-hr period was the average across the 2 diary cards of the sum of awake hours spent on without TD in each 24-hour diary card. The percentage of 24 hr day spent on without TD= awake time spent on without TD divided by 24 × 100. BL is defined as the last non-missing assessment measured on or before the first dose date, change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of on time in hours" (Least Squares Mean)
Treatment Group A: Placebo7.32
Treatment Group B: 4 mg/Day5.03
Treatment Group C: 8 mg/Day11.19
Treatment Group D: 12 mg/Day8.99
Treatment Group E: 16 mg/Day10.40
Treatment Group F: 24 mg/Day9.34

[back to top]

"Change From Baseline in the Percent of a 24-hour Day Spent Off at Week 4 of the Maintenance Period"

"The off state is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia), with or without additional features such as tremor or rigidity. Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of day awake hours spent off per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent off in each 24-hour diary card. The percentage of 24 hour day spent off= awake time spent off divided by 24 x 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of off time in hours" (Least Squares Mean)
Treatment Group A: Placebo-7.94
Treatment Group B: 4 mg/Day-8.50
Treatment Group C: 8 mg/Day-12.17
Treatment Group D: 12 mg/Day-9.75
Treatment Group E: 16 mg/Day-11.65
Treatment Group F: 24 mg/Day-9.86

[back to top]

"Change From Baseline in the Percent of a 24-hour Day Spent on at Week 4 of the Maintenance Period"

"Par. were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of day awake hours spent on per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent on in each 24-hour diary card. The percentage of a 24-hour day spent on = Awake time spent on divided by 24 × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of on time in hours" (Least Squares Mean)
Treatment Group A: Placebo7.08
Treatment Group B: 4 mg/Day4.99
Treatment Group C: 8 mg/Day11.20
Treatment Group D: 12 mg/Day9.28
Treatment Group E: 16 mg/Day10.94
Treatment Group F: 24 mg/Day9.76

[back to top]

"Change From Baseline in Unified Parkinson Disease Rating Scale (UPDRS) Motor Score With Participants in an on State, at Week 4 of the Maintenance Period"

"The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the par.. One of the six features include the Part III-motor examination where scores can range 0 to 108 with par. in an on state where the maximum score indicates the worse condition. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on scale (Least Squares Mean)
Treatment Group A: Placebo-4.75
Treatment Group B: 4 mg/Day-10.38
Treatment Group C: 8 mg/Day-8.43
Treatment Group D: 12 mg/Day-8.34
Treatment Group E: 16 mg/Day-8.86
Treatment Group F: 24 mg/Day-10.06

[back to top]

"Change From Baseline in UPDRS Activities of Daily Living (ADL) Score With Participants in an on State, at Week 4 of the Maintenance Period"

"The UPDRS Part II is the ADL score and can range from 0 to 52 as determined by the physician. The higher score indicates the worse condition. Test were performed when the par. is in the on state of PD. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on scale (Least Squares Mean)
Treatment Group A: Placebo-1.32
Treatment Group B: 4 mg/Day-3.08
Treatment Group C: 8 mg/Day-3.06
Treatment Group D: 12 mg/Day-2.18
Treatment Group E: 16 mg/Day-2.63
Treatment Group F: 24 mg/Day-3.04

[back to top]

"Change From Baseline in UPDRS ADL Score With Participants in an Off State, at Week 4 of the Maintenance Period"

"The UPDRS Part II is the ADL score and can range from 0 to 52 as determined by the physician. The higher score indicates the worse condition. Test was performed when the par is in the off state of PD. The off time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on scale (Least Squares Mean)
Treatment Group A: Placebo-2.94
Treatment Group B: 4 mg/Day-4.50
Treatment Group C: 8 mg/Day-4.72
Treatment Group D: 12 mg/Day-4.29
Treatment Group E: 16 mg/Day-5.76
Treatment Group F: 24 mg/Day-4.77

[back to top]

"Percent Change From Baseline in Awake Time Spent Off at Week 4 of the Maintenance Period"

"The off state is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia), with or without additional features such as tremor or rigidity. Par. were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent off per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent off in each 24-hour diary card. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL values multiplied (×) the results with 100. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of off time in hours" (Least Squares Mean)
Treatment Group A: Placebo-30.44
Treatment Group B: 4 mg/Day-30.47
Treatment Group C: 8 mg/Day-46.65
Treatment Group D: 12 mg/Day-37.26
Treatment Group E: 16 mg/Day-48.36
Treatment Group F: 24 mg/Day-34.37

[back to top]

"Percent Change From Baseline in Awake Time Spent on at Week 4 of the Maintenance Period"

"Par. were asked to recordawake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent on per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent on in each 24-hour diary card. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL values × 100. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of on time in hours" (Least Squares Mean)
Treatment Group A: Placebo21.31
Treatment Group B: 4 mg/Day15.05
Treatment Group C: 8 mg/Day35.68
Treatment Group D: 12 mg/Day31.28
Treatment Group E: 16 mg/Day32.34
Treatment Group F: 24 mg/Day32.43

[back to top]
=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period"-NCT01494532">

"Percentage of Participants With a >=1 Hour Reduction in Baseline Off Time at Week 4 of the Maintenance Period"

"The off time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. Percentage of participants meeting the criterion (LS mean on inverse linked scale), odds ratio with 95% CI and p-value comparing against placebo were estimated by Generalized Estimating Equations (GEE) model. Baseline 'off-time', treatment, visit and treatment*visit are included in the model." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Interventionpercentage of participants (Least Squares Mean)
Treatment Group A: Placebo72.1
Treatment Group B: 4 mg/Day70.1
Treatment Group C: 8 mg/Day80.6
Treatment Group D: 12 mg/Day73.5
Treatment Group E: 16 mg/Day83.2
Treatment Group F: 24 mg/Day81.4

[back to top]
=2 Hours Reduction in Baseline Off Time at Week 4 of the Maintenance Period"-NCT01494532">

"Percentage of Participants With a >=2 Hours Reduction in Baseline Off Time at Week 4 of the Maintenance Period"

"The off time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. Percentage of participants meeting the criterion (LS mean on inverse linked scale), odds ratio with 95% CI and p-value comparing against placebo were estimated by Generalized Estimating Equations (GEE) model. Baseline 'off-time', treatment, visit and treatment*visit are included in the model." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Interventionpercentage of participants (Least Squares Mean)
Treatment Group A: Placebo53.7
Treatment Group B: 4 mg/Day45.6
Treatment Group C: 8 mg/Day68.2
Treatment Group D: 12 mg/Day53.6
Treatment Group E: 16 mg/Day63.2
Treatment Group F: 24 mg/Day51.3

[back to top]

"Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) Off Time at Week-4 of Maintenance Period"

"The responder rate was defined as the percentage of par with greater than or equal to (>=) 20 percent (%) reduction in their individual BL off time at Week 4 of the Maintenance Period. The off time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. Responder Rate (Least Squares [LS] means on inverse linked scale), odds ratio with 95% CI and p-value comparing against placebo were estimated by Generalized Estimating Equations (GEE) model. Baseline total awake time 'Off', treatment, visit and treatment*visit are included in the model." (NCT01494532)
Timeframe: Week 4 of the Maintenance Period (Study Week 17)

Interventionpercentage of participants (Least Squares Mean)
Treatment Group A: Placebo65.4
Treatment Group B: 4 mg/Day68.0
Treatment Group C: 8 mg/Day75.4
Treatment Group D: 12 mg/Day64.3
Treatment Group E: 16 mg/Day77.9
Treatment Group F: 24 mg/Day72.0

[back to top]

Change From Baseline for Total Sleep Time During the Night Time Hours of Sleep at Week 4 of the Maintenance Period

"Par. were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total sleep hours during the night time hours of sleep was the average across the 2 diary cards of the sum of time (hours) asleep during night time in each 24-hour diary card. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionHours (Least Squares Mean)
Treatment Group A: Placebo0.22
Treatment Group B: 4 mg/Day0.86
Treatment Group C: 8 mg/Day0.22
Treatment Group D: 12 mg/Day0.15
Treatment Group E: 16 mg/Day0.14
Treatment Group F: 24 mg/Day0.04

[back to top]

Change From Baseline in Total Sleep Time During the Night Time Hours of Sleep as a Percentage of a 24-hour Day, at Week 4 of the Maintenance Period

"Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total sleep hours during the night time hours of sleep was the average across the 2 diary cards of the sum of time (hours) asleep during night time in each 24-hour diary card. The percentage of a 24-hour day spent asleep during the night time hours = Total sleep hours during the night time hours of sleep divided by 24 × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionPercentage of time in hours (Least Squares Mean)
Treatment Group A: Placebo0.91
Treatment Group B: 4 mg/Day3.57
Treatment Group C: 8 mg/Day0.92
Treatment Group D: 12 mg/Day0.63
Treatment Group E: 16 mg/Day0.58
Treatment Group F: 24 mg/Day0.18

[back to top]

Change From Baseline in UPDRS Part I at Week 4 of the Maintenance Period

"The UPDRS Part I scores mentation, behavior and mood as determined by a physician and par. were tested during the on phase of PD. This component of the UPDRS is the total score for 4 items (the items 1 to 4 include intellectual impairment, thought disorder, motivation / initiative, and depression) and may have a value ranging from 0 to 16 as determined by a physician. The higher score (16) indicates the maximum score and the worse condition. All 4 items have to be present for a total score to be calculated. If one or more items are missing, the total score for the component would also be missing. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the individual post-randomization values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline (BL) and Week 4 of the Maintenance Period (Study Week 17)

InterventionScore on scale (Least Squares Mean)
Treatment Group A: Placebo-0.24
Treatment Group B: 4 mg/Day-0.44
Treatment Group C: 8 mg/Day-0.33
Treatment Group D: 12 mg/Day-0.24
Treatment Group E: 16 mg/Day-0.47
Treatment Group F: 24 mg/Day-0.45

[back to top]

Percent Change From Baseline in Total Sleep Time During the Night Time Hours of Sleep, at Week 4 of the Maintenance Period

"Par. were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total sleep hours during the night time hours of sleep was the average across the 2 diary cards of the sum of time (hours) asleep during night time in each 24-hour diary card. BL is defined as the last non-missing assessment measured on or before the first dose date. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL value × 100. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionPercentage of total sleep time in hours (Least Squares Mean)
Treatment Group A: Placebo3.99
Treatment Group B: 4 mg/Day10.79
Treatment Group C: 8 mg/Day4.94
Treatment Group D: 12 mg/Day3.41
Treatment Group E: 16 mg/Day3.60
Treatment Group F: 24 mg/Day0.91

[back to top]

Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy

The percentage of participants who withdrew from the study due to lack of efficacy as defined by either the participant or the investigator is presented here. All participants with a non-missing efficacy observation at Baseline and at least one post-Baseline efficacy assessment at any time during the study were analyzed. (NCT01494532)
Timeframe: From start of study treatment until end of treatment (assessed up to 18 weeks)

InterventionPercentage of participants (Number)
Treatment Group A: Placebo0
Treatment Group B: 4 mg/Day0
Treatment Group C: 8 mg/Day0
Treatment Group D: 12 mg/Day0
Treatment Group E: 16 mg/Day3
Treatment Group F: 24 mg/Day0

[back to top]

Responder Rate According to the Clinical Global Impression-global Improvement (CGI-I) Scale at Week 4 of the Maintenance Period

"The CGI-I scale allows the investigator to rate the participant's total improvement since the beginning of treatment (Baseline). Baseline is defined as the last non-missing assessment measured on or before the first dose date. The scale is rated from 1-7 where 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The responder rate is defined as the percentage of participants with a score of 1 or 2. The Generalized Estimating Equations (GEE) model was used to determine CGI responder rate with treatment, visit, and treatment by visit interaction included in the model. Only scheduled visits were included." (NCT01494532)
Timeframe: Week 4 of the Maintenance Period (Study Week 17)

InterventionPercentage of participants (Number)
Treatment Group A: Placebo35
Treatment Group B: 4 mg/Day28
Treatment Group C: 8 mg/Day39
Treatment Group D: 12 mg/Day42
Treatment Group E: 16 mg/Day46
Treatment Group F: 24 mg/Day56

[back to top]

"Percent Change From Baseline in Awake Time Spent on Without TD at Week 4 of the Maintenance Period"

"Dyskinesias are involuntary twisting, turning movements caused by medication during on time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Par. were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent on without TD per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent on without TD in each 24-hour diary card. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL values × 100. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of on time in hours" (Least Squares Mean)
Treatment Group A: Placebo24.55
Treatment Group B: 4 mg/Day15.20
Treatment Group C: 8 mg/Day35.20
Treatment Group D: 12 mg/Day32.02
Treatment Group E: 16 mg/Day34.45
Treatment Group F: 24 mg/Day29.58

[back to top]

"Change From Baseline (BL) in Total Awake Time Spent Off at Week 4 of Maintenance Period"

"Off time is defined as the state in which the participants(par) symptoms include lack of mobility(bradykinesia) with or without additional features such as tremor or rigidity. Par were asked to record awake time off , awake time on, troublesome dyskinesias(TD) during awake time on, or time asleep for 30 minute intervals in 24 hr diary cards for 2 days preceding visits. Total number of awake hrs spent off per 24-hr period was the average of the 2 diary cards of the sum of awake hours spent off in each 24-hr diary card. BL is the last non-missing assessment measured on or before the first dose, change from BL was calculated by subtracting the BL values from the MP Week 4 values. Mixed Model Repeated Measures (MMRM) model used BL total awake time 'Off', treatment, visit and treatment by visit" (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionHours (Least Squares Mean)
Treatment Group A: Placebo-1.91
Treatment Group B: 4 mg/Day-2.04
Treatment Group C: 8 mg/Day-2.92
Treatment Group D: 12 mg/Day-2.34
Treatment Group E: 16 mg/Day-2.80
Treatment Group F: 24 mg/Day-2.37

[back to top]

"Change From Baseline in Absolute Awake Time Spent on at Week 4 of the Maintenance Period"

"Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent on per 24-hour period was the average across the 2 diary cards of the sum of the awake hours spent on in each 24 hour diary card. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionHours (Least Squares Mean)
Treatment Group A: Placebo1.70
Treatment Group B: 4 mg/Day1.20
Treatment Group C: 8 mg/Day2.69
Treatment Group D: 12 mg/Day2.23
Treatment Group E: 16 mg/Day2.62
Treatment Group F: 24 mg/Day2.34

[back to top]

"Change From Baseline in Absolute Awake Time Spent on Without Troublesome Dyskinesia (TD) at Week 4 of the Maintenance Period"

"Dyskinesias are involuntary twisting, turning movements caused by medication during on time in Parkinson's Disease (PD). TD is defined as those movements that interfere with function and cause meaningful discomfort. Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit. The total number of awake hours spent on without TD per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent on without TD in each 24 hour diary card. The change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from Mixed Model Repeated Measures (MMRM). Par with a non-missing efficacy observation at BL and during the MP were analyzed." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

InterventionHours (Least Squares Mean)
Treatment Group A: Placebo1.76
Treatment Group B: 4 mg/Day1.21
Treatment Group C: 8 mg/Day2.69
Treatment Group D: 12 mg/Day2.16
Treatment Group E: 16 mg/Day2.49
Treatment Group F: 24 mg/Day2.24

[back to top]

"Change From Baseline in the Percent Awake Time Spent Off at Week 4 of the Maintenance Period"

"The off state is defined as the state in which the participants' symptoms include lack of mobility(bradykinesia), with or without additional features such as tremor or rigidity. Par were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent off per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent off in each 24-hour diary card. The percentage of awake time spent off= Awake time spent off divided by (Awake time spent off + Awake time spent on) × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of off time in hours" (Least Squares Mean)
Treatment Group A: Placebo-12.43
Treatment Group B: 4 mg/Day-11.60
Treatment Group C: 8 mg/Day-18.41
Treatment Group D: 12 mg/Day-15.36
Treatment Group E: 16 mg/Day-17.81
Treatment Group F: 24 mg/Day-15.01

[back to top]

"Change From Baseline in the Percent Awake Time Spent on at Week 4 of the Maintenance Period"

"Par. were asked to record awake time off, awake time on, TD during awake time on, or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent on per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent on in each 24-hour diary card. The percentage of awake time spent on= Awake time spent on divided by (Awake time spent on + Awake time spent off) × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM." (NCT01494532)
Timeframe: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Intervention"Percentage of on time in hours" (Least Squares Mean)
Treatment Group A: Placebo12.43
Treatment Group B: 4 mg/Day11.60
Treatment Group C: 8 mg/Day18.41
Treatment Group D: 12 mg/Day15.36
Treatment Group E: 16 mg/Day17.81
Treatment Group F: 24 mg/Day15.01

[back to top] [back to top] [back to top]

Number of Participants With the Indicated Adverse Events During the Follow-up Phase

An adverse event is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. In addition to the data recorded at the follow-up visit, SAEs occurring up to and including 2 days after the last dose of down-titration medication are included in the Follow-up Phase. (NCT01536574)
Timeframe: 4- to 14-day Follow-up Phase, beginning after the date of the last dose of down-titration medication (up to and during Study Weeks 26 and 27)

,
InterventionParticipants (Number)
Facial palsyParkinsonian rest tremorLymphopeniaHallucinationChoking sensation
Placebo in Parent DB Study, Ropinirole PR in OL Study11010
Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study00101

[back to top]

Number of Participants With an Adverse Event During the Follow-up Phase

AE=any untoward medical occurrence (UMO), temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. SAE=any UMO that, at any dose, results in death, is life threatening, requires hospitalization/prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomoly/birth defect. The Investigator determined if an AE/SAE was related to investigational product. Medical/scientific judgment was used to determine whether SAE reporting was appropriate in situations in which an event may not have met the SAE definition. (NCT01536574)
Timeframe: 4- to 14-day Follow-up Phase, beginning after the date of the last dose of down-titration medication (up to and during Study Weeks 26 and 27)

,
InterventionParticipants (Number)
Any AEAE related to IPAny SAE
Placebo in Parent DB Study, Ropinirole PR in OL Study320
Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study210

[back to top]

Mean Gambling Symptom Assessment Scale (G-SAS) Score at Week 24

The G-SAS is a reliable and valid self-reported measure of gambling symptoms. It is comprised of twelve questions aimed at evaluating gambling symptoms; each item is scored on a 5-point scale from 0 (no symptoms) to 4 (extreme symptoms). The total score ranges from 0 to 48, where 0=least severe and 48=most severe. (NCT01536574)
Timeframe: Week 24

InterventionScores on a scale (Mean)
Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study0.9
Placebo in Parent DB Study, Ropinirole PR in OL Study1.3

[back to top]

Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label Treatment Phase and the Down-titration Phase)

AE=any untoward medical occurrence (UMO), temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP. SAE=any UMO that, at any dose, results in death, is life threatening, requires hospitalization/prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomoly/birth defect. The Investigator determined if an AE/SAE was related to investigational product. Medical/scientific judgment was used to determine whether SAE reporting was appropriate in situations in which an event may not have met the SAE definition. (NCT01536574)
Timeframe: From the start of treatment (Baseline) up to Week 25

,
InterventionParticipants (Number)
Any AEAE Related to Investigational Product (IP)Any SAESAE Related to Investigational Product (IP)AE Leading to DeathAE Leading to Withdrawal
Placebo in Parent DB Study, Ropinirole PR in OL Study56354104
Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study58332004

[back to top]

Mean Change From Baseline in the Gambling Symptom Assessment Scale (G-SAS) Score at Week 24

The G-SAS is a reliable and valid self-reported measure of gambling symptoms. It is comprised of twelve questions aimed at evaluating gambling symptoms; each item is scored on a 5-point scale from 0 (no symptoms) to 4 (extreme symptoms). The total score ranges from 0 to 48, where 0=least severe and 48=most severe. Change from Baseline is calculated as the value at Week 24 minus the Baseline value. (NCT01536574)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Mean)
Ropinirole PR in Parent DB Study, Ropinirole PR in OL Study-0.1
Placebo in Parent DB Study, Ropinirole PR in OL Study-0.3

[back to top]

UPDRS Part 2 Sum Score

"Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.~UPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement." (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

InterventionScores on a scale (Mean)
SPM 962-3.6
Ropinirole-2.9
Placebo-1.3

[back to top]

UPDRS Part 3 Sum Score

"Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing.~UPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement." (NCT01628926)
Timeframe: baseline, 8 and 10 weeks after dosing

,,
InterventionScores on a scale (Mean)
8 weeks after dosing10 weeks after dosing
Placebo-5.5-5.3
Ropinirole-8.4-8.8
SPM 962-9.7-9.9

[back to top]

Effective Rate in UPDRS Part 3 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing. (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

,,
InterventionPercentage of participants (Number)
≥20% decrease≥30% decrease
Placebo56.639.8
Ropinirole69.160.6
SPM 96280.569.5

[back to top]

On Time

Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day. (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

InterventionHours/day (Mean)
SPM 9621.3
Ropinirole1.7
Placebo0.2

[back to top]

On Time With Dyskinesia Disturbing Daily Activities

Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time). (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

InterventionHours (Mean)
SPM 9621.3
Ropinirole0.6
Placebo-0.2

[back to top]

On Time Without Dyskinesia Disturbing Daily Activities

"Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing.~On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day." (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

InterventionHours/day (Mean)
SPM 9621.1
Ropinirole1.6
Placebo0.3

[back to top]

Parkinson's Disease Sleep Scale-2 (PDSS-2)

Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement. (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

InterventionScores on a scale (Mean)
SPM 962-3.1
Ropinirole-3.4
Placebo-1.8

[back to top]

Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score

"Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.~UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement." (NCT01628926)
Timeframe: baseline, 16 weeks after dosing

InterventionScores on a scale (Mean)
SPM 962-10.9
Ropinirole-9.5
Placebo-4.5

[back to top]

Clinical Global Impression (CGI)

"Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline.~The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement." (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

,,
InterventionPercentage of Participants (Number)
DecreasedDecreased (by at least 2 points)IncreasedIncreased (by at least 2 points)
Placebo30.93.74.90
Ropinirole49.18.54.20
SPM 96250.38.03.10

[back to top]

Dystonia (at an Early Hour)

Change (LOCF) from baseline in occurrence of Dystonia (at an early hour). (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

,,
InterventionPercentage of participants (Number)
DecreasedDecreased (by at least 2 events)IncreasedIncreased (by at least 2 events)
Placebo7.42.53.70
Ropinirole10.94.23.00.6
SPM 96210.41.81.20

[back to top]

Dystonia (in the Daytime)

Change (LOCF) from baseline in occurrence of Dystonia (in the daytime). (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

,,
InterventionPercentage of Participants (Number)
DecreasedDecreased (by at least 2 events)IncreasedIncreased (by at least 2 events)
Placebo3.72.54.91.2
Ropinirole7.95.52.40.6
SPM 9628.63.73.71.8

[back to top]

Effective Rate in UPDRS Part 2 Sum Score

Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing. (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

,,
InterventionPercentage of participants (Number)
≥20% decrease≥30% decrease
Placebo47.028.9
Ropinirole56.743.3
SPM 96265.255.9

[back to top]

Off Time

Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day. (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

InterventionHours/day (Mean)
SPM 962-1.3
Ropinirole-2.0
Placebo-0.4

[back to top]

Effective Rate in Off Time

"Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing.~On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day." (NCT01628926)
Timeframe: Baseline, 16 weeks after dosing

,,
InterventionPercentage of participants (Number)
≥20% decrease≥30% decrease
Placebo47.440.4
Ropinirole65.561.9
SPM 96261.855.5

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Long-term Phase

"The Japanese UPDRS assesses the status of PD participants objectively. Part 2 evaluates activities of daily living on 13 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 52. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value at Week 13. If the value at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data.Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. On state is defined as the state at which PD symptoms are well controlled by the drug. The score of UPDRS part 2 in off status is rated as '0' (Normal/None), if L-dopa adjunct participants do not have diurnal fluctuations." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionPercent change (Mean)
Week 17, On status, n=35, 12Week 21, On status, n=33, 11Week 25, On status, n=33, 12Week 37, On status, n=26, 12Week 49, On status, n=20, 9Week 52, On status, n=19, 9Week 17, Off status, n=26, 13Week 21, Off status, n=24, 12Week 25, Off status, n=24, 13Week 37, Off status, n=20, 13Week 49, Off status, n=16, 11Week 52, Off status, n=15, 11
Ropinirole CR - High Dose Group: Long Term Phase2.3-0.1-1.78.027.87.5-1.4-4.41.46.11.97.1
Ropinirole CR - Maintenance Group: Long Term Phase-5.8-7.1-0.7-8.61.80.7-3.6-6.0-5.26.344.526.2

[back to top]

"Change From Baseline in Actual Hours of Awake Time Spent On at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Change from Baseline in awake time spent On(actual hours) is calculated as awake time spent On (hours) at the week 17, 21, 25, 37, 49 and 52 value minus awake time spent On (hours) at Baseline. Baseline is defined as the value at Week 13. If the value evaluated at week 13 was missing then first observed value post week 13 was used as a Baseline. The analyses for Long term phase was performed using the OC data. The OC (observed Case) dataset was defined as the dataset consisting of observed data without any missing data imputation." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
Interventionhours (Mean)
Week 17, n=36, 15Week 21, n=34, 14Week 25, n=34, 15Week 37, n=29, 15Week 49, n=26, 12Week 52, n=23, 12
Ropinirole CR - High Dose Group: Long Term Phase0.560.43-0.040.26-0.190.36
Ropinirole CR - Maintenance Dose Group: Long Term Phase0.570.730.230.37-0.56-0.56

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Dose Increase Effect Verification Phase

"The Japanese UPDRS assesses the status of PD participants objectively. Part 2 evaluates activities of daily living on 13 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 52. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. On state is defined as the state at which PD symptoms are well controlled by the drug. The score of UPDRS part 2 in off status is rated as '0' (Normal/None), if L-dopa adjunct participants do not have diurnal fluctuations." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionPercent change (Mean)
Week 2, On status, n=55, 16Week 4, On status, n=55, 16Week 6, On status, n=55, 16Week 8, On status, n=55, 16Week 12, On status, n=55, 16Week 2, Off status, n=48, 15Week 4, Off status, n=48, 15Week 6, Off status, n=48, 15Week 8, Off status, n=48, 15Week 12, Off status, n=48, 15
Ropinirole CR - High Dose Group-22.3-21.9-21.4-14.3-4.7-11.7-15.0-17.0-14.7-15.2
Ropinirole CR - Maintenance Dose Group-4.6-13.0-12.9-9.0-9.3-4.2-4.4-9.7-10.9-10.1

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 3 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase

The Japanese UPDRS assessed the status of PD participants objectively. Part 3 evaluated motor examination on 27 items, response for each items were scored numerically from 0-4. The total score for the 27 items ranged from 0 to 108. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value evaluated at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionPercent change (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group-12.0-17.4-21.6-25.5-23.1
Ropinirole CR - Maintenance Dose Group-11.8-21.9-22.9-22.9-27.6

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 3 Total Score at the Indicated Visits in the Long Term Phase

The Japanese UPDRS assessed the status of PD participants objectively. Part 3 evaluated motor examination on 27 items, response for each items were scored numerically from 0-4. The total score for the 27 items ranged from 0 to 108. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data. (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionPercent change (Mean)
Week 17, n=41, 16Week 21, n=39, 16Week 25, n=40, 17Week 37; n=33, 17Week 49; n=26, 14Week 52; n=25, 14
Ropinirole CR - High Dose Group: Long Term Phase-5.4-10.5-10.3-6.4-3.4-4.1
Ropinirole CR - Maintenance Group: Long Term Phase6.2-6.02.650.243.216.2

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase

"The Japanese UPDRS assessed the status of PD participants objectively. Part 4 evaluated complications on 11 items, response for 4 items were scored numerically from 0-4 and response for other 7 items were Yes/No questions and responses are numerically scored as 0 for No and 1 for Yes. The total score for the 11 items ranged from 0 to 23. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value evaluated at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionPercent change (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group-7.9-4.1-7.21.4-6.6
Ropinirole CR - Maintenance Dose Group-1.9-6.5-4.93.59.5

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Long-term Phase

"The Japanese UPDRS assesses the status of PD participants objectively. Part 4 evaluates complications on 11 items, response for 4 items were scored numerically from 0-4 and response for other 7 items were Yes/No questions and responses are numerically scored as 0 for No and 1 for Yes. The total score for the 11 items ranged from 0 to 23. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionPercent change (Mean)
Week 17, n=30, 15Week 21, n=28, 14Week 25, n=28, 15Week 37, n=23, 15Week 49, n=18, 13Week 52, n=17, 13
Ropinirole CR - High Dose Group: Long Term Phase13.111.316.411.327.523.7
Ropinirole CR - Maintenance Dose Group: Long Term Phase7.16.818.749.540.035.4

[back to top]

Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at Week 12 in the CR High-dose Group

The Japanese Unified Parkinson's Disease Rating Scale (UPDRS) assesses the status of Parkinson's Disease (PD) participants objectively. Part III assessed motor examination on 27 items. Participants received a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Baseline is defined as the value evaluated at Week 0. Mean change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline. The analyses for the Dose Increase Effect Verification Phase was performed using the last observation carried forward (LOCF) data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. The imputation was conducted using the data within only the Dose Increase Effect Verification Phase; therefore, the value observed in the Dose Increase Effect Verification Phase was not used to impute a missing data in the Long-term Phase. (NCT01929317)
Timeframe: Baseline and Week 12

InterventionScores on a scale (Mean)
Ropinirole CR - High Dose Group-4.8

[back to top]

Number of Participants With an Improvement (Responder) in the Clinical Global Impression (CGI) Global Improvement Scale at Week 12

The CGI global improvement scale allows the investigator to rate the participant's total improvement since the beginning of treatment (Baseline). Scores on the scale range from 1 to 7 (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse). Participants with a CGI global improvement score of <=2 (representing much improved or very much improved) were considered to be moderate improvement (responder). The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data. (NCT01929317)
Timeframe: Week 12

InterventionParticipants (Number)
Ropinirole CR - High Dose Group19
Ropinirole CR - Maintenance Dose Group6

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Long Term Phase

The Japanese UPDRS assessed the status of PD participants objectively. Part I evaluated mentation, behavior, and mood on 4 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 16. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data. (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionPercent change (Mean)
Week 17, n=15, 7Week 21, n=14, 7Week 25, n=14, 7Week 37; n=9, 7Week 49; n=6, 5Week 52; n=6, 5
Ropinirole CR - High Dose Group: Long Term Phase13.3-7.13.60.020.812.5
Ropinirole CR - Maintenance Group: Long Term Phase-9.5-31.0-26.2-11.915.05.0

[back to top]

"Change From Baseline in Actual Hours of Awake Time Spent On at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Change from Baseline in awake time spent On(actual hours) is calculated as awake time spent On (hours) at the indicated visit minus awake time spent On (hours) at Baseline. Baseline is defined as the value at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
Interventionhours (Mean)
Week 2, n=53, 17Week 4, n=53, 18Week 6, n=53, 18Week 8, n=53, 18Week 12, n=53, 18
Ropinirole CR - High Dose Group-0.39-0.12-0.01-0.110.07
Ropinirole CR - Maintenance Dose Group-0.46-0.60-0.61-0.96-0.79

[back to top]

"Change From Baseline in Actual Hours of Awake Time Spent On Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Participants were asked to record the duration of their on periods and asleep in diary cards every day. Change from Baseline in awake time spent On without troublesome dyskinesias (actual hours) is calculated as [awake time spent On minus awake time spent On with troublesome dyskinesias] (hours) at visit minus [awake time spent On minus awake time spent On with troublesome dyskinesias] (hours) at Baseline. Baseline is defined as the value at Week 13. If the value evaluated at week 13 was missing then first observed value post week 13 was used as a Baseline. The analyses for Long term phase was performed using the OC data. In the OC data, no imputation was carried for any missing data" (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
Interventionhours (Mean)
Week 17, n=36, 15Week 21, n=34, 14Week 25, n=34, 15Week 37, n=29, 15Week 49, n=26, 12Week 52, n=23, 12
Ropinirole CR - High Dose Group: Long Term Phase0.240.21-0.15-0.09-0.500.08
Ropinirole CR - Maintenance Dose Group: Long Term Phase0.601.230.251.020.04-0.21

[back to top]

"Change From Baseline in Actual Hours of Awake Time Spent OnWithout Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Change from Baseline in awake time spent On without troublesome dyskinesias (actual hours) is calculated as [awake time spent On minus awake time spent On with troublesome dyskinesias] (hours) at visit minus [awake time spent On minus awake time spent On with troublesome dyskinesias] (hours) at Baseline. Baseline is defined as the value at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
Interventionhours (Mean)
Week 2, n=53, 17Week 4, n=53, 18Week 6, n=53, 18Week 8, n=53, 18Week 12, n=53, 18
Ropinirole CR - High Dose Group-0.40-0.14-0.06-0.050.11
Ropinirole CR - Maintenance Dose Group-0.59-0.71-0.63-1.01-0.74

[back to top]

"Change From Baseline in Percentage of Awake Time Spent On at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Participants were asked to record the duration of their on periods and asleep in diary cards every day. Percentage of awake time spent on is defined as sum of two days on time (hours) divided by sum of two days awake time (hours) and multiplified by 100. Change from Baseline was calculated by subtracting the Baseline value (percentage of awake time spent on) from week 17, 21, 25, 37, 49 and 52 value (percentage of awake time spent on). Baseline is defined as the value at Week 13. If the value evaluated at week 13 was missing the first observed value post week 13 was used as a Baseline.The analyses for Long term phase was performed using the OC data. In the OC data, no imputation was carried for any missing data." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
Interventionpercentage of awake time spent on (Mean)
Week 17, n=36, 15Week 21, n=34, 14Week 25, n=34, 15Week 37, n=29, 15Week 49, n=26, 12Week 52, n=23, 12
Ropinirole CR - High Dose Group: Long Term Phase2.811.20-1.020.13-0.231.80
Ropinirole CR - Maintenance Dose Group: Long Term Phase3.824.623.423.27-2.68-1.14

[back to top]

"Change From Baseline in Percentage of Awake Time Spent On Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"

"On state is defined as the state at which PD symptoms are well controlled by the drug. Par. were asked to record the duration of their on periods and asleep in diary cards every day. Percentage of awake time spent On without troublesome dyskinesias is defined as sum of two days on time without troublesome dyskinesias [On time minus On time with troublesome dyskinesias] (hours) divided by sum of two days awake time (hours) and multiplified by 100. Change from Baseline was calculated by subtracting the Baseline value (percentage of awake time spent On without troublesome dyskinesias) from week 17, 21, 25, 37, 49 and 52 value (percentage of awake time spent On without troublesome dyskinesias). Baseline is defined as the value at Week 13. If the value evaluated at week 13 was missing the first observed value post week 13 was used as a Baseline.The analyses for Long term phase was performed using the OC data. In the OC data, no imputation was carried for any missing data." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
Interventionpercentage of awake time spent on (Mean)
Week 17, n=36, 15Week 21, n=34, 14Week 25, n=34, 15Week 37, n=29, 15Week 49, n=26, 12Week 52, n=23, 12
Ropinirole CR - High Dose Group: Long Term Phase0.70-0.16-1.70-1.71-2.00-0.05
Ropinirole CR - Maintenance Dose Group: Long Term Phase4.047.313.106.930.450.53

[back to top]

"Change From Baseline in the Actual Hours of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Change from Baseline was calculated by subtracting the Baseline value (actual hours of awake time spent off) from the week 17, 21, 25, 37, 49 and 52 value (proportion of awake time spent off). Baseline is defined as the value at Week 13. If the value evaluated at week 13 was missing then first observed value post week 13 was used as a Baseline.The analyses for long term phase was performed using the OC data. In the OC data, no imputation was carried for any missing data" (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
Interventionhours (Mean)
Week 17, n=26, 13Week 21, n=24, 12Week 25, n=24, 13Week 37, n=20, 13Week 49, n=18, 11Week 52, n=15, 11
Ropinirole CR - High Dose Group: Long Term Phase-0.63-0.400.040.01-0.24-0.62
Ropinirole CR - Maintenance Dose Group: Long Term Phase-0.50-0.65-0.52-0.460.910.45

[back to top]

"Change From Baseline in the Actual Hours of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Change from Baseline in awake time spent Off(actual hours) is calculated as awake time spent Off (hours) at the indicated visit minus awake time spent Off (hours) at Baseline. Baseline is defined as the value at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
Interventionhours (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group0.140.090.01-0.08-0.27
Ropinirole CR - Maintenance Dose Group0.440.040.370.770.81

[back to top]

"Change From Baseline in the Percentage of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Percentage of awake time spent off is defined as sum of two days off time (hours) divided by sum of two days awake time (hours) and multiplied by 100. Change from Baseline was calculated by subtracting the Baseline value (percentage of awake time spent off) from week 17, 21, 25, 37, 49 and 52 value (percentage of awake time spent off). Baseline is defined as the value at Week 13, If the value evaluated at week 13 was missing then first observed value post week 13 was used as a Baseline. The analyses for Long term phase was performed using the OC data. In the OC data, no imputation was carried for any missing data." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
Interventionpercentage of awake time spent off (Mean)
Week 17, n=26, 13Week 21, n=24, 12Week 25, n=24, 13Week 37, n=20, 13Week 49, n=18, 11Week 52, n=15, 11
Ropinirole CR - High Dose Group: Long Term Phase-4.16-2.590.49-0.99-1.33-3.62
Ropinirole CR - Maintenance Dose Group: Long Term Phase-4.41-5.39-3.95-4.562.931.24

[back to top]

"Change From Baseline in the Percentage of Awake Time Spent Off at the Indicated Visits Only in Participants Who Received L-dopa Adjunct"

"Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. Participants were asked to record the duration of their off periods and asleep in diary cards every day. Percentage of awake time spent off is defined as sum of two days off time (hours) divided by sum of two days awake time (hours) and multiplied by 100. Change from Baseline was calculated by subtracting the Baseline value (percentage of awake time spent off) from the post Baseline value (percentage of awake time spent off). Baseline is defined as the value at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
Interventionpercentage of awake time spent off (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group1.360.62-0.090.19-1.24
Ropinirole CR - Maintenance Dose Group2.390.482.704.654.74

[back to top]

Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase

The Japanese UPDRS assesses the status of PD participants objectively. Part I evaluated mentation, behavior, and mood on 4 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 16. A higher score indicates more severe PD symptoms. Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 0. The analyses for the Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at the planned visit. (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionScores on a scale (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group-0.0-0.1-0.1-0.10.1
Ropinirole CR - Maintenance Dose Group-0.1-0.2-0.1-0.1-0.1

[back to top]

Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Long-term Phase

The Japanese UPDRS assessed the status of PD participants objectively. Part I evaluated mentation, behavior, and mood on 4 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 16. A higher score indicates more severe PD symptoms.Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data. Full Analysis Set 2 (FAS2) Population comprised of all participants in the FAS1 and shifted to Long-term Phase, excluding those participants who received no dose of study medication and participants without UPDRS part III total score data after supply of the investigational product. (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionScores on a scale (Mean)
Week 17; n=42,17Week 21; n=40, 16Week 25; n=40, 17Week 37; n=33, 17Week 49; n=26, 14Week 52; n=25, 14
Ropinirole CR - High Dose Group: Long Term Phase0.10.20.20.20.20.2
Ropinirole CR - Maintenance Group: Long Term Phase0.1-0.2-0.10.10.10.2

[back to top]

Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Dose Increase Effect Verification Phase

"The Japanese UPDRS assesses the status of PD participants objectively. Part 2 evaluated activities of daily living on 13 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 52. A higher score indicates more severe PD symptoms. Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 0. The analyses for the Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. On state is defined as the state at which PD symptoms are well controlled by the drug. The score of UPDRS part 2 in off status is rated as '0' (Normal/None), if L-dopa adjunct participants do not have diurnal fluctuations." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionScores on a scale (Mean)
Week 2, On status, n=61, 20Week 4, On status, n=61, 20Week 6, On status, n=61, 20Week 8, On status, n=61, 20Week 12, On status, n=61, 20Week 2, Off status, n=53, 18Week 4, Off status, n=53, 18Week 6, Off status, n=53, 18Week 8, Off status, n=53, 18Week 12, Off status, n=53, 18
Ropinirole CR - High Dose Group-1.0-1.4-1.6-1.4-1.1-1.0-1.3-1.7-1.4-1.4
Ropinirole CR - Maintenance Dose Group-0.2-0.3-0.5-0.2-0.2-0.3-0.4-0.8-1.3-1.3

[back to top]

Number of Participants Remaining in the Study

(NCT01929317)
Timeframe: From the start of the study medication (Week 0) until Week 52

InterventionParticipants (Number)
Ropinirole CR - High Dose Group25
Ropinirole CR - Maintenance Dose Group14

[back to top]

Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Long Term Phase

"The Japanese UPDRS assesses the status of PD participants objectively. Part 2 evaluates activities of daily living on 13 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 52. A higher score indicates more severe PD symptoms.Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value at Week 13. If the value at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data.Off state is defined as the state at which PD symptoms are not adequately controlled by the drug. On state is defined as the state at which PD symptoms are well controlled by the drug. The score of UPDRS part 2 in off status is rated as '0' (Normal/None), if L-dopa adjunct participants do not have diurnal fluctuations." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionScores on a scale (Mean)
Week 17, On status, n=42, 17Week 21, On status, n=40, 16Week 25, On status, n=40, 17Week 37, On status, n=33, 17Week 49, On status, n=26, 14Week 52, On status, n=25, 14Week 17, Off status, n=36, 15Week 21, Off status, n=34, 14Week 25, Off status, n=34, 15Week 37, Off status, n=29, 15Week 49, Off status, n=24, 12Week 52, Off status, n=23, 12
Ropinirole CR - High Dose Group: Long Term Phase-0.1-0.4-0.20.00.0-0.2-0.4-0.4-0.20.90.40.4
Ropinirole CR - Maintenance Group: Long Term Phase0.10.0-0.10.20.60.1-0.5-0.7-1.50.00.80.8

[back to top]

Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase

"The Japanese UPDRS assessed the status of PD participants objectively. Part 4 evaluated complications on 11 items, response for 4 items were scored numerically from 0-4 and response for other 7 items were Yes/No questions and responses are numerically scored as 0 for No and 1 for Yes. The total score for the 11 items ranged from 0 to 23. A higher score indicates more severe PD symptoms. Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 0. The analyses for the Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit." (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionScores on a scale (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group-0.3-0.2-0.20.0-0.1
Ropinirole CR - Maintenance Dose Group-0.2-0.2-0.30.10.1

[back to top]

Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Long Term Phase

"The Japanese UPDRS assessed the status of PD participants objectively. Part 4 evaluated complications on 11 items, response for 4 items were scored numerically from 0-4 and response for other 7 items were Yes/No questions and responses are numerically scored as 0 for No and 1 for Yes. The total score for the 11 items ranged from 0 to 23. A higher score indicates more severe PD symptoms.Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data." (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52

,
InterventionScores on a scale (Mean)
Week 17, n=42, 17Week 21, n=40, 16Week 25, n=40, 17Week 37; n=33;17Week 49; n=26,14Week 52; n=25, 14
Ropinirole CR - High Dose Group: Long Term Phase0.10.30.40.50.90.6
Ropinirole CR - Maintenance Group: Long Term Phase-0.1-0.10.21.11.20.8

[back to top]

Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits

The Japanese Unified Parkinson's Disease Rating Scale (UPDRS) assesses the status of Parkinson's Disease (PD) participants objectively. Part III assessed motor examination on 27 items. Participants received a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Baseline is defined as the value evaluated at Week 0. Mean change from Baseline was calculated as the total score at Week 12 minus the total score at Baseline. The analyses for the Dose Increase Effect Verification Phase was performed using the last observation carried forward (LOCF) data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. The imputation was conducted using the data within only the Dose Increase Effect Verification Phase; therefore, the value observed in the Dose Increase Effect Verification Phase was not used to impute a missing data in the Long-term Phase. (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionScores on a scale (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group-2.9-3.8-4.6-5.2-4.8
Ropinirole CR - Maintenance Dose Group-2.7-4.4-5.0-4.5-5.7

[back to top]

Mean Change From Baseline in UPDRS Part 3 Total Score at the Indicated Visits for Long Term Phase

The Japanese UPDRS assesses the status of PD participants objectively. Part 3 evaluates motor examination on 27 items, response for each items were scored numerically from 0-4. The total score for the 27 items ranged from 0 to 108. A higher score indicates more severe PD symptoms. Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The analyses performed using the OC data. In the OC data, no imputation was carried for any missing data. (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49, 52

,
InterventionScores on a scale (Mean)
Week 17; n=41, 16Week 21, n=39, 16Week 25, n=40, 17Week 37; n=33, 17Week 49; n=26, 14Week 52; n=25, 14
Ropinirole CR - High Dose Group: Long Term Phase-1.2-2.5-2.1-1.9-2.2-1.9
Ropinirole CR - Maintenance Group: Long Term Phase-0.7-1.9-0.61.40.6-0.6

[back to top]

Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in Long Term Phase.

The Japanese UPDRS assesses the status of Parkinson's Disease (PD) participants objectively. Part III assessed motor examination on 27 items. Participants received a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Number of participants achieving a 30% or greater and 20% or greater reduction from Baseline in UPDRS total part III score at Weeks 17, 21, 25, 37, 49 and 52,are presented using OC data. Change from Baseline was calculated by subtracting the Baseline value from the post Baseline value. Baseline is defined as the value evaluated at Week 13. If the value evaluated at Week 13 was missing, then first observed value post Week 13 was used as Baseline. The OC (observed Case) dataset was defined as the dataset consisting of observed data without any missing data imputation. (NCT01929317)
Timeframe: Baseline (Week 13), Weeks 17, 21, 25, 37, 49, 52

,
InterventionParticipants (Number)
Week 17, >=30% reduction from Baseline; n=41,16Week 21, >=30% reduction from Baseline; n=39,16Week 25, >=30% reduction from Baseline; n=40, 17Week 37, >=30% reduction from Baseline; n=33,17Week 49, >=30% reduction from Baseline; n=26, 14Week 52, >=30% reduction from Baseline; n=25, 14Week 17, >=20% reduction from Baseline; n=41,16Week 21, >=20% reduction from Baseline; n=39,16Week 25, >=20% reduction from Baseline; n=40, 17Week 37, >=20% reduction from Baseline; n=33,17Week 49, >=20% reduction from Baseline; n=26, 14Week 52, >=20% reduction from Baseline; n=25, 14
Ropinirole CR - High Dose Group: Long Term Phase58989681516141312
Ropinirole CR - Maintenance Group: Long Term Phase233312233334

[back to top]

Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase

The Japanese UPDRS assesses the status of Parkinson's Disease (PD) participants objectively. Part III assessed motor examination on 27 items. Participants received a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Number of participants achieving a 30% or greater and 20% or greater reduction from Baseline in UPDRS total part III score at Weeks 2, 4, 6, 8, and 12 are presented using LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. The imputation was conducted using the data within only the Dose Increase Effect Verification Phase; therefore, the value observed in the Dose Increase Effect Verification Phase was not used to impute a missing data in the Long-term Phase. (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionParticipants (Number)
Week 2, 30% or greater reduction from BaselineWeek 4, 30% or greater reduction from BaselineWeek 6, 30% or greater reduction from BaselineWeek 8, 30% or greater reduction from BaselineWeek 12, 30% or greater reduction from BaselineWeek 2, 20% or greater reduction from BaselineWeek 4, 20% or greater reduction from BaselineWeek 6, 20% or greater reduction from BaselineWeek 8, 20% or greater reduction from BaselineWeek 12, 20% or greater reduction from Baseline
Ropinirole CR - High Dose Group10172130271626303531
Ropinirole CR - Maintenance Dose Group45677511101113

[back to top]

Percent Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase

The Japanese UPDRS assessed the status of PD participants objectively. Part I evaluated mentation, behavior, and mood on 4 items, response for each item were scored numerically from 0-4. The total score for the 4 items ranged from 0 to 16. A higher score indicates more severe PD symptoms. Percent change from Baseline was calculated as Post baseline value minus Baseline value, divided by Baseline value and multiplied by 100. Baseline is defined as the value evaluated at Week 0. The analyses for Dose Increase Effect Verification Phase was performed using the LOCF data. In the LOCF data, the last available data was used for the imputation for missing data at a planned visit. (NCT01929317)
Timeframe: Baseline, Weeks, 2, 4, 6, 8 and 12

,
InterventionPercent change (Mean)
Week 2Week 4Week 6Week 8Week 12
Ropinirole CR - High Dose Group-6.2-14.5-15.2-16.4-7.4
Ropinirole CR - Maintenance Dose Group-16.7-41.7-29.2-29.2-29.2

[back to top]

Number of Subjects With Unchanged Tumor Size

Radiologic assessment of tumor size before and after treatment will be made by MRI. (NCT03038308)
Timeframe: 6-12 months

InterventionParticipants (Count of Participants)
ROP Intervention7

[back to top]

Percentage of Subjects That Achieved Stable PRL Normalization

Serum prolactin concentrations (PRL levels) were measured in patients at baseline and at follow-up. (NCT03038308)
Timeframe: 6-12 months

Interventionpercentage of participants (Number)
ROP Intervention50

[back to top]

Frequency of Muscle Cramps as Assessed by Patient Survey

Compare the incidence of muscle cramps in patients using vitamin E versus ropinirole. Patients complete a survey that assesses the frequency of muscle cramps from once weekly or less to multiple episodes per day. Frequency scale is 0 to 3 with 0 being once weekly or less and 3 being multiple episodes a day. Survey is completed at the end of 3 months on study intervention. (NCT03176966)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Vitamin E Taken Nightly for 3 Months1.14
Ropinirole Taken Nightly for 3 Months1.23

[back to top]

Muscle Cramp Severity as Assessed by Patient Survey

Compare the severity of muscle cramps in patients using vitamin E versus ropinirole. Patients complete a survey that assesses muscle cramp pain on a scale from 0 to 10 with 0 being no pain and 10 being hurts worst. Survey is completed at the end of 3 months of study intervention. (NCT03176966)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Vitamin E Taken Nightly for 3 Months6.57
Ropinirole Taken Nightly for 3 Months6.00

[back to top]

Total Number of Adverse Events Across Participants

Safety and tolerability of ropinirole implant(s) presented as the total number of adverse events experienced by the analysis population. (NCT03250117)
Timeframe: 0-12 weeks

InterventionEvents (Number)
Cohort 14

[back to top]

"Mean Change From Baseline of Awake Time Off"

"Efficacy of ropinirole implants presented as mean change from baseline of awake time Off. Diaries were completed for 2 consecutive days prior to the visit, used to record motor state in half-hour intervals over a 24-hour period (during waking hours). Off refers to when medication has worn off and is no longer providing benefit with regard to mobility, slowness and stiffness. Daily totals for waking hours were normalized to a 16-hour waking day and averaged across the 2 days" (NCT03250117)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 6, 8, 10, 12

Interventionhours (Mean)
Week 1Week 2Week 3Week 4Week 6Week 8Week 10Week 12
Cohort 1-1.36-1.67-2.26-1.33-1.22-0.83-1.77-1.43

[back to top]

"Mean Change From Baseline of Awake Time On"

"Efficacy of ropinirole implants presented as mean change from baseline of awake time on. Diaries were completed for 2 consecutive days prior to the visit, used to record motor state in half-hour intervals over a 24-hour period (during waking hours). On refers to when medication is providing benefit with regard to mobility, slowness and stiffness, regardless of dyskinesia. Daily totals for waking hours were normalized to a 16-hour waking day and averaged across the 2 days." (NCT03250117)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 6, 8, 10, 12

Interventionhours (Mean)
Week 1Week 2Week 3Week 4Week 6Week 8Week 10Week 12
Cohort 10.801.111.700.770.660.110.930.58

[back to top]

Mean Change From Baseline in MDS-UPDRS Total Score

Efficacy of ropinirole implants presented as the mean change from baseline in MDS-UPDRS total score. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Scale [MDS-UPDRS] is a questionnaire and examination rating motor and non-motor experiences, and motor complications. Score is summed to range from 0 to 272. Higher score indicates more severe symptoms/outcome. (NCT03250117)
Timeframe: Baseline and Weeks 4, 8 and 12

Interventionunits on a scale (Mean)
Week 4Week 8Week 12
Cohort 14.010.67.3

[back to top]